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Resumo 
As catinonas sintéticas, comummente designadas por β-ceto-anfetaminas, são 
substâncias psicostimulantes que surgiram no panorama de consumo recreacional durante 
o século XXI, sendo consumidas como alternativa a drogas de abuso ilícitas, como as 
anfetaminas e a cocaína. Ao longo dos últimos anos foram reportados vários casos de 
intoxicações e mortes associados ao consumo de β-ceto-anfetaminas. Os efeitos adversos 
incluem agitação severa, hipertensão, taquicardia, hipertermia, paranóia e psicose aguda, 
bem como danos em vários órgãos, tais como cérebro, fígado, rins, coração e tecido 
muscular. No entanto, os mecanismos subjacentes à toxicidade nos órgãos-alvo ainda não 
foram totalmente compreendidos. Considerando as semelhanças químicas e 
farmacológicas entre as catinonas sintéticas e as anfetaminas clássicas, postulou-se a 
existência de mecanismos toxicológicos comparáveis. 
O primeiro objetivo desta tese passou pela avaliação in vitro do potencial 
hepatotóxico de quatro catinonas frequentemente consumidas, nomeadamente a 3,4-
metilenodioximetcatinona (metilona), a 3,4-metilenodioxipirovalerona (MDPV), a 
pentedrona e a 4-metiletcatinona (4-MEC), em culturas primárias de hepatócitos de rato e 
células HepaRG diferenciadas, num estudo comparativo com a já extensamente estudada 
e hepatotóxica 3,4-metilenodioximetanfetamina (MDMA). Os resultados obtidos mostraram 
que todas as β-ceto-anfetaminas induziram morte celular em ambos os modelos in vitro de 
uma forma dependente da concentração. Os estudos mecanísticos conduzidos em culturas 
primárias de hepatócitos de rato suportam a capacidade das β-ceto-anfetaminas de induzir 
hepatotoxicidade in vitro através do aumento do stress oxidativo, da perturbação das 
funções mitocondriais e da indução de morte celular por apoptose. A MDPV e a pentedrona 
foram as substâncias com maior potencial hepatotóxico, sendo mais tóxicas do que a 
própria MDMA, enquanto a metilona exibiu um menor potencial hepatotóxico. De destacar 
a correlação direta verificada entre o potencial tóxico das catinonas e as suas 
características lipofílicas. Foi observada ainda uma redução parcial da morte celular na 
presença do inibidor da CYP2D6, quinidina, resultados que salientam a importância da 
bioativação metabólica na hepatotoxicidade das catinonas sintéticas.  
A hipertermia é um dos efeitos agudos inerentes ao abuso de β-ceto-anfetaminas. 
Os resultados obtidos mostraram que o aumento da temperatura por si só interfere com o 
estado redox intracelular, observando-se também o agravamento de todos os efeitos 
hepatotóxicos da MDPV em condições hipertérmicas, caracterizado pelo aumento da 
produção de espécies reativas de oxigénio e azoto, depleção de glutationa e ATP, e 
aumento dos níveis de cálcio intracelular. A morte celular por apoptose foi precipitada pelo 
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aumento da temperatura de incubação, com um aumento da prevalência de necrose celular 
a concentrações mais elevadas de MDPV. 
Foi igualmente avaliado o potencial neurotóxico in vitro da metilona e da MDPV em 
células SH-SY5Y dopaminérgicas. Verificou-se que ambos os derivados induzem morte 
neuronal de forma dependente da concentração, com aumento da produção de espécies 
reativas de oxigénio e azoto e depleção da glutationa, bem como disfunção mitocondrial, 
caracterizada pela despolarização da membrana mitocondrial e depleção de ATP. A 
indução de morte celular por apoptose foi também um mecanismo comum a estas duas 
catinonas, observando-se a ativação de mecanismos intrínsecos e extrínsecos, formação 
de núcleos picnóticos, condensação de cromatina e prevalência de células num estadio 
avançado de apoptose. 
Curiosamente, foi possível observar a formação de vacúolos citoplasmáticos após 
exposição das células neuronais às β-ceto-anfetaminas por microscopia de contraste de 
fase, sugerindo a indução de autofagia. Os dados obtidos no último trabalho desta tese 
demonstraram que tanto a metilona como a MDPV induzem alterações morfológicas 
congruentes com ativação autofágica em neurónios dopaminérgicos, com formação de 
autofagossomas e ativação de marcadores de autofagia, tais como a formação de 
organelos vesiculares acídicos e aumento da expressão da proteína LC3-II, de uma forma 
dependente da concentração e do tempo de exposição. Os resultados mostraram ainda 
que a autofagia surge como um efeito primário da neurodegeneração induzida pelas β-
ceto-anfetaminas, verificando-se a ativação dos marcadores autofágicos antes da indução 
de morte celular ou da ativação de caspase 3. Foi também demonstrado que o agente 
antioxidante N-acetil-L-cisteína detém efeitos neuroprotectores, levando a uma reversão 
completa da formação de espécies reativas de oxigénio e azoto e uma diminuição parcial 
de atividade autofágica e apoptótica induzidas pela metilona e pela MDPV, evidenciando a 
importância do stress oxidativo na regulação dos mecanismos de morte celular programada 
incitados pelas drogas de abuso em estudo. 
Em conclusão, os resultados apresentados nesta tese contribuíram 
significativamente para a compreensão dos mecanismos inerentes aos efeitos 
hepatotóxicos e neurotóxicos das β-ceto-anfetaminas. Verificou-se que a toxicidade in vitro 
das catinonas sintéticas está relacionada com a indução de stress oxidativo e disfunção 
mitocondrial em ambos os órgãos-alvo, bem como a iniciação de morte celular por 
apoptose. Foi igualmente demonstrada a importância da autofagia nos efeitos 
neurodegenerativos destes psicostimulantes, com uma possível correlação entre stress 
oxidativo, autofagia e apoptose celular. 
 
Palavras-chave: β-ceto-anfetaminas; hepatotoxicidade; neurotoxicidade; estudos in vitro. 
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Abstract 
  
Synthetic cathinones, often termed β-keto amphetamines, are psychostimulant 
substances that have been emerging in the 21st century and flooded recreational settings 
as alternatives to illicit drugs of abuse, including amphetamines and cocaine. Inevitably, 
several cases of intoxications and deaths related to the abuse of β-keto amphetamines 
have been reported over the years. Adverse effects include severe agitation, hypertension, 
tachycardia, hyperthermia, paranoia and acute psychosis, as well as end-organ effects 
targeting the brain, liver, kidney, heart and muscle tissue. However, the mechanisms 
underlying target-organ toxicity have hitherto not been fully elucidated. Due to the chemical 
and pharmacological similarities shared with non-keto amphetamines, we hypothesized 
comparable toxicological mechanisms for cathinones. 
The first purpose of the present work was to assess the in vitro hepatotoxic potential 
and the mechanisms of cytotoxicity elicited by four commonly abused cathinone derivatives, 
namely 3,4-methylenedioxymethcathinone (methylone or βk-MDMA), 3,4-
methylenedioxypyrovalerone (MDPV), pentedrone and 4-methylethcathinone (4-MEC), 
using primary cultured rat hepatocytes (PRH) and differentiated HepaRG cells, in a 
comparative study with the well-known hepatotoxicant 3,4-
methylenedioxymethamphetamine (MDMA).  
Data obtained in this work showed that all β-keto amphetamines elicit hepatic cell 
death in both in vitro models in a concentration-dependent manner. Results from 
mechanistic studies support the ability of β-keto amphetamines to elicit in vitro 
hepatotoxicity through oxidative stress, mitochondrial dysfunction and apoptotic cell death. 
MDPV and pentedrone were the stronger hepatotoxic substances, even more potent than 
MDMA, whereas methylone was the least deadly derivative. The differences in drug potency 
herein found were directly correlated with its predicted lipophilicity. A partial reversion of cell 
death occurred in the presence of the CYP2D6 inhibitor, quinidine, supporting an important 
role for metabolic bioactivation in the overall hepatotoxic effects of synthetic cathinones. 
Hyperthermia is a common clinical complication following β-keto amphetamines 
abuse, and the rise in temperature was determined to greatly potentiate the hepatotoxicity 
of amphetamines. Our data showed that the rise in temperature per se disturbed the redox 
system, and exacerbated all MDPV-elicited hepatotoxic effects, with enhancement in the 
production of reactive oxygen (ROS) and nitrogen (RNS) species, glutathione (GSH) and 
ATP depletion, and increased intracellular free calcium levels. Cell death by apoptosis was 
hastened under hyperthermic conditions, apparently shifting to necrosis at higher 
concentrations of MDPV. 
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The neurotoxic potential of the β-keto amphetamines methylone and MDPV was 
also studied in vitro, using dopaminergic SH-SY5Y cells. These drugs elicited 
concentration-dependent neuronal cell death, prompting the generation of ROS and RNS 
followed by the depletion of GSH, as well as mitochondrial impairment, characterized by the 
disruption of the mitochondrial membrane potential (Δψm) and ATP depletion. Apoptosis 
was also a common cell death pathway for methylone and MDPV, with activation of both 
intrinsic and extrinsic pathways, evident formation of pyknotic nuclei and chromatin 
condensation, and prevalence of cells in a late apoptotic stage. Interestingly, the formation 
of cytoplasmic vacuoles following exposure of neuronal cells to β-keto amphetamines was 
apparent under a phase-contrast microscopy, suggesting the induction of autophagy. The 
results of the last work showed that both methylone and MDPV instigated morphological 
changes consistent with autophagy in dopaminergic SH-SY5Y cells, including the formation 
of autophagosomes, and activation of autophagy markers, such as the formation of acidic 
vesicular organelles (AVOs) and increased expression of the autophagy-related protein 
LC3-II, in a time- and concentration-dependent manner. Importantly, data supported the 
triggering of autophagy as an early event of β-keto amphetamines-induced 
neurodegeneration, with the autophagic markers being activated prior to any significant 
effects on cell death or caspase 3 activation. Additionally, we showed that the antioxidant 
agent N-acetyl-L-cysteine (NAC) exhibits neuroprotective effects against methylone- and 
MDPV-induced cell death, leading to a complete inhibition of ROS and RNS generation, 
and partially deterring both apoptotic and autophagic activity, which supports a key role for 
oxidative stress in the regulation of programmed cell death pathways elicited by these 
drugs. 
In conclusion, the data herein presented greatly contribute for a better understanding 
of the mechanisms underlying the hepatotoxic and neurotoxic effects of β-keto 
amphetamines, a prominent novel group of hazardous drugs of abuse. We showed that the 
in vitro cytotoxic effects of synthetic cathinones involve the triggering of oxidative stress and 
mitochondrial dysfunction in both target-organs. These substances also triggered intrinsic 
and extrinsic apoptotic cell death pathways in both neuronal and hepatic models. Autophagy 
was also shown to play a key role in the neurodegenerative effects of these psychostimulant 
drugs, with an apparent, but hitherto not fully understood, crosstalk between oxidative 
stress, autophagy and apoptotic cell death. 
 
Keywords: β-keto amphetamines; hepatotoxicity, neurotoxicity; in vitro studies.  
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Thesis layout 
This thesis is organized in 4 major sections. 
Section I is a general introduction that comprises the current state of the art of β-
keto amphetamine (cathinone) derivatives and their abuse. This section includes a review 
article for theoretical support entitled ‘Khat and synthetic cathinones: a review’ (Valente 
MJ, Guedes de Pinho P, Bastos ML, Carvalho F, Carvalho M (2014) Arch of Toxicol, 
88(1):15-45, doi: 10.1007/s00204-013-1163-9), and a brief review on the mechanisms of 
hepatotoxicity and neurotoxicity of β-keto amphetamines. 
Section II encompasses the main objectives underlying this thesis, enacting the 
subsequent experimental wort presented. 
Section III includes the main studies conducted for the purposes of this thesis, 
organized in four manuscripts of original research, including three published articles and 
one submitted manuscript. 
Section IV presents an integrated discussion of all the work described in Section III. 
Section V contains the main conclusions attained from the conducted work, as well 
as potential future studies. 
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Section I – General introduction 
The global scenario of drug abuse has suffered a baffling transformation in the past few 
decades, with a shift of abuse patterns from classical illicit drugs to new psychoactive 
substances (NPS). NPS comprise hundreds of synthetic compounds from various chemical 
groups, which emerged as an attempt to outwit drug legislation through the manufacturing 
of psychostimulant drugs that were not controlled, ending up being labelled as ‘legal highs’ 
(Evans-Brown and Sedefov 2017). From 2009 to 2016, the Early Warning System of the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) identified and 
currently monitors almost 600 NPS. From these, 103 are synthetic cathinones – about half 
detected between 2014 and 2015 –, making this the second largest group of NPS after 
synthetic cannabinoids (EMCDDA-Europol 2016; EMCDDA 2016). 
Synthetic cathinones are derivatives of cathinone, a natural occurring 
psychostimulant alkaloid present in the fresh leaves of the Catha edulis (or khat) plant, 
structurally similar to amphetamine (figure 1). They began to be sold legally online or at 
smartshops as alternatives to illicit drugs such as 3,4-methylenedioxymethamphetamine 
(MDMA) and cocaine, labelled as ‘bath salts’ and ‘plant feeders’ (figure 2) and deceptively 
advertised as ‘not for human consumption’ (Valente et al. 2014). Due to their chemical 
resemblance to amphetamine derivatives, with the difference being the presence of a 
ketone group in the β-position of the alkyl side chain (figure 1), these designer drugs are 
often termed β-keto amphetamines (Zaitsu et al. 2011). 
Figure 1: Chemical structures of amphetamine and cathinone, and general structural representation of 
cathinone derivatives. 
Notwithstanding all the efforts made so far to control the manufacturing and 
marketing of synthetic cathinones (Valente et al. 2014), dozens of new structural derivatives 
emerge in the recreational markets every year, hindering the development of an effective 
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regulatory system for these NPS. Furthermore, several derivatives that are already under 
legal control conquered a prominent place in illicit drug markets. This is the case of 4-
methylmethcathinone (4-MMC or mephedrone), 3,4-methylenedioxymethcathinone 
(methylone or βk-MDMA) and 3,4-methylenedioxypyrovalerone (MDPV), which were the 
first three synthetic cathinones to be scheduled as controlled substances in the United 
States and in several European Union member states, and are still three of the most 
commonly abused derivatives (Ashrafioun et al. 2016; Bretteville-Jensen et al. 2013; 
EMCDDA-Europol 2016; EMCDDA 2016; van Amsterdam et al. 2015), being responsible 
for several cases of intoxication and deaths even after banning (Busardo et al. 2015; Grapp 
et al. 2017; Karila et al. 2016). 
Figure 2: Packages of ‘plant feeders’ containing synthetic cathinones. Material apprehended by the 
Portuguese Judicial Police after the closing of local smartshops due to the new legislative control measures 
regarding ‘legal highs’ in force since April 2013, which penalizes the commercialization and use of a total of 159 
NPS, including 33 cathinone derivatives. 
Depending on the structural substitution(s) made to the original molecule of 
cathinone, synthetic cathinones are divided into different chemical groups, and the 
pharmacological and toxicological properties, as well as the subjective and adverse effects 
may vary among groups and derivatives (Valente et al. 2014).  
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Subjective and adverse effects of synthetic cathinones range from amphetamine- to 
cocaine-like, depending on their chemical properties and pharmacological mechanisms. 
General desired effects include euphoria, enhanced sociability and empathy feelings, 
creativity enhancement, increased state of wakefulness and alertness, and increased libido. 
The most common adverse clinical symptoms are cardiac, neurological and psychiatric 
effects, consistent with the sympathomimetic toxidrome, and characterized by severe 
hypertension, tachycardia, chest pains, seizures, aggressiveness and extreme agitation, 
hyperthermia, paranoia, delirium and acute psychosis (Hohmann et al. 2014; Prosser and 
Nelson 2012; Spiller et al. 2011; Valente et al. 2014). Abuse of cathinones also induces 
end-organ effects, including rhabdomyolysis, cerebral and lung edema, myocardial 
infarction, acute renal and liver failure, or even multiorgan system failure, which may 
ultimately lead to death (Adebamiro and Perazella 2012; Borek and Holstege 2012; 
Hohmann et al. 2014; Omer and Doherty 2011; Ross et al. 2012; Valsalan et al. 2017; 
Warrick et al. 2012). 
The general introduction of this thesis intends to provide an overview of the current 
state of the art of β-keto amphetamine (cathinone) derivatives and their abuse. It includes 
a review article (‘Khat and synthetic cathinones: a review’), providing detailed information 
on historical background, prevalence and patterns of abuse, legal status, chemical aspects, 
pharmacokinetics and pharmacodynamics, subjective and adverse effects of these 
psychoactive substances. It also includes a brief review on the mechanisms of 
hepatotoxicity and neurotoxicity of β-keto amphetamines. 
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analogs are introduced into the legal market. chemically, 
these substances are structurally related to amphetamine. 
For this reason, cathinone derivatives share with this drug 
both central nervous system stimulating and sympathomi-
metic features. Reports of intoxication and deaths related 
to the use of ‘bath salts’ have been frequently described 
over the last years, and several attempts to apply a leg-
islative control on synthetic cathinones have been made. 
However, further research on their pharmacological and 
toxicological properties is fully required in order to access 
the actual potential harm of synthetic cathinones to general 
public health. The present work provides a review on khat 
and synthetic cathinones, concerning their historical back-
ground, prevalence, patterns of use, legal status, chem-
istry, pharmacokinetics, pharmacodynamics, and their 
physiological and toxicological effects on animals and 
humans.
Keywords Khat · Synthetic cathinones · Bath salts · 
Pharmacokinetics · Pharmacodynamics · Toxicity
Introduction
cathinone is the major naturally occurring psychoactive 
component found in the leaves of the Catha edulis plant, 
commonly known as khat. The first cathinone derivatives 
were originally synthesized in the beginning of the twenti-
eth century for therapeutic purposes, but it was only in the 
last decade that the recreational use of these synthetic com-
pounds gained public attention (Balint et al. 2009; Kelly 
2011). Synthetic cathinones are included in a larger group 
of psychoactive substances generally designated by ‘legal 
highs’. They are indiscriminately abused for their cocaine 
and amphetamine-like pharmacological effects, usually 
Abstract For centuries, ‘khat sessions’ have played a 
key role in the social and cultural traditions among sev-
eral communities around Saudi Arabia and most east 
African countries. The identification of cathinone as the 
main psychoactive compound of khat leaves, exhibiting 
amphetamine-like pharmacological properties, resulted in 
the synthesis of several derivatives structurally similar to 
this so-called natural amphetamine. Synthetic cathinones 
were primarily developed for therapeutic purposes, but 
promptly started being misused and extensively abused for 
their euphoric effects. In the mid-2000’s, synthetic cathi-
nones emerged in the recreational drug markets as legal 
alternatives (‘legal highs’) to amphetamine, ‘ecstasyʼ, or
cocaine. currently, they are sold as ‘bath salts’ or ‘plant 
foodʼ, under ambiguous labels lacking information about
their true contents. cathinone derivatives are conveniently 
available online or at ‘smartshops’ and are much more 
affordable than the traditional illicit drugs. Despite the 
scarcity of scientific data on these ‘legal highs’, synthetic 
cathinones use became an increasingly popular practice 
worldwide. Additionally, criminalization of these deriva-
tives is often useless since for each specific substance that 
gets legally controlled, one or more structurally modified 
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labeled ‘not for human consumption’, and sold as ‘plant 
food’ or ‘bath salts’ in order to bypass legislative restric-
tions in several countries (Bretteville-Jensen et al. 2013; 
Fass et al. 2012; van Hout and Brennan 2011).
Methcathinone (ephedrone, ‘cAT’) and 4-methylmeth-
cathinone (mephedrone, 4-MMc) were the first cathi-
none derivatives to be produced. Mephedrone, along with 
methylone (3,4-methylenedioxy-N-methylcathinone, βk-
MDMA) and MDPv (3,4-methylenedioxypyrovalerone), 
rapidly emerged in recreational drug markets as the main 
ingredients of ‘bath salts’, becoming readily accessible on 
the Internet and at the so-called ‘head’ or ‘smartshops’. By 
the end of 2011, these three compounds were provisionally 
scheduled in the United States of America (USA) under 
drug legislation for further analysis of potential harm (Jerry 
et al. 2012; Kelly 2011; Prosser and Nelson 2012). None-
theless, legal regulation of synthetic drugs like cathinone 
derivatives is rather difficult to attain success, since they 
are easily replaced by novel compounds after minor struc-
ture modifications. consequently, for each drug that gets 
banned, new and more powerful analogs will reach the licit 
drug markets.
Due to their legal status, users are deceivingly led to 
believe that these drugs are safe to consume. However, 
several cases of ‘bath salts’-related intoxication and deaths 
have been reported over the last years (James et al. 2011; 
Kovacs et al. 2012; Murray et al. 2012; wood et al. 2010a). 
Despite the scarcity of experimental data on the pharmaco-
logical and toxicological properties of these ‘legal highs’, 
based on the structural similarities of cathinone deriva-
tives with other amphetamines like MDMA (3,4-methyl-
enedioxymethamphetamine, ‘ecstasy’), identical effects are 
predictable.
The purpose of this work is to provide a thorough report 
on the currently known synthetic cathinone derivatives, and 
to review their chemical, pharmacological, and toxicologi-
cal properties.
Historical background
Khat (Catha edulis) is a flowering evergreen plant that 
grows wild in the Horn of Africa and in the Southwest Ara-
bian Peninsula. For centuries, the chewing of fresh khat 
leaves, for their gratifying stimulant effects, has been a tra-
dition in local communities, especially at cultural and reli-
gious ceremonies, including funerals and weddings. Khat 
chewing is also widely practiced on a daily basis, at the 
so-called khat sessions, where men gather and chat for sev-
eral hours, usually after work. These sessions are a major 
social and cultural phenomenon in this area, particularly in 
Yemen (Al-Motarreb et al. 2002; Balint et al. 2009; car-
valho 2003).
Recently, and following the improvement of the routes 
for transportation and distribution, the availability of khat 
leaves ceased to be exclusive to the native regions, and 
immigrants spread their use to western countries (Alem 
et al. 1999; Griffiths et al. 2010), although with the limita-
tion that only fresh khat leaves may achieve the aimed psy-
chotropic effects.
The khat plant was first described during an expedition 
to egypt and Yemen in 1761–1763, by a Swedish botanist 
named Peter Forskal, who identified C. edulis as a mem-
ber of the family celastraceae. In 1775, Karsten Niebuhr, 
Forskal’s travelling companion and the only survivor of the 
expedition, named khat as C. edulis Forsk (Al-Motarreb 
et al. 2002; Dhaifalah and Santavy 2004; Kalix 1984).
The fresh khat leaves contain over forty compounds, 
including alkaloids, tannins, flavonoids, terpenoids, ster-
ols, glycosides, amino acids, vitamins, and minerals (Balint 
et al. 2009; cox and Rampes 2003; Halbach 1972; Kalix 
1984). In the first attempt to identify the active principle(s) 
of khat, Fluckiger and Gerock (1887) detected a psychoac-
tive compound they named katin, which was later identified 
by wolfes (1930) as (+)-norpseudoephedrine, an Ephedra
alkaloid. For the following three decades, (+)-norpseu-
doephedrine, commonly known as cathine, was believed 
to be the major active component of khat, although some 
evidences showed that cathine stimulant effect was insuf-
ficient as the sole responsible for khat pharmacological 
effects (Halbach 1972; Kalix 1984; Szendrei 1980; Zelger 
et al. 1980). Thus, in 1975, a βk-analog and precursor of 
cathine, the (−)-α-aminopropiophenone, or cathinone,
was isolated in the United Nations’ Narcotics laboratory 
(United Nations 1975). early studies showed that cathi-
none is 7- to 10-fold more potent than cathine but degrades 
rapidly, thus explaining the need to chew fresh khat leaves 
(cox and Rampes 2003; Kalix and Khan 1984; Kelly 
2011; Knoll 1979; Nencini and Ahmed 1989). cathinone 
appeared in the recreational Israeli markets in the early 
2000’s, in 200 mg capsules, under the brand name ‘Hagi-
gat’, which was sold as a natural psychostimulant and aph-
rodisiac (Bentur et al. 2008).
Besides cathine, cathinone can also be metabolized into 
(−)-norephedrine (Brenneisen et al. 1986). These three
alkaloids belong to the khat phenylalkylamine family.
with the purpose of synthesizing a series of ephedrine 
homologs, Hyde et al. (1928) optimized earlier methods 
and obtained purified α-methylaminopropiophenone, also 
known as methcathinone or ephedrone (ePH). In the fol-
lowing year, Saem de Burnaga Sanchez (1929) described 
a method for the chemical synthesis of 4-methylmethcathi-
none, generally named mephedrone (MePH).
Due to their central nervous system (cNS) stimu-
lant properties, some synthetic cathinone derivatives, 
such as m-chloro-N-tert-butyl-cathinone (bupropion), 
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N,N-diethylcathinone (diethylpropion, amfepramone), and 
N,N-dimethylcathinone (dimethylpropion, metamfepra-
mone), were primarily developed for therapeutic purposes, 
mainly as antidepressants and anorectic drugs (canning 
et al. 1979; cunningham 1963; Markantonis et al. 1986; 
Seaton et al. 1961; Soroko et al. 1977). However, whereas 
these three derivatives exhibited minor misuse potential, 
ePH, which was also meant to be marketed as an anti-
depressant, displayed strong addictive potential, with a 
cocaine-like stimulus more potent than cocaine and cathi-
none itself (Young and Glennon 1993). This resulted in 
ePH misuse and abuse, known by the street names ‘Jeff’ 
or ‘cat’, first in the former Soviet Union and later in the 
USA (clein and Benady 1962; emerson and cisek 1993; 
Goldstone 1993; Griffith et al. 1983; Kuenssberg 1962). 
consequently, since the early 90’s, ePH has been impli-
cated in several cases of intoxications. It can be easily syn-
thesized at home through the oxidation of readily available 
pharmaceuticals containing ephedrine or pseudoephedrine 
with potassium permanganate, in the presence of acetic 
acid. As a result, ePH intoxications typically manifest as 
a manganese-induced Parkinsonism (Belhadj-Tahar and 
Sadeg 2005; colosimo and Guidi 2009; de Bie et al. 2007; 
Gorgaslidze et al. 1993; Iqbal et al. 2012; Sanotsky et al. 
2007; varlibas et al. 2009).
A few years later, in 1996, methylone was synthesized 
and patented as an antidepressant and anti-Parkinsonism 
agent. with a psychostimulant potency close to the one 
observed with MDMA itself, methylone ended not being 
ever marketed for the expected purposes (Dal cason et al. 
1997).
By the same time, derivatives of α-PPP (α-pyrrolidino
propiophenone), the pyrrolidine N-substituted cathinone, 
started appearing during seizures on the German drug 
market (Maurer et al. 2004; Springer et al. 2003c; west-
phal et al. 2007). Similarly to other aminopropiophenone 
derivatives, several substances from pyrrolinophenone fam-
ily were initially synthesized for clinical uses. In the early 
1970’s, 4-methyl-α-pyrrolidinopentanophenone, or pyrov-
alerone, was developed to treat obesity, chronic fatigue, 
and lethargy (Gardos and cole 1971; Goldberg et al. 1973; 
Prosser and Nelson 2012). However, due its strong addic-
tive properties, and after the report of abuse by polydrug 
users, pyrovalerone was withdrawn from clinical treatments 
(Deniker et al. 1975; Prosser and Nelson 2012; Sauer et al. 
2009; Yohannan and Bozenko Jr 2010). later, some α-PPP 
derivatives with a potent central muscle relaxant effect 
entered the Japanese markets (Morikawa et al. 1987; Saki-
tama et al. 1995; Yamazaki et al. 1987).
The pyrrolidinophenone family includes several other 
psychoactive substances that, unlike pyrovalerone, were 
never intended for therapeutic use. These substances are 
MPPP (4-methyl-α-pyrrolidinopropiophenone), MPHP 
(4-methyl-α-pyrrolidinohexiophenone), MPBP (4-methyl-
α-pyrrolidinobutiophenone), MOPPP (4-methoxy-α-
pyrrolidinopropiophenone), MDPPP (3,4-methylenedioxy-
α-pyrrolidinopropiophenone), and MDPv (Peters et al. 
2005; Springer et al. 2002, 2003a, b, d).
Recreationally, the first generation of synthetic cathi-
nones to be sold in the markets includes methylone, which 
emerged in the mid-2000’s under the brand name ‘explo-
sion’, first in the Netherlands and Japan, and later in Aus-
tralia and New Zealand. This was the first of these sub-
stances to be marketed via the Internet and at smartshops, 
making it readily accessible, affordable, and easy to pur-
chase (Bossong et al. 2005; Maheux et al. 2010; Zaitsu 
et al. 2011). Since then, methylone poisonings have been 
frequently reported, in single consumption (carbone et al. 
2013; Kovacs et al. 2012), but mostly in combination/
mixture with other psychoactive substances (Boulanger-
Gobeil et al. 2012; cawrse et al. 2012; Pearson et al. 2012; 
Shimizu et al. 2007; warrick et al. 2012).
MePH, colloquially known as ‘M-cat’, ‘Meph’, ‘Sub-
coca’, ‘Topcat’, or ‘miaow miaow’, is another first-gen-
eration cathinone derivative. It is originally from Israel, 
where it started being sold as a legal alternative to cocaine 
or ‘ecstasy’, and available in capsules named Neodove at 
the online company Neorganics (Brunt et al. 2011; Deluca 
et al. 2009b; vekariya 2012).
Possibly the most well-known and more studied sub-
stance in the market of synthetic cathinones, MePH became 
popular in europe only recently, right after it was banned 
in Israel, by 2008. MePH was first identified in Finland, 
in March 2008, and was reported in the same year to the 
european Monitoring centre for Drugs and Drug Addiction 
(eMcDDA) and europol, via the european Union (eU) 
early-warning system (eMcDDA-europol 2009; Kelly 
2011). This interest in MePH was promptly disseminated 
throughout all europe, especially in the United Kingdom 
(UK) and Ireland, and even Australia (Bruno et al. 2012; 
James et al. 2011; Mcelrath and O’Neill 2011; Measham 
et al. 2010; van Hout and Brennan 2011). However, it was 
only in 2010 that the first case of MePH exposure in the 
USA was reported by the National Poison Data System 
(Bronstein et al. 2011).
Besides MePH, other five synthetic cathinone deriva-
tives were identified and reported in 2008, namely eth-
cathinone (N-ethylcathinone, ethylpropion), flephedrone 
(4-fluoromethcathinone, 4-FMc) and its positional isomer 
3-fluoromethcathinone (3-FMc), butylone (β-keto-meth
ylbenzodioxolylbutanamine, βk-MBDB), and MDPv
(eMcDDA-europol 2009).
evidences on ethcathinone recreational use are scarce, 
and, aside one case of poisoning with ethcathinone com-
bined with methylone reported last year (Boulanger-Gobeil 
et al. 2012), little is known about this substance.
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equally lacking information in the literature are buphe-
drone (α-methylaminobutyrophenone, MABP) and meth-
edrone (4-methoxymethcathinone). Buphedrone was 
one of the series of ephedrine homologs synthesized in 
1928 by Hyde et al. (1928) and, as a positional isomer 
of MePH, like ethcathinone, was one of the first choices 
for alternative ‘legal high’ after MePH was banned. Two 
cases of buphedrone use were reported in Poland, one 
of which was a fatal case as a result from a car crash for 
driving under the influence of this substance and MDPv 
(Zuba et al. 2013).
like buphedrone, methedrone emerged as a MePH sub-
stitute. Two fatal cases related with methedrone intake were 
reported in Sweden by 2009, which contributed for the 
decision of the Swedish government to schedule this sub-
stance as a narcotic drug by the end of that year (wikstrom 
et al. 2010).
The fluorinated MePH derivatives, flephedrone and 
3-fluoromethcathinone, were the next derivatives to reach
the markets, followed by butylone and ethylone (3,4-meth-
ylenedioxy-N-ethylcathinone, bk-MDeA), and finally
MDPv (Archer 2009; eMcDDA-europol 2009; Zaitsu
et al. 2009). contrary to ethcathinone, these five cathinone
derivatives, along with methylone, became commonly
available for purchase, usually in the mixtures of several
cathinones and other psychoactive drugs (Zuba and Byrska
2013). Public interest on these derivatives, as alternatives
to MePH, greatly increased after the last one became con-
trolled in the eU. Nonetheless, MePH remained available
in the illicit drug market for the following period and is still
currently a matter of concern to public health (eMcDDA
2012; Mcelrath and O’Neill 2011). Attesting this tendency,
eMcDDA-europol notified, in the annual joint implemen-
tation report, a record number of 15 new synthetic cathi-
nones being marketed in 2010, versus the 4 derivatives
reported in 2009 and 6 in the year before (eMcDDA-
europol 2009, 2010, 2011).
Due to the continuous search for new, legal, less expen-
sive, and more powerful highs by drug users, the synthesis 
of novel cathinone derivatives became a fruitful industry, 
leading to a fast emergence of new alternative substances 
every year. As a consequence of the criminalization of 
MePH derivatives, a group of products named ‘energy’ 
(NRG), advertised as naphthyl cathinone analogs, started 
entering the recreational scene (Measham et al. 2011). 
NRG-1, the first one of these preparations to be marketed, 
was purported to contain naphthylpyrovalerone, or naphy-
rone, which was also the first of the second-generation syn-
thetic derivatives to be reported via the eU early-warning 
system, in 2010 (eMcDDA-europol 2011). Nonetheless, 
studies on the chemical composition of NRG-1 revealed 
that only a minor part of the available preparations of this 
brand actually contained naphyrone. In fact, Brandt et al. 
(2010a, b, 2011) showed that most samples of NRG-
type products analyzed contained illegal synthetic cathi-
nones, namely MePH, flephedrone, butylone, MDPv, 
pentylone (β-keto-methylbenzodioxolylpentanamine, βk-
MBDP), 4-Mec (4-methyl-N-ethylcathinone), MDPBP 
(3,4-methylenedioxy-α-pyrrolidinobutiophenone), and 
MPPP, which raises serious health concerns to users and 
demands criminal repercussions to sellers.
By the same time, the so-called third-generation syn-
thetic cathinones started showing up, first 3,4-DMMc 
(3,4-dimethylmethcathinone) and then pentedrone (α-met
hylaminovalerophenone) and α-PvP (α-pyrrolidinovalerop
henone; α-pyrrolidinopentiophenone) (eMcDDA-europol 
2010, 2011). Aside a few studies on their chemical charac-
terization, metabolism, and distribution (locos and Reyn-
olds 2012; Maheux and copeland 2012; Marinetti and 
Antonides 2013; Shima et al. 2013), there is limited toxico-
logical data in the literature regarding these substances and 
for most of the derivatives reported so far.
Figure 1 summarizes the major historical events associ-
ated with khat and synthetic cathinone derivatives.
Fig. 1  Time line of the main events related to the khat plant and synthetic cathinones
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Prevalence, patterns of use, and legal status
The majority of khat chewers is located in Yemen, where 
recent reports estimate that up to 90 % of the adult males 
and approximately 50 % of the general adult population 
consume khat leaves on a daily basis. High prevalence is 
also observed in many east African countries, including 
Somalia, ethiopia, Uganda, and Kenya (Al-Motarreb et al. 
2002; Al-Mugahed 2008; Alem et al. 1999; Dhaifalah and 
Santavy 2004; Manghi et al. 2009; Tesfaye et al. 2008).
The use of khat was, for many decades, confined to 
the regions where C. edulis grows. However, due to the 
improvement of distribution routes, the emergence of 
online markets for fresh khat leaves, and the immigration 
from native countries to europe and USA, khat chewing 
has been globalized (Alem et al. 1999; cox and Rampes 
2003; Feyissa and Kelly 2008; Griffiths et al. 2010).
Khat leaves are identified by many local names, includ-
ing qat, qaat, chat, and miraa. They are harvested early in 
the morning and sold in bundles of about 100–200 g of 
fresh leaves wrapped in banana leaves in order to preserve 
their freshness. chewing one bundle per day is considered 
a moderate and usual consumption. There are several types 
of khat bundles available, and prices vary according to 
the quality and potency of their effects. In eastern Africa 
countries, khat may cost from US0.5$ for the cheaper and 
less potent type, and up to US20$ per kilo of cleaner and 
stronger leaves. In the United Kingdom, each bundle costs 
between 3 and 7£ (US4.7 to 11$), but it may reach the 50$ 
in the USA (Balint et al. 2009; cox and Rampes 2003; 
Fasanmade et al. 2007; Hansen 2010; Klein et al. 2009; 
Klein et al. 2012; Patel et al. 2005).
currently, khat legal status is ambiguous. In 1993, 
cathinone was placed into Schedule I of the controlled 
Substances Act, whereas cathine was already ruled as a 
Schedule Iv substance in 1988 (Drug enforcement Admin-
istration 1993a, b). Khat may fall into Schedule I sub-
stances when containing detectable levels of cathinone. 
Nonetheless, its legal status is often challenged, especially 
among immigrants living in countries where khat is legally 
controlled (Klein et al. 2012). Khat is currently illegal in 
the USA and canada, and was banned in several european 
countries, including Ireland, France, Denmark, Germany, 
Sweden, Norway, and more recently the Netherlands. How-
ever, it is still legal in the United Kingdom, Portugal, Aus-
tralia, and in most eastern Africa countries (Arunotayanun 
and Gibbons 2012; Gezon 2012; Klein et al. 2012).
All over the world, the development of new drugs has 
been a target of increasing public attention, mostly in the 
last decade. In europe, over 150 novel psychoactive sub-
stances were reported to the eMcDDA from 2005 to 2011, 
from which 34 were synthetic cathinones (eMcDDA-
europol 2011). cathinone analogs, together with synthetic 
cannabinoids, represent two-thirds of all the notified sub-
stances since 2005, in a group that includes also legal 
phenethylamines, piperazines, and tryptamines, the so-
called legal highs (eMcDDA 2012).
In order to circumvent legislative control, synthetic 
cathinones are ambiguously advertised as ‘bath salts’, 
‘plant food’, or even ‘hoover freshener’, and labeled ‘not 
for human consumption’ (Bretteville-Jensen et al. 2013; 
Fass et al. 2012; van Hout and Brennan 2011).
‘Bath salts’ are sold under several inexplicit brand 
names, including Bloom, Blue Silk, Ivory wave, Purple 
wave, and vanilla Sky, and purchased locally at conveni-
ence stores and head- or smartshops, or conveniently over 
Internet suppliers, being readily accessible, affordable, 
and technically legal (coppola and Mondola 2012; Gersh-
man and Fass 2012; Kelly 2011; Mas-Morey et al. 2012; 
Spiller et al. 2011; volkow 2011). Nonetheless, there is a 
lack of information, reliability, and consistency on the 
chemical composition of the available products, and most 
of those allegedly containing legal substances are actually 
composed by formerly banned compounds, the most com-
mon being MePH, methylone, and MDPv (Brandt et al. 
2010b; Fass et al. 2012; Prosser and Nelson 2012; Ramsey 
et al. 2010). As a result, despite their recent scheduling as 
controlled substances within the USA and elsewhere, ille-
gal synthetic cathinones frequently appear in psychoactive 
products labeled as ‘bath salts’ still on the market. Addi-
tionally, as the law is always a step behind, several new 
cathinone derivatives keep emerging in the recreational 
markets every year to avoid detection or legal scrutiny.
Synthetic cathinones are generally sold in the form of a 
white or yellowish amorphous or crystalline powder, or in 
capsules, and are usually found as 200 mg to 10 g packets, 
costing approximately 10–20$ per gram, but can also be 
purchased in bulk quantities for discounts. cathinone deriv-
atives in tablets are more uncommon (Bretteville-Jensen 
et al. 2013; coppola and Mondola 2012; Dargan et al. 
2011; Fass et al. 2012; Karila and Reynaud 2011; Kelly 
2011; Prosser and Nelson 2012; Yohannan and Bozenko Jr 
2010).
MePH is usually found as a white or colored hydrochlo-
ride salt and is likely to be sold as a racemic mixture of the 
stereoisomeric R and S forms. An unpleasant odor to the 
compound, as a mixture of chloride, vanilla, and urine, was 
described by MePH users. MDPv, commonly available as 
a white light tan powder, was also reported to develop an 
odor when exposed to air (Gibbons and Zloh 2010; Gorun 
et al. 2010; Yohannan and Bozenko Jr 2010).
Ingestion, either by swallowing capsules or ‘bombing’ 
(the powder is swallowed after being wrapped in a cigarette 
paper) (Deluca et al. 2009b), and nasal insufflation (‘snort-
ing’), more specifically by ‘keying’ (a key is dipped in the 
powder and then insufflated) (lindsay and white 2012) are 
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the main routes for the administration of these substances. 
Inhalation, gingival and sublingual delivery, intravenous 
injection, and rectal administration have also been reported 
(coppola and Mondola 2012; Gershman and Fass 2012; 
Karila and Reynaud 2011; lindsay and white 2012; Mas-
Morey et al. 2012; Prosser and Nelson 2012).
The increasing popularity of these substances may 
be linked to several reasons. Users resort to the synthetic 
cathinones for their cocaine and MDMA-like psychostimu-
lant effects, but are usually misled by the term ‘legal high’, 
and thus often believe they are safe to consume. Neverthe-
less, the fact that they can be legally purchased may be per-
suasive for both new consumers and illicit drug users. Fur-
thermore, it was also suggested a connection between the 
peak of synthetic cathinones demand in 2010 and the loss 
of purity of cocaine samples and ‘ecstasy’ pills seized in 
2009 (Measham et al. 2010).
estimations on the prevalence of synthetic cathinones 
are very difficult to attain, and surveys on self-report abuse 
are still currently the only source for this matter. However, 
the majority of these surveys corresponds to specific groups 
and, consequently, is not representative of the general 
population.
An online survey targeting UK club-goers conducted by 
the end of 2009 reported that 41.3 % of the 2,295 respond-
ents had used MePH, with a total of 15.1 % reporting a 
weekly or more frequent use. On the other hand, only 10.8 
and 1.9 % had consumed methylone and MDPv, respec-
tively (winstock et al. 2011). MePH was determined to be 
the fourth more commonly used drug in europe, after can-
nabis, ‘ecstasy’, and cocaine, sixth if considering alcohol 
and tobacco, and the most abused ‘legal high’ (europol–
eMcDDA 2010; winstock et al. 2011).
The UK club scene is one of the most thriving markets 
for MePH abuse, even after its legal restriction. In fact, 
in an in situ drug survey conducted at two ‘gay-friendly’ 
South london dance clubs by 2011, 41 % of the respond-
ents had taken or planned to take MePH on the night of the 
survey, against the 27 % determined in 2010 in the same 
conditions (Measham et al. 2011). Of note, MePH was 
considered the favorite drug of all (20.4 %), followed by 
cocaine (14.9 %) (wood et al. 2012).
Also in the United Kingdom, a self-report question-
naire conducted in high schools, colleges, and universities 
in Scotland revealed that 20.3 % of the students had used 
MePH at least once, 4.4 % consumed it on a daily basis, 
and 17.6 % had already experienced addiction or depend-
ence symptoms (Dargan et al. 2010).
The 2010/2011 British crime Survey found that the 
prevalence of MePH use among adults aged 16–59 was 
roughly the same as the one observed with ‘ecstasy’ 
(1.4 %), whereas among users from 16 to 24 years, the 
levels of use of this synthetic cathinone were comparable 
to powder cocaine (both 4.4 %) (Smith and Flatley 2011).
The concomitant use of synthetic cathinones with other 
substances is a common practice worldwide, and it may 
include other substituted cathinones, several kinds of ‘legal 
highs’, illicit and prescription drugs, anesthetic agents, and 
alcohol (Deluca et al. 2009b; James et al. 2011; Karila and 
Reynaud 2011; Maskell et al. 2011).
In Finland, the prevalence of MDPv use was assessed 
in drivers suspected to be under the influence of drugs. 
From August 2009 to August 2010, 5.7 % (259 drivers) of 
all cases of confirmed driving under the influence of drugs 
were found positive for MDPv, with blood concentrations 
ranging from 0.016 to 8.400 mg/l. Alcohol was present 
in a minor part of these cases (only 22 of the 259 driv-
ers), and regularly under the legal limit for alcohol in Fin-
land. However, 80 and 67 % of the MDPv-positive drivers 
were also positive for amphetamine and benzodiazepines, 
respectively, and 54 % had the 3 types of drugs combined 
(Kriikku et al. 2011).
In Ireland, 13.9 % of a total number of 209 urine sam-
ples from attendees at the Drug Treatment centre Board 
were positive for MePH, while methylone was found in 
3.3 % of the samples (McNamara et al. 2010).
An Australian study showed that the consumption of 
cathinone derivatives is frequent among regular ‘ecstasy’ 
users (17 and 0.5 % using MePH and MDPv, respectively) 
(Bruno et al. 2012).
Also, in Australia, an online prevalence assessment tar-
geting same-sex-attracted people between 18 and 25 years 
old revealed that 4 % of the respondents had been using 
MePH (lea et al. 2011), which is proportionally lower 
than the UK findings, suggesting that synthetic cathinones 
may have entered the european markets in a much higher 
degree than in Australia.
Statistics on the prevalence of use of synthetic cathi-
nones in the USA are limited. Recent data from the Ameri-
can Association of Poison control centers (AAPcc) 
reported a significant increase in calls related to ‘bath salts’ 
exposure from 2010 (304) to 2011, with a record num-
ber of 6136 calls, followed by a decrease to 2,656 calls in 
2012 (AAPcc 2013). when comparing the number of calls 
made to national poison control centers in the USA and the 
United Kingdom, between 2009 and 2012, it was observed 
a similar number normalized per month and population. 
However, the peak of calls in the United Kingdom occurred 
more than one year earlier than in the USA (Spyker et al. 
2012).
The legal status of synthetic cathinones differs greatly 
from country to country, and even between states, and is 
always changing according to new findings on possible 
risks for the public safety.
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After the report of several cases of intoxication and some 
MePH-related deaths in europe (Maskell et al. 2011), 
eMcDDA conducted a risk assessment report on this sub-
stance (eMcDDA 2011). Supported by the report findings, 
MePH was classified as a controlled drug under the UK 
Misuse of Drugs Act of 1971 and was banned, along with 
other cathinone derivatives, on April 2010 (Morris 2010; 
vardakou et al. 2012).
europe has responded to the rising concern over the use 
of MePH by subjecting it to ‘control measures and criminal 
penalties’ throughout the eU. In a Decision of 2 December, 
the council of the eU banned the drug, calling on Member 
States to introduce controls in line with their national law 
(council 2010).
In Portugal, new legislative control measures regard-
ing ‘legal highs’ were introduced last April, penalizing the 
commercialization and use of a total of 159 substances, 
and 33 of them are synthetic cathinones. The Portuguese 
Government (2013) remarked as being illegal to produce, 
import, export, market, distribute, advertise, deliver, or pos-
sess these substances, and this ultimately resulted in the 
closing of smartshops all over the country. This new law 
also predicts a progressive update of the list of controlled 
substances every 18 months.
Until the fourth trimester of 2011, the synthetic cathi-
nones were unscheduled in the USA, but human consump-
tion was considered illegal under the Federal Analog Act 
of 1986. On October 21, 2011, the Drug enforcement 
Administration temporary scheduled MePH, methylone, 
and MDPv, under Schedule I of the controlled Substances 
Act, criminalizing the sale and possession of these sub-
stances until final ruling on the requirement for further 
control. The scheduling of methylone was later extended 
until last April, and all three derivatives remained Sched-
ule I substances and are permanently banned in the USA 
(Bretteville-Jensen et al. 2013; Drug enforcement Admin-
istration 2011, 2012).
Chemistry
Synthetic cathinones are phenylalkylamine derivatives, 
closely related to amphetamines, the difference being the 
ketone group introduced at the β-position of the amino 
alkyl chain attached to the phenyl ring. For this reason, 
these ‘legal highs’ are often entitled βk-amphetamines 
(Zaitsu et al. 2011).
cathinone derivatives are analogs of the natural cathi-
none (Fig. 2a) and are synthesized by adding diverse sub-
stituents at different locations of the cathinone molecule, as 
depicted in Fig. 2b.
So far, more than 30 cathinone derivatives have been 
identified in the licit and illicit recreational drug markets, 
Fig. 2  chemical structure of cathinone (a) and general structure of 
synthetic cathinones (b)
Table 1  Synthetic cathinones: common names and corresponding 
chemical designation
common names chemical name
ephedrone, methcathinone α-Methylaminopropiophenone
Mephedrone, 4-MMc 4-Methylmethcathinone
Bupropion, amfebutamone m-chloro-N-tert-butyl-cathinone
Dimethylpropion, metamfepra-
mone
N,N-Dimethylcathinone
Diethylpropion, amfepramone N,N-Diethylcathinone
Flephedrone, 4-FMc 4-Fluoromethcathinone
3-FMc 3-Fluoromethcathinone
ethcathinone, ethylpropion N-ethylcathinone
4-Mec 4-Methylethcathinone
Methedrone 4-Methoxymethcathinone
Buphedrone α-Methylaminobutyrophenone
Pentedrone α-Methylaminovalerophenone
3,4-DMMc 3,4-Dimethylmethcathinone
Methylone, βk-MDMA 3,4-Methylenedioxy-N-methyl-
cathinone
ethylone, βk-MDeA 3,4-Methylenedioxy-N-ethyl-
cathinone
Butylone, βk-MBDB β-Keto-methylbenzodioxolylbut
anamine
Pentylone, βk-MBDP β-Keto-methylbenzodioxolylpen
tanamine
α-PPP α-Pyrrolidinopropiophenone
Pyrovalerone 4-Methyl-α-
pyrrolidinopentanophenone
α-PvP α-Pyrrolidinovalerophenone
MPPP 4-Methyl-α-
pyrrolidinopropiophenone
MOPPP 4-Methoxy-α-
pyrrolidinopropiophenone
MPBP 4-Methyl-α-
pyrrolidinobutiophenone
MPHP 4-Methyl-α-
pyrrolidinohexiophenone
MDPv 3,4-Methylenedioxypyrovalerone
MDPPP 3,4-Methylenedioxy-α-
pyrrolidinopropiophenone
MDPBP 3,4-Methylenedioxy-α-
pyrrolidinobutiophenone
Naphyrone Naphthylpyrovalerone
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with more or less data available in the literature for each 
substance. In Table 1 are resumed the main synthetic deriv-
atives available so far.
chemically, this group of ‘legal highs’ can be separated 
into four families. The first known synthetic cathinone ana-
logs were frequently N-alkylated cathinones at R1 and/or 
R2, some of which with ring substituents (R3). This fam-
ily of cathinones includes substances that were primarily 
synthesized for therapeutic purposes, namely the anorectics 
diethylpropion and dimethylpropion and the antidepressant 
bupropion, and derivatives that were in fact introduced into 
the recreational drug market: ethcathinone, ePH, MePH, 
flephedrone (and its isomer 3-FMc), 4-Mec, methedrone, 
buphedrone, pentedrone, and 3,4-DMMc (Fig. 3).
Instead of an alkylation or halogenation at R3, a 
3,4-methylenedioxy group can be added to the benzyl ring 
(Dal cason 1997). This group encompasses the N-meth-
ylated and N-ethylated derivatives methylone and ethy-
lone, and also butylone and pentylone, which result from 
an alkylation at R1 and R4, respectively (Fig. 4a). Of note, 
this family of cathinone derivatives is structurally simi-
lar to 3,4-methylenedioxyamphetamines (Fig. 4b), some 
of which regularly abused substances, namely MDMA, 
MDeA (3,4-methylenedioxyethamphetamine), and MBDB 
(3,4-methylenedioxy-α-ethyl-N-methylphenethylamine) 
(Zaitsu et al. 2011).
Another group of synthetic cathinones is the pyrrolidi-
nophenone-like family, which is characterized by a pyr-
rolidinyl substitution at the nitrogen atom (westphal et al. 
2007). These compounds are derivatives of α-PPP (Fig. 5). 
MPPP is the result of a ring methylation of α-PPP, and the 
alkylation at R4 of MPPP produces MPBP, pyrovalerone, 
and MPHP. α-PvP results from the insertion of an ethyl 
group at R4, while a 4-methoxy substitution in the ring of 
α-PPP leads to the formation of MOPPP.
A further α-PPP derivative was mentioned in the 
eMcDDA data base regarding drug profiling of synthetic 
cathinones. The substance is the 4-methyl-α-pyrrolidino-
α-methylpropiophenone, resulting from a methylation 
of MPPP at R5. It is the only cathinone derivative to have 
an alkyl substitution at this point, but no further informa-
tion concerning this substance is available in the literature 
(http://www.emcdda.europa.eu/publications/drug-profiles/
synthetic-cathinones).
Fig. 3  chemical structures of 
N-alkylated cathinone deriva-
tives. 4-MEC 4-methylethcathi-
none, 3,4-DMMC 3,4-dimethyl-
methcathinone
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From the combination of these two last groups appears 
the synthetic cathinone family that has both the 3,4-meth-
ylenedioxy ring substitution and the N-pyrrolidinyl moiety 
(Kelly 2011), namely MDPPP, MDPBP, and MDPv (Fig. 6).
Naphyrone, a second-generation derivative presenting 
a naphthyl ring, displays a unique structural characteris-
tic, not seen in any other reported synthetic cathinones so 
far. Brandt et al. (2010c) showed that NRG-1 products, 
Fig. 4  chemical structures 
of 3,4-methylenedioxy-
N-alkylated cathinone 
derivatives (a) and related 
3,4-methylenedioxyampheta-
mines (b). MDMA 3,4-meth-
ylenedioxymethamphetamine, 
MDEA 3,4-methylenediox-
yethamphetamine, MBDB 
3,4-methylenedioxy-α-ethyl-N-
methylphenethylamine, MBDP 
3,4-methylenedioxy-α-propyl-
N-methylphenethylamine
Fig. 5  chemical structures 
of N-pyrrolidine cathi-
none derivatives. α-PPP 
α-pyrrolidinopropiophenone, 
MPPP 4-methyl-α-
pyrrolidinopropiophenone, 
MOPPP 4-methoxy-α-
pyrrolidinopropiophenone, 
α-PVP 
α-pyrrolidinovalerophenone, 
MPBP 4-methyl-α-
pyrrolidinobutiophenone, 
MPHP 4-methyl-α-
pyrrolidinohexiophenone
Fig. 6  chemical structures of 3,4-methylenedioxy-N-pyrrolidine cathinone derivatives. MDPPP 3,4-methylenedioxy-α-pyrrolidinopropiophenone, 
MDPBP 3,4-methylenedioxy-α-pyrrolidinobutiophenone, MDPV 3,4-methylenedioxypyrovalerone
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generally advertised as containing naphyrone, may contain 
two isomers of this compound, namely β- and α-naphyrone 
(Fig. 7), and not only the β isomer, as it is regularly 
described in the literature.
Pharmacokinetics
In a single khat session, approximately 100–500 g of khat 
leaves is slowly chewed for several hours (Feyissa and 
Kelly 2008). cathinone is the main active alkaloid present 
in the khat plant and was found to be present at around 78–
343 mg per 100 g of fresh leaves (Arunotayanun and Gib-
bons 2012; Klein et al. 2012; Sakitama et al. 1995).
The psychostimulant effects induced by khat appear 
after approximately half an hour of chewing and last for 
about 3 h (Brenneisen et al. 1990; Kalix 1996). During this 
time, nearly 90 % of the alkaloids are efficiently released 
from the leaves. The absorption of these compounds occurs 
in two phases: the main route is through the oral mucosa, 
with 60 % of cathinone being efficiently absorbed, and the 
second route takes place in the stomach and small intestine 
after the juice has been swallowed (Arunotayanun and Gib-
bons 2012; Feyissa and Kelly 2008; Toennes et al. 2003; 
Toennes and Kauert 2002).
wilder et al. (1994) determined a maximal plasma 
concentration of cathinone of 127 ± 53 ng/ml, attained
127 ± 30 min after ingestion of one dose of 0.8 mg/kg
body weight. In another study, for one dose of 0.8–1 mg/
kg, a mean peak of cathinone of 83 ng/ml is reached within 
1.5–3.5 h (Halket et al. 1995). For a lower dose (0.6 mg/kg 
of body weight), Toennes et al. (2003) described a lower 
maximal plasma cathinone concentration (58.9 ± 18.8 ng/
ml), attained at a comparable time after ingestion 
(2.31 ± 0.65 h). These results suggest that plasma concen-
tration of cathinone, but not the time of peaking, is depend-
ent on the dose ingested.
less than 7 % of the ingested dose of cathinone appears 
unchanged in the urine, being mainly eliminated in the 
form of its metabolites, cathine, and norephedrine (Bren-
neisen et al. 1986; Toennes and Kauert 2002).
The doses of synthetic cathinones that are usually con-
sumed may greatly vary from derivative to derivative, 
depending on the potency of their effects and the route of 
administration (Kelly 2011; Prosser and Nelson 2012). Fur-
thermore, due to the variable nature of the contents of the 
purchased ‘bath salts’, regarding concentrations and purity 
of the products, the pharmacokinetics and pharmacody-
namics inherent to actual exposure is rather unpredictable 
(Brandt et al. 2010a, b; Davies et al. 2010).
cozzi et al. (1999) showed that methylone and ePH are 
less potent than their related non-keto phenylalkylamines, 
respectively, MDMA and methamphetamine (MeTH), 
regarding in vitro neurotransmitter uptake inhibition. Gen-
erally, the presence of the β-keto group increases the polar-
ity of the synthetic cathinones, resulting in a decrease in 
their ability to cross the blood–brain barrier (BBB) (Hill 
and Thomas 2011; lindsay and white 2012; Schifano 
et al. 2011). consequently, to attain equipotent effects, 
the doses of synthetic cathinones reported by the users are 
usually higher than those reported for the related ampheta-
mines, and for some derivatives, like MePH, there is often 
the need to repeat the dose shortly after the first intake 
(Archer 2009; Deluca et al. 2009b; Kelly 2011; Prosser and 
Nelson 2012). This polarity issue occurs mainly with the 
N-alkylated derivatives, but not so much with the pyrroli-
dine family of cathinones, since the presence of the pyrro-
lidine ring greatly reduces the polarity of these compounds
(coppola and Mondola 2012). Nonetheless, methylone and
MDPv, as well as ePH and MePH, exhibited high permea-
bility in human brain capillary endothelial cells expressing
blood-to-brain and brain-to-blood transporters. Among the
four derivatives, the BBB was most permeable to MDPv
and MePH in this order, and evidences suggest that the first
one is actively transported into the brain via specific blood-
to-brain influx carriers (Simmler et al. 2013).
Doses of MePH between 20 and 50 mg are known to 
elicit some psychostimulant effects, but self-reported dos-
ages for a typical session range from 500 mg to 1 g of pow-
der (Deluca et al. 2009b; Prosser and Nelson 2012; win-
stock et al. 2011). when insufflated, 20–75 mg of MePH 
induces a rapid onset of effects, which last less than 2 h. 
Typical oral dosages range from 150 to 250 mg, with the 
onset of expected effects within 45 min after ingestion, and 
duration of action of almost 5 h. Intravenous administration 
of this derivative has a faster onset of stimulation, peaking 
10–15 min after injection, and lasting for less than 30 min. 
Binging and mixing routes of administration in a single 
session is frequent and have the intent to achieve both rapid 
and long-lasting effects (Karila and Reynaud 2011; Mas-
Morey et al. 2012; Prosser and Nelson 2012).
MDPv redosing is also common but, unlike MePH, 
MDPv can induce stimulant effects at dosages as low as 
Fig. 7  chemical structures of β- and α-naphyrone
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5 mg. Typical administered doses can go up to 20 mg or 
higher when redosing. Intakes of over 200 mg of MDPv 
at once have been reported; however, for doses higher than 
15 mg, some users report extremely unpleasant ‘come-
down’ effects (Deluca et al. 2009a). The onset of action and 
the potency of effects are similar to the two main routes of 
administration (oral and intranasal), and occur in less than 
30 min after consumption. MDPv-induced stimulation lasts 
for 2–3.5 h after intranasal intake and up to 7/8 h when 
ingested (Deluca et al. 2009a; Karila and Reynaud 2011).
Methylone was primarily sold in 5-ml tubes, but is cur-
rently available in the form of powder or capsules. com-
mon oral dosages range from 100 to 300 mg, with doses 
higher than 250 mg being considered a ‘heavy’ consump-
tion. The effects are reported within 15–30 min, with the 
duration of over 3 h. However, some stimulating effects 
may be experienced during the 24 h following intake 
(Bossong et al. 2005; Karila and Reynaud 2011; lopez-
Arnau et al. 2013; warrick et al. 2012).
little information on butylone use is available in the lit-
erature. Online data of self-reported use suggest that usual 
doses of this derivative are similar to methylone, with stim-
ulation lasting for 4–6 h (Karila and Reynaud 2011; war-
rick et al. 2012).
The natural cathinone, like all synthetic cathinones, 
undergoes phase I metabolism after absorption, namely a 
reduction of the β-keto group to an alcohol catalyzed by 
liver microsomal enzymes (Brenneisen et al. 1986; Guan-
tai and Maitai 1983), producing cathine and norephedrine 
(Fig. 8). In the specific case of cathinone, the metabolism 
was determined to be stereoselective, with the princi-
pal metabolite of the stereoisomer S-(−)-cathinone being
norephedrine, whereas R-(+)-cathinone is metabolized
into cathine (Mathys and Brenneisen 1992). The amount 
of norephedrine excreted in urine was found to be much 
higher than the amount ingested due to a combination of 
absorbed norephedrine (also present in khat leaves) and 
the product of cathinone metabolism (Toennes and Kauert 
2002).
This stereoselective metabolism was also demonstrated 
for dimethylpropion and then proposed for ePH (Fig. 9) 
(Markantonis et al. 1986; Sparago et al. 1996). The reduc-
tion of ePH and dimethylpropion originates ephedrine and 
methylephedrine, respectively, which are further metabo-
lized into norephedrine and ephedrine through a N-demeth-
ylation (emerson and cisek 1993; Paul and cole 2001).
For MePH, three phase I metabolic pathways were 
determined both in rat and human urine samples, with 7 
metabolites being identified in the human samples. Besides 
the N-demethylation of the primary amine, MePH can 
undergo oxidation in the ring methyl group, producing an 
alcohol that can be further oxidized to give a carboxylic 
acid and then reduced at the β-keto group (Fig. 10). The 
first metabolite resulting from MePH N-demethylation 
may also be oxidized or reduced (Meyer et al. 2010b). 
cytochrome P450 (cYP) 2D6 (cYP2D6) was found to be 
the main responsible enzyme for the phase I metabolism of 
MePH in human liver microsomes (Pedersen et al. 2013).
Recently, Khreit et al. (2013) developed an in vitro 
method for the characterization of the phase I and II meta-
bolic pathways of MePH. Rat hepatocytes were incubated 
with MePH for 2 h, after which the supernatant was ana-
lyzed by lc–MS. Seventeen metabolites were identified, 
from which 7 were phase II metabolites, resulting from the 
reactions of acetylation (Fig. 10a) and/or glucuronidation 
(Fig. 10b). Regarding the reduced metabolites, phase II 
metabolism at the hydroxyl groups may also be expected.
The metabolism of 3,4-methylenedioxy cathinones, 
including methylone, butylone, and ethylone, has been 
characterized (Kamata et al. 2006; Zaitsu et al. 2009): the 
three pathways being the N-dealkylation (minor pathway), 
Fig. 8  Phase I metabolism of cathinone. [R], reduction [adapted 
from (Brenneisen et al. 1986)]
Fig. 9  Metabolism of ephed-
rone and dimethylpropion. [R], 
reduction; [DM], N-demethyl-
ation [adapted from (Markan-
tonis et al. 1986)]
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the reduction of the β-keto moiety, and finally, the dem-
ethylenation followed by a O-methylation mediated by 
the catechol O-methyltransferase (cOMT) (Fig. 11). The 
three hydroxylated metabolites resulting from the two last 
pathways are more likely to undergo phase II metabolism, 
namely glucuronidation and sulfonation of the alcohol 
group, and the conjugates are excreted in the urine, along 
with the unmetabolized drugs (coppola and Mondola 2012; 
Shima et al. 2009; Zaitsu et al. 2009).
like in other synthetic cathinones, for pyrrolidine deriv-
atives, such as MDPv and α-PvP, the ketone group in the 
side amine chain is converted into an alcohol (Fig. 12). 
Regarding MDPv, the 3,4-methylenedioxy ring is metabo-
lized the same way as the βk-methylenedioxyamphetamines 
(see Fig. 11), producing the catechol and the methoxy 
catechol pyrovalerone. Strano-Rossi et al. (2010) deter-
mined these to be the main MDPv metabolites, which may 
be sulfonated or glucuronidated, and later excreted in the 
urine.
Demethylenation was also the main pathway established 
for the degradation of MDPPP in a metabolic in vitro study 
using human liver microsomes. Besides cYP2D6, the iso-
enzyme cYP2c19 was determined to be almost equally 
responsible for this reaction, from which results the metab-
olite di-OH-PPP (Springer et al. 2005).
Further biotransformation of the pyrrolidine group was 
proposed, specifically for MDPv and α-PvP (Meyer et al. 
2010a; Sauer et al. 2009). For instance, the pyrrolidine ring 
can be degraded, producing primary amines. On the other 
hand, the side chain and the position 2′ of the pyrrolidine 
Fig. 10  Phase I metabolism 
of mephedrone and phase II 
metabolites. [R], reduction; 
[DM], N-demethylation; [Ox], 
oxidation [adapted from (Meyer 
et al. 2010b; Khreit et al. 2013)]
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ring may be hydroxylated, followed by dehydrogenation to 
a ketone and to a lactam, respectively. Finally, the ring can 
open to the corresponding aliphatic aldehyde and undergo 
further oxidation, producing a carboxylic acid (Fig. 12). In 
the particular case of α-PvP, the phenyl ring can be hydrox-
ylated, most probably in the position 4′ (Sauer et al. 2009). 
The resulting metabolites, along with others detaining a 
hydroxyl group, can partially undergo phase II metabolism.
Similar metabolic pathways were recently proposed by 
Meyer et al. (2013) for β-naphyrone.
It is worth noticing that the metabolism of flephedrone 
is predictably slower than other synthetic cathinones, as 
fluorination often results in more stable compounds, and 
is consequently more resistant to enzymatic cleavage of 
the c–F bond (westphal et al. 2010). like α-PvP, phase I 
metabolism of this ‘legal high’ includes hydroxylation of 
the phenyl ring, besides the common β-keto reduction and 
N-demethylation to give a primary amine, as determined
in rabbit liver slices and human liver microsomes (Meyer
et al. 2012; Pawlik et al. 2012). N-demethylation of flephe-
drone is mainly mediated by the human cYP2B6 enzyme,
but the isoenzymes 2D6, 2c19, 2e1, and 3A4 are able to
catalyze this reaction too. Furthermore, the metabolite
resulting from the β-keto reduction can be excreted as a 
glucuronic acid conjugate (Meyer et al. 2012).
Pharmacodynamics
As depicted in Fig. 13, cathinone is the β-keto analog of 
amphetamine, while its metabolites (cathine and norephed-
rine) are structurally closely related to noradrenaline. The 
chemical similarity between cathinone and amphetamine, 
and the amphetamine-like subjective effects of khat chew-
ing, led to the designation of ‘natural amphetamine’ given 
to cathinone (Kalix 1992).
In fact, cathinone shares with amphetamine both cNS 
stimulant and sympathomimetic effects. early studies on 
the pharmacological activity of the khat leaves showed 
that cathinone, cathine, and norephedrine are capable of 
inducing an amphetamine-like cNS dopamine release, 
with cathinone being the most potent of the three alkaloids 
(Kalix 1983; Kalix and Braenden 1985).
It is of note that, as for amphetamine, the presence of 
a methyl group at the α-position of the phenylethylamine 
side chain prevents the inactivation of cathinone, cathine, 
Fig. 11  Phase I metabolism 
of the 3,4-methylenedioxy-
N-alkylated cathinone deriva-
tives. [R], reduction; [DA],
N-dealkylation; [DMN], dem-
ethylenation; [M], O-methyl-
ation [adapted from (Kamata
et al. 2006; Zaitsu et al. 2009)]
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and norephedrine through monoamine oxidase (MAO) 
(Siegel et al. 1999). Furthermore, it was shown that cathi-
none inhibits MAO more strongly than amphetamine 
(Nencini et al. 1984) and is more selective toward the iso-
enzyme MAO-B (Osorio-Olivares et al. 2004), whose inhi-
bition leads to a decrease in dopamine degradation, and 
Fig. 12  Phase I metabolic 
pathways common to α-PvP 
and MDPv. [R], reduction; 
[OH], hydroxylation; [DH], 
dehydrogenation; [Ox], oxida-
tion [adapted from (Meyer et al. 
2010a; Sauer et al. 2009)]
Fig. 13  chemical structures 
of cathinone, cathine, nore-
phedrine, amphetamine, and 
noradrenaline
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consequently to the synaptic accumulation of this catecho-
lamine. Additionally, cathinone was found to be more lipo-
philic than its metabolites, favouring its penetration into the 
cNS (Kalix 1991).
In view of the peripheral actions, khat chewing or cathi-
none administration is accompanied by a sympathomimetic 
syndrome, which is characterized by increased heart rate 
and blood pressure, mydriasis, and hyperthermia, among 
other effects. These effects suggest a mode of action simi-
lar to amphetamine, i.e., cathinone promotes release of cat-
echolamines at nerve endings (Kalix 1992).
Since ‘legal highs’ are a rather recent matter of concern, 
and due to the shortage of reliable information in the lit-
erature on their molecular pharmacology, research regard-
ing synthetic cathinones often resorts to comparisons with 
illicit drugs with similar subjective effects, namely amphet-
amine and cocaine. In fact, synthetic cathinones, likewise 
amphetamines [for review, see (carvalho et al. 2012)], 
were shown to exert their effects by interacting with plasma 
membrane monoamine transporters, namely dopamine 
transporter (DAT), noradrenaline transporter (NeT), and 
serotonin transporter (SeRT), resulting in an increased con-
centration of these biogenic amines in the synaptic cleft 
(Baumann et al. 2012; cameron et al. 2013; cozzi et al. 
1999; lisek et al. 2012; lopez-Arnau et al. 2012; Simmler 
et al. 2013; Sogawa et al. 2011). However, different affini-
ties toward these transporters are observed between cathi-
none derivatives. when interacting with monoamine 
membrane transporters, drugs can be classified as either 
substrates (translocated into cells where they disrupt vesic-
ular storage and stimulate non-exocytotic release of neu-
rotransmitters by reversing the normal direction of trans-
porter flux), like amphetamines, or blockers, like cocaine, 
which ultimately leads to different repercussions regarding 
long-term effects (Baumann et al. 2013a). Recent experi-
ments with different study models (e.g., in vivo microdialy-
sis in rats and in vitro rat brain synaptosomes and human 
embryonic kidney cells (HeK293 cell line) expressing 
DAT and SeRT) showed that MePH, methylone, ethylone, 
butylone, and naphyrone act as non-selective inhibitors for 
all catecholamine transporters and, with the exception of 
naphyrone, also as serotonin releasers, similar to MDMA 
(Baumann et al. 2012, 2013a; Simmler et al. 2013). con-
trarily, MDPv was shown to induce powerful cocaine-like 
effects when tested in rat brain synaptosomes. MDPv acts 
as a pure monoamine-selective transporter blocker, with 
high potency for DAT and NeT (50-fold and 10-fold more 
potent than cocaine, respectively), but weak for SeRT (10-
fold less potent than cocaine) (Baumann et al. 2013b; cam-
eron et al. 2013).
Similar mechanism of action was determined for pyrov-
alerone, whose structure is closely related to MDPv. Pyrov-
alerone and MDPv are very potent, and selective DAT and 
NeT inhibitors, but unlike amphetamines, do not evoke 
monoamine release (Baumann et al. 2013a, b; Simmler 
et al. 2013).
ePH and flephedrone were shown to act as preferen-
tial dopamine and noradrenaline uptake inhibitors and 
dopamine releasers, similar to the mechanism of action of 
amphetamine and methamphetamine (Simmler et al. 2013).
In addition, all cathinones were shown to efficiently per-
meate an in vitro blood–brain barrier model, with MDPv 
exhibiting very high transmembrane permeability (Simmler 
et al. 2013).
like other drugs of abuse, such as cocaine, MDMA, and 
MeTH, the affinity toward NeT may be related to the sym-
pathomimetic effects experienced with cathinone deriva-
tives, while the potency to inhibit DAT may be associated 
with their psychostimulant effects and addictive potential. 
On the other hand, a greater affinity for SeRT has been 
associated with the symptoms of paranoia and hallucina-
tions, similar to those observed with classic hallucinogenic 
drugs, including psilocybin, mescaline, and lSD. Further-
more, symptoms of depression and anhedonia could be 
resultant from both serotonin and dopamine putative deple-
tion induced by these compounds (Baumann et al. 2012; 
cameron et al. 2013; cozzi et al. 1999; lisek et al. 2012; 
lopez-Arnau et al. 2012; McGraw and McGraw 2012; 
Schifano et al. 2011; Simmler et al. 2013; Sogawa et al. 
2011).
MePH, one of the most abused synthetic cathinone 
worldwide, demonstrated to detain a unique psycho-
stimulant profile, sharing pharmacological properties that 
appear to be similar to both MeTH and MDMA. On one 
hand, MePH is capable of inducing MDMA- and cocaine-
like subjective effects, which may contribute to its indis-
criminate abuse (carhart-Harris et al. 2011; Deluca et al. 
2009b). On the other hand, it causes dopamine release at 
much greater levels than MDMA and comparable to those 
induced by MeTH. This may be problematic when regard-
ing chronic and long-term consumption, as MePH may 
present enhanced abuse liability, confirmed by its ability to 
elicit self-administration patterns in animal models (Had-
lock et al. 2011), and the tendency for users to frequently 
binge on MePH (Deluca et al. 2009b), just like MeTH.
Physiological and toxicological effects in animal studies
Khat and several synthetic cathinones have been shown to 
affect locomotor behavior in animals, but at variable poten-
cies and different time course of actions (Marusich et al. 
2012). Both acute and repeated oral administrations of C. 
edulis (200 mg/kg) or cathinone (15 mg/kg) significantly 
enhanced the locomotor activity and aggressive behaviors 
in male Sprague–Dawley rats (Banjaw et al. 2006).
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Several studies have demonstrated MePH’s ability to 
elicit locomotor hyperactivity in rats and mice, with the 
vesicular serotonin content and DAT inhibition playing 
key roles in this effect (lisek et al. 2012; lopez-Arnau 
et al. 2012; Martinez-clemente et al. 2013; Marusich et al. 
2012; Miller et al. 2013; Motbey et al. 2012a; Shortall et al. 
2013a; wright et al. 2012a).
Similarly, methylone, butylone, flephedrone, 3-FMc, 
methedrone, and MDPv were shown to induce a dose-
dependent hyperlocomotion on rats and mice too (Fante-
grossi et al. 2013; lopez-Arnau et al. 2012, 2013; Maru-
sich et al. 2012), specially MDPv, which was found to 
elicit hyperactivity at intraperitoneal doses as low as 1 mg/
kg, being 10-fold more potent than cocaine (Marusich et al. 
2012).
Additionally, MePH was also implicated in cognitive 
processes. In fact, MePH administration improved visuos-
patial memory and learning processes in rhesus monkeys 
(wright et al. 2012b), but significantly reduced the work-
ing memory performance in mice, and induced long-term 
memory impairment in rats (den Hollander et al. 2013; 
Motbey et al. 2012b).
cardiovascular toxicity is a well-known feature of 
MePH abuse. Meng et al. (2012) showed that this sub-
stance elicits significant increases in heart rate, blood pres-
sure, and cardiac contractility in guinea pigs, but does not 
act directly as a pro-arrhythmic drug. Increases in heart rate 
and mean arterial pressure induced by MePH were also 
determined in rats (varner et al. 2013).
Some synthetic cathinones could be established as 
affecting thermoregulation in animal models. For instance, 
sustained and significant increases in rectal temperature 
were observed in male lister hooded rats injected with 
cathinone or ePH (Shortall et al. 2013b), as well as in 
wistar rats orally administered with cathinone (Tariq et al. 
1989). Repeated administrations of methylone evoked sig-
nificant hyperthermia in male Sprague–Dawley rats, with 
an increase of approximately 2 °c 5 h after intravenous 
injection, at a concentration as low as 3 mg/kg (Baumann 
et al. 2012). MDPv was also shown to induce a dose-
dependent hyperthermia in mice, but only when adminis-
tered in a warm ambient temperature of 28 °c (Fantegrossi 
et al. 2013).
Some inconsistency concerning the thermoregulatory 
properties of MePH is found in the literature. On one hand, 
MePH was found to induce a dose-dependent hyperthermia 
in Sprague–Dawley rats administered with four subsequent 
doses of 10 or 25 mg/kg (Hadlock et al. 2011) or three con-
secutive 3 or 10 mg/kg doses (Baumann et al. 2012), and in 
mice with a binge-like administration of 4 doses of 20 or 
40 mg/kg. In this last study, when injecting the highest dose 
of MePH, it was observed an immediate drop on the core 
body temperature, followed by a rapid return and exceeding 
the controls to a prolonged hyperthermic status (Angoa-
Pérez et al. 2012). On the other hand, a single subcutane-
ous administration of MePH (1–10 mg/kg) was shown to 
induce significant hypothermia in wistar rats, especially at 
a low ambient temperature (wright et al. 2012a). MePH 
was also shown to induce a dose-dependent reduction in 
body temperature in male Sprague–Dawley rats at an ambi-
ent temperature of 20 °c, but not at 30 °c (Miller et al. 
2013), as well as a transient decrease in rectal tempera-
ture in male lister hooded rats at 19–22 °c (Shortall et al. 
2013b). Taken together, these findings appear to be consist-
ent with the conversion of MePH-induced hypothermia 
at single doses to the hyperthermic effects after a binging 
session.
Similarly to MDMA and MeTH, MePH causes a rapid 
decrease in striatal DAT and hippocampal SeRT function. 
However, despite the serotonergic depletion, and unlike 
MeTH, a binge-like treatment in rats with this cathinone 
derivative does not elicit persistent dopaminergic deficits 
and thus does not cause toxicity at dopamine nerve termi-
nals (Angoa-Pérez et al. 2012; Hadlock et al. 2011). None-
theless, MePH was shown to potentiate the neurotoxicity 
evoked by other illicit drugs, such as MeTH, amphetamine, 
and MDMA (Angoa-Pérez et al. 2013).
Few studies regarding potential neurotoxic effects of 
synthetic cathinones, other than MePH, are available in the 
literature. One early study on ePH-induced effects in mice 
demonstrated that this derivative has no long-term effects 
on serotonin neurons, but evokes significant toxic effects 
on dopaminergic nerve endings (Sparago et al. 1996). On 
the other hand, methylone produces dose-related increases 
in extracellular dopamine and serotonin, but has no long-
term effects in cortical or striatal amines (Baumann et al. 
2012).
Finally, evidences from animal studies also support the 
reinforcing properties and abuse liability of synthetic cathi-
nones, specifically with MePH and MDPv, confirmed by 
their ability to elicit self-administration patterns in rats 
(Aarde et al. 2013a, b; Hadlock et al. 2011; Motbey et al. 
2013; watterson et al. 2012b). A dose-dependent reinforcer 
efficacy was also reported in rats administered with methyl-
one (watterson et al. 2012a).
Subjective effects and adverse toxic reactions 
in humans
Khat chewing is characterized by a rapid onset of psycho-
stimulant effects. Users often describe increased energy 
and excitement, and euphoric sensations, which historically 
resulted in their use to treat the symptoms of melancho-
lia and depression. Users also experience improved sense 
of alertness, enhanced self-esteem, and increased ability 
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to concentrate, associate ideas, and communicate, which 
greatly contributes to the social character of this tradition 
(Alem et al. 1999; cox and Rampes 2003; Dhaifalah and 
Santavy 2004).
Unpleasant physical or psychological effects emerge 
right after users stop chewing the leaves, but symptoms like 
restlessness, anxiety, and hypnagogic hallucinations may 
be experienced also during the process of chewing (Balint 
et al. 2009; cox and Rampes 2003; Granek et al. 1988).
withdrawal symptoms are similar to those observed with 
amphetamine or cocaine, and include insomnia, depression, 
lack of concentration, aggressiveness, lethargy, and differ-
ent types of psychosis (Al-Motarreb et al. 2002; Alem et al. 
1999; Halbach 1972; Giannini and castellani 1982; Kelly 
2011).
chronic use of khat is commonly followed by severe 
cardiac, neurological, psychological, and gastrointestinal 
complications, and several cases of khat-related deaths 
have been reported (chapman et al. 2010; corkery et al. 
2011). Peripheral effects, such as increased blood pressure 
and heart rate, have been associated with enhanced risk of 
myocardial infarction and acute coronary vasospasm (Al-
Motarreb et al. 2005; Ali et al. 2010; Alkadi et al. 2002). 
esophagitis, gastritis, and oral mucosal keratosis are typi-
cal consequences of the astringency of khat leaves. It has 
been shown that khat chewing also delays gastric empty-
ing and intestinal absorption, which may contribute to mal-
nutrition (Al-Habori 2005; Al-Motarreb et al. 2002). Oral 
cancer, acute and chronic liver disease, and cirrhosis have 
also been associated with long-term consumption of C. 
edulis (chapman et al. 2010; Fasanmade et al. 2007; Kassie 
et al. 2001; Peevers et al. 2010; Roelandt et al. 2011; Soufi 
et al. 1991).
Finally, the most common neurological features of 
chronic abuse include insomnia, depression, impaired 
working memory, and psychosis. Khat chewing may also 
precipitate psychosis in patients already predisposed or 
with preexisting psychiatric disorders (Al-Motarreb et al. 
2010; colzato et al. 2011; coppola and Mondola 2012; 
cox and Rampes 2003; Odenwald 2007).
Subjective effects may vary between synthetic cathi-
nones, but are similar to those experienced with khat. Gen-
eral desired effects encompass mild euphoria, enhanced 
empathy, decreased sense of insecurity and hostility, and 
increased libido (Deluca et al. 2009b; Prosser and Nelson 
2012; Yohannan and Bozenko Jr 2010). Users also report 
unwanted effects, such as sweating, nausea and vomiting, 
headaches and dizziness, vertigo, confusion and impaired 
short-term memory, muscle twitching, palpitations and 
tremor, tachycardia and hypertension, and ultimately anhe-
donia, depression with suicidal ideations, psychosis, tol-
erance, and dependence (Bentur et al. 2008; coppola and 
Mondola 2012; Karila and Reynaud 2011; Prosser and Nel-
son 2012; Sammler et al. 2010).
like khat, adverse clinical features associated with syn-
thetic cathinones abuse commonly include psychiatric, 
neurological, cardiac, and gastrointestinal symptoms, and 
existent data are normally referent to MePH abuse.
Hallucinations, paranoia, panic attacks, aggressive-
ness, chest pain, and seizures associated with ‘bath salts’-
induced intoxication are typical side effects reported to the 
AAPcc (2013). Similar effects were described to the UK 
National Poisons Information Services during the period of 
March 2009 and February 2010. In a total of 131 telephone 
inquiries regarding MePH use, 24 % suffered from agita-
tion or aggressiveness, and 22 and 13 % reported tachycar-
dia and chest pain, respectively. Psychotic symptoms were 
also recurrent (14 %), among other usual signs of intoxi-
cation, such as headaches, nausea, palpitations, peripheral 
vasoconstriction, and convulsions (James et al. 2011).
Agitation was also the most commonly described side 
effect after MePH use in a Scottish emergency department, 
followed by chest pain and paresthesia (Regan et al. 2011). 
Typical sympathomimetic features reported to the Swedish 
Poisons centres include tachycardia, restlessness, mydria-
sis, hypertension, and anxiety (europol–eMcDDA 2010).
Hyponatremia and hyperthermia are two well-known 
features among ‘ecstasy’ users. The first one is also occa-
sionally associated with MePH-induced intoxication, sug-
gesting a mechanism of action similar to MDMA, i.e., 
increased serotonin-mediated antidiuretic hormone secre-
tion, with consequent decrease of sodium concentration in 
the blood (Sammler et al. 2010; wood et al. 2010a). A case 
of methylone-induced hyponatremia, following several 
episodes of seizures, was also reported (Boulanger-Gobeil 
et al. 2012).
Hyperthermia is a toxicological effect that has been 
associated with the consumption of different cathinone 
derivatives, including MePH, methylone, butylone, meth-
edrone, and particularly MDPv (Borek and Holstege 2012; 
Fröhlich et al. 2011; Garrett and Sweeney 2010; levine 
et al. 2013; lusthof et al. 2011; Penders et al. 2012; Regu-
nath et al. 2012; Rojek et al. 2012; warrick et al. 2012; 
wikstrom et al. 2010).
Besides all the adverse reactions described so far, sev-
eral other effects may be associated with intoxication by 
synthetic cathinones abuse, including acute liver failure, 
acute kidney injury and rhabdomyolysis, and also symp-
toms related to the serotonin syndrome, such as hyperten-
sion, hyperreflexia, and tremor (Borek and Holstege 2012; 
carhart-Harris et al. 2011; coppola and Mondola 2012; 
Dargan et al. 2011; eMcDDA 2011; Fröhlich et al. 2011; 
Mugele et al. 2012; Prosser and Nelson 2012; vardakou 
et al. 2011; warrick et al. 2012). Table 2 summarizes case 
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reports concerning khat and synthetic cathinones-induced 
intoxication.
Concluding remarks
chewing khat leaves for their psychostimulant effects has 
been a social and cultural habit among Saudi Arabian and 
east African communities, for several centuries. cathinone 
is the main psychoactive substance found in the leaves of 
the C. edulis. chemically, cathinone is the β-keto analog 
of amphetamine, thus detaining similar main subjective 
effects, namely euphoria and increased energy. Unwanted 
clinical effects following khat abuse often include hallu-
cinations, agitation, and anxiety. chronic abuse may lead 
to severe neurological, cardiovascular, and gastrointestinal 
complications, including depression, psychosis, myocardial 
infarction, and acute liver failure.
Structurally modified cathinone derivatives were primar-
ily synthesized for clinical use, mainly as antidepressants 
and anorectic agents, but promptly started being misused. 
Synthetic cathinones reached the recreational drug markets 
and have been sold as ‘bath salts’, as legal alternatives to 
illicit drugs like ‘ecstasy’ and cocaine, being conveniently 
available online and locally, at the so-called smartshops. 
So as to avoid legal control measures, these substances are 
labeled ‘not for human consumption’ and sold under decep-
tive labels lacking information on the product contents or 
on their potential harm for human health.
Over the last decade, it has been observed a great 
increase in the popularity of these ‘legal highs’, with over 
30 synthetic derivatives having been identified so far. Infor-
mation on their pharmacological and toxicological proper-
ties is scarce, but several ‘bath salts’-induced intoxication 
cases and deaths have been reported worldwide.
MePH, methylone, and MDPv are currently the main 
constituents of ‘bath salts’, but since their scheduling as 
controlled substances and criminal penalization, they have 
been gradually replaced by other derivatives with minor 
structural modifications to the natural cathinone.
In vivo data using animal models and in vitro methods 
have been crucial for the determination of the pharma-
cokinetics and pharmacodynamics of these compounds, as 
well as to elucidate the pharmacological and toxicological 
effects of the synthetic cathinones.
A rapid onset of effects is observed for the majority of 
the synthetic cathinones, with duration and potency greatly 
varying between derivatives. Following absorption, syn-
thetic cathinones undergo phase I metabolism, with cYP 
isoenzymes mediating the main pathways. Phase II meta-
bolic pathways may include reactions of acetylation, glucu-
ronidation or sulfonation of the hydroxyl groups, with the 
resultant metabolites being excreted in the urine.
like amphetamine, MeTH, and MDMA, synthetic 
cathinones exert their effects by interacting with catecho-
lamine transporters (DAT, NeT, and SeRT), which results 
in increased synaptic concentrations of these monoamines. 
However, the selectivity of synthetic cathinones for these 
transporters varies considerably.
In vivo studies have also shown that synthetic cathinones 
are able to elicit locomotor hyperactivity, increased heart 
rate and hypertension. Some of them detain hyperthermic 
properties, as well. evidences also support the reinforcing 
properties and abuse liability of MePH, methylone, and 
MDPv.
like khat, synthetic cathinones induce euphoric and 
empathogenic effects. likewise, chronic abuse may result 
in adverse effects such as anxiety, agitation, hallucinations, 
paranoid delusions, tachycardia, hypertension, hyperre-
flexia, and eventually lead to acute liver and kidney failure 
and rhabdomyolysis.
Although many synthetic cathinones are currently 
under legal control in the eU state members and in most 
US states, criminalization of all cathinone derivatives is 
hard to attain. Some of them, like MePH, have acquired 
a significant place in the illicit drug markets and still 
remain a matter of public concern. Additionally, several 
new derivatives emerge in the recreational legal markets 
every year.
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Hepatotoxicity and neurotoxicity of β-keto amphetamines: 
possible underlying cellular mechanisms 
Clinical evidence has established liver damage and CNS injury as common 
complication following cathinones abuse (Borek and Holstege 2012; Carbone et al. 2013; 
Gavriilidis et al. 2015; Hohmann et al. 2014; Kramer et al. 2016; Murray et al. 2012; Omer 
and Doherty 2011; Ross et al. 2012; Valsalan et al. 2017), and postmortem studies further 
confirmed bioaccumulation in these target organs (Cawrse et al. 2012; Marinetti and 
Antonides 2013; McIntyre et al. 2013; Sykutera et al. 2015). 
A limited number of in vitro hepato- and neurotoxicity studies on β-keto 
amphetamines have been reported in recent past years, showing a general increase in cell 
death in a concentration- and time-dependent manner (Araujo et al. 2015; den Hollander et 
al. 2014; den Hollander et al. 2015; Matsunaga et al. 2017; Nakagawa et al. 2009; Rosas-
Hernandez et al. 2016a; Wojcieszak et al. 2016). However, the cellular mechanisms 
underlying the toxic potential of cathinones towards the brain and the liver are still not 
completely understood.  
The putative mechanisms of cytotoxicity elicited by synthetic cathinones in these 
target organs will be presented and discussed in the following sections. In the lack of 
experimental evidence, we will conduct a parallel comparison of what may be expected 
from these new substances to what is widely known for amphetamine derivatives. 
Long-term neurotransmitter depletion and oxidation of biogenic amines 
β-Keto amphetamines exert their psychostimulant effects by interacting with 
membrane neurotransmitter transporters at the CNS, including noradrenaline (NA), 
serotonin (5-HT or 5-hydroxytryptamine) and dopamine (DA) transporters (NAT, SERT and 
DAT, respectively). Some cathinone derivatives act as relatively non-selective substrates 
for monoamine transporters, evoking transporter-mediated release of catecholamines into 
the synaptic cleft by reversing the normal transporter flux (Fleckenstein et al. 2007). This is 
the case of 4-MMC and methylone, which produce dose-related increases in extracellular 
DA and 5-HT in vivo, and an in vitro DA and NA releasing ability comparable to MDMA but 
inferior to methamphetamine (Baumann et al. 2012). Some cathinones act as pure 
transporter blockers like cocaine, with low to no monoamine release potential. This includes 
the pyrrolidine derivatives MDPV, pyrovalerone and α-pyrrolidinovalerophenone (α-PVP) as 
well as non-pyrrolidine derivatives such as pentedrone, which present strong NAT and DAT 
inhibitory activity, and minimal effects on SERT (Baumann et al. 2013b; Marusich et al. 
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2014; Simmler et al. 2013a; Simmler et al. 2014). Interestingly, MDPV was shown to be 
much more potent than cocaine with regards to the inhibition of transporter-mediated uptake 
in vitro (11- and 51-fold more effective on NAT and DAT inhibition in rat brain synaptosomes, 
respectively) and the ability to increase the extracellular levels of dopamine in vivo (10-fold 
more effective in the nucleus accumbens of conscious rats) (Baumann et al. 2013b). There 
are also cathinone derivatives that present a mixed mode of action, such as 4-
methylethcathinone (4-MEC), which functions as SERT substrate/5-HT releaser and NAT 
and DAT blocker (Saha et al. 2015; Simmler et al. 2014). Either by reversing the flux of 
catecholamines, or by blocking their reuptake, synthetic cathinones promote the 
accumulation of DA, 5-HT and/or NE in the synaptic cleft, which results in sympathetic 
overstimulation due to increased binding of these neurotransmitters to postsynaptic 
receptors. The greater affinity towards DAT, comparatively to SERT, renders MDPV and 
related compounds a more stimulant profile and appears to contribute to higher reinforcing 
properties and greater propensity for abuse and addiction (Aarde et al. 2015; Baumann et 
al. 2016; Bonano et al. 2014; Eshleman et al. 2017; King et al. 2015; Simmler et al. 2013b; 
Watterson et al. 2014). In contrast, cathinone derivatives that present a lower DAT/SERT 
ratio on transporter inhibition, such as methylone and 4-MEC, are more empathogenic 
substances and appear to have lower abuse potential (Baumann et al. 2016; Creehan et al. 
2015; Eshleman et al. 2017; Simmler et al. 2014; Watterson et al. 2012). Notwithstanding, 
other factors may contribute for the overall abuse potential of β-keto amphetamines, 
including their lipophilicity and pharmacokinetics. In fact, despite its low DAT/SERT ratio in 
comparison to METH, MDPV or even methylone (Baumann et al. 2012; Simmler et al. 
2013a), the ability of 4-MMC to substitute for METH or cocaine in discriminative stimulus 
effects, to induce conditioned place preference and to sustain a behavior of self-
administration, support rewarding and reinforcing properties, as well as a great abuse 
potential for this derivative (Bonano et al. 2014; Creehan et al. 2015; Gatch et al. 2013; 
Hadlock et al. 2011; Lisek et al. 2012; Motbey et al. 2013; Vandewater et al. 2015). This 
reflects in the highly addictive properties and uncontrolled bingeing behavior reported by 4-
MMC users (Deluca et al. 2009b; Freeman et al. 2012; Schifano et al. 2011). 
The neurotoxicity of amphetamines has been associated to the loss of DAT and 
SERT activity and the long-term depletion of DA and 5-HT (Cadet et al. 2007; Fleckenstein 
et al. 2007). There are a few studies regarding the neurotoxic effects of synthetic 
cathinones, which collectively present mixed results. For instance, persistent reductions of 
striatal DAT density were observed in abstinent methcathinone users, with levels 
comparable to those of users of its non-keto analogue, METH (McCann et al. 1998). 
Methcathinone was also shown to have the potential to damage both DA and 5-HT neurons, 
with evident differences between species and enantiomers (Sparago et al. 1996), and to 
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decrease the activities of tyrosine hydroxylase (TH) and tryptophan hydroxylase, the rate-
limiting enzymes for the synthesis of DA and 5-HT, respectively, with consequent decline in 
the levels of these two neurotransmitters and their metabolites in rat striatum (Gygi et al. 
1997). The work of Hadlock et al. (2011) revealed that repeated administration of 4-MMC 
in rats causes a significant decrease in the striatal DAT and hippocampal SERT functions, 
and a persistent serotonergic, but not dopaminergic, deficit. Accordingly, methylone 
administration also lead to a persistent decline of 5-HT in the frontal cortex, striatum and 
hippocampus of binge-treated rats, to levels comparable to those of amphetamine, but no 
significant effects were found in DA levels, neither for any monoamine in mice (den 
Hollander et al. 2013). In contrast, Baumann et al. (2012) showed that, contrarily to MDMA, 
neither 4-MMC nor methylone exhibit long-term changes in cortical or striatal amines after 
repeated administrations in rats. 4-MMC was also shown to lack neurotoxic effects towards 
dopaminergic nerve endings of the striatum of binge-treated mice (Angoa-Perez et al. 
2012). However, 4-MMC enhanced the neurotoxic effects of amphetamine, METH and 
MDMA in the same model, with a significant decrease in striatal levels of DA, DAT and TH 
(Angoa-Perez et al. 2013), which raises concerns on the potentially dangerous interaction 
of synthetic cathinones with drugs that are commonly co-abused. Interestingly, despite the 
absence of prolonged neurotransmitter deficit in some of these studies, significant long-
term cognitive and neurochemical effects were determined after 4-MMC administration in 
rats and mice (den Hollander et al. 2013). The underlying mechanisms for an apparent 
persistent effect of β-keto amphetamines in SERT and lack of long-term toxicity on the DA 
system remain largely unknown.  
Long-term dopaminergic and serotonergic toxicity induced by amphetamines has 
been associated with their ability to interfere with the vesicular uptake of monoamines, by 
acting as a substrate of the vesicular monoamine transporter (VMAT), in particular VMAT2, 
which is the isoform expressed in CNS neurons (Erickson et al. 1996). Amphetamines act 
by competing with the neurotransmitters for VMAT2-mediated uptake or reversing the 
normal transporter flux, or through dissipation of the vesicular transmembrane pH difference 
that drives the uptake, as a consequence of the nonionic diffusion of amphetamine 
derivatives into the vesicles (Fleckenstein et al. 2007; Rudnick and Wall 1992; Schuldiner 
et al. 1993; Sulzer et al. 2005). Evidence suggest that β-keto amphetamines also detain the 
ability to inhibit VMAT2-mediated transport of 5-HT, NAT and DAT, though with a general 
lower affinity and potency than those of classical amphetamines (Asser et al. 2016; Cozzi 
et al. 1999; Eshleman et al. 2013; Lopez-Arnau et al. 2012; Pifl et al. 2015). For instance, 
Cozzi et al. (1999) showed that methcathinone and methylone were over 10-fold less potent 
than their non-keto analogues METH and MDMA, respectively, regarding the inhibition of 
5-HT uptake via VMAT2 in bovine chromaffin granules. Eshleman et al. (2013) assessed
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the ability of different cathinone derivatives to inhibit the vesicular uptake of 5-HT and to 
stimulate the release of NA at the human VMAT2 (hVMAT2) in transfected HEK cells, in a 
comparison study with METH and MDMA. Results showed that all cathinones were 
substantially weaker than the amphetamine analogues, with effects occurring at high 
micromolar concentrations. Butylone, 4-MMC and methylone were also shown to 
significantly inhibit VMAT2-mediated uptake of DA in an in vitro model of rat striatal 
synaptosomes, with 4-MMC being 6- and 24-fold stronger than methylone and butylone, 
respectively, with a half maximal inhibitory concentration (IC50) of 3.40 µM  (Lopez-Arnau et 
al. 2012) . However, when assessing the uptake of DA by hVMAT2 in a human striatum 
model, the IC50 of 4-MMC rises to 223 µM, 11-fold higher than MDMA (Pifl et al. 2015). 
Taken together, these data suggest that the inhibition of vesicular uptake of 
neurotransmitters by synthetic cathinones, though possible, may not be significant at 
physiological concentrations. Nevertheless, the contribution of this mechanism of action to 
the overall toxicity of β-keto amphetamines should not be disregarded. 
Reduced VMAT2 uptake leads to a rise of unsequestered catecholamines within the 
presynaptic cytoplasm. Neurotransmitter turnover within the presynaptic terminal is 
balanced by its synthesis, release and metabolic inactivation. Monoamine oxidase (MAO) 
is a mitochondrial enzyme responsible for the first step of catecholamines deamination and 
consequent inactivation, with formation of aldehydes (Eisenhofer et al. 2004). Like 
amphetamines, the methyl substitution at the α-carbon present in several cathinone 
derivatives may hamper their deamination through this enzyme (Nencini et al. 1984), a 
mechanism partially accountable for amphetamine’s prolonged action in the CNS (Liechti 
2015). Furthermore, amphetamines also function as MAO inhibitors, hindering 
catecholamines inactivation and consequently increasing their availability for release 
(Steinkellner et al. 2011). Cathinone was determined to inhibit MAO with higher potency 
than amphetamine (Nencini et al. 1984), and Osorio-Olivares et al. (2004) showed that a 
series of aryl substituted cathinones, including 4-MMC, also exhibit MAO inhibitory activity. 
Nevertheless, the role of MAO inhibition by synthetic cathinones on drug-induced toxicity is 
yet to be fully elucidated. A general representation of the putative pharmacological 
mechanisms of action of synthetic cathinones at the CNS is presented in figure 3. 
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Figure 3: Putative pharmacological modes of action of β-keto amphetamines at the central nervous 
system. β-keto amphetamines may act as blockers of NAT, DAT and SERT (1), inhibiting the uptake of 
catecholamines by the presynaptic terminals, and/or substrates (2), evoking transporter-mediated release of 
monoamines via reversal of normal transporter flux. Synthetic cathinones also inhibit VMAT2-mediated vesicular 
uptake of neurotransmitters (3), though with much lower potency than amphetamines, leading to the increase 
of neurotransmitters in the cytoplasm either by competing for the uptake as substrates, or by reversing the 
normal transporter flux. Evidence suggest the β-keto amphetamines may also inhibit MAO (4), the enzyme 
responsible for the inactivation of monoamines, which results in diminished neurotransmitter degradation. Both 
inhibitory mechanisms may further increase the availability of unsequestered biogenic amines to be released 
into the synaptic cleft (5). Catecholamines accumulated in the synaptic cleft bind to postsynaptic receptors (6), 
which results in overstimulation of postsynaptic cells and sympathetic activation. DAT – dopamine transporter; 
NET – norepinephrine transporter; SERT – serotonin transporter; MAO – monoamine oxidase; VMAT2 – 
vesicular membrane transporter 2. 
 
Unsequestered catecholamines within the synaptic terminal may undergo oxidative 
metabolism or autoxidation, with formation of highly reactive products that may induce 
oxidative stress, amplifying the toxicity of stimulant drugs (Cashman et al. 1999; Eisenhofer 
et al. 2004). Biogenic amines are metabolized intraneurally through several pathways. 5-
HT is metabolized in two steps: first it undergoes oxidative deamination by MAO, yielding 
5-hydroxyindole-3-acetaldehyde, which is further oxidized by aldehyde dehydrogenase into 
the end-product 5-hydroxyindoleacetic acid (Lam et al. 2010). Oxidative deamination of the 
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catecholamines DA and NE results in the formation of the biogenic aldehydes 3,4-
dihydroxyphenylacetaldehyde (DOPAL) and 3,4-dihydroxyphenylglycolaldehyde 
(DOPEGAL), respectively. DOPAL and DOPEGAL can be further metabolized either 
through reduction by aldehyde reductase, oxidation by aldehyde dehydrogenase or O-
methylation by catechol O-methyltransferase (COMT), with the main end-products being 
the homovanillic and vanillylmandelic acid, respectively (Eisenhofer et al. 2004). Growing 
evidence supporting the neurotoxic potential of endogenous DOPAL and DOPEGAL have 
emerged from the late 90’s (Burke et al. 2003; Burke et al. 2001; Kristal et al. 2001; Legros 
et al. 2004; Mattammal et al. 1995), and several mechanisms have been proposed for the 
observed toxicity, including protein adduction, isoquinoline formation, production of free 
radicals and reactive oxygen species (ROS), and triggering of mechanisms that lead to 
apoptotic cell death (Marchitti et al. 2007).  
Additionally to the mentioned catabolic pathways of monoamines, non-enzymatic 
oxidation may also take place, and the blocking of metabolism by MAO inhibitors, such as 
amphetamine and probably cathinone derivatives, may contribute to the rise of 
catecholamines autoxidation (Hurtado-Guzman et al. 2002). During this process, highly 
reactive ortho-quinones, hydroquinones, semiquinones and the aminochrome end-products 
are formed, which can further increase the neurotoxicity of psychostimulant drugs through 
increased production of ROS during redox cycling and oxidative stress, formation of 
covalent adducts with sulfhydryl groups with consequent depletion of glutathione (GSH) and 
enzymatic inactivation, as well as energy depletion due to uncoupling of ATP synthesis 
(Bindoli et al. 1992; Bindoli et al. 1989; Delcambre et al. 2016; Graham 1978). 
The altered release of neurotransmitters may also play a role in β-keto 
amphetamines-elicited hepatotoxicity. The activation of α-adrenergic receptors located in 
the membrane of hepatocytes by endogenous catecholamines released due to cathinones 
action on membrane transporters can result in hepatic microvascular vasoconstriction and 
consequent compromise of liver perfusion, decreased hepatic GSH content, rise in cytosolic 
levels of free calcium and increased mitochondrial oxidation (Gonzalez-Manchon et al. 
1988; Randle et al. 2008; Roberts et al. 1997; Taylor et al. 1983). Of note, evidence show 
that several cathinone derivatives, including 4-MMC and methcathinone, also have some 
binding affinity towards α-adrenergic receptors (Simmler et al. 2013a; Simmler et al. 2014), 
in particular α1-adrenoceptor, which is the predominant receptor in liver cells (Kulcsar-
Gergely and Kulcsar 1989).  
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Lipophilicity and blood-to-brain dysfunction 
The ability to cross cellular membranes may also influence the cytotoxic potential of 
drugs of abuse by modulating the amount that actually reaches the target cells. The 
neurotoxicity of psychostimulant substances is particularly co-related with the blood-brain 
barrier (BBB) permeability (Goncalves et al. 2014; Sharma et al. 2007; Yamamoto et al. 
2010). Amphetamine derivatives have been shown to induce BBB dysfunction (Bowyer et 
al. 2008; Kiyatkin and Sharma 2009; Yamamoto and Bankson 2005). Although the 
mechanisms underlying the amphetamines-induced BBB damage have not been fully 
elucidated, evidence support a contributive role from drug-induced hyperthermia and 
oxidative stress (Ramirez et al. 2009; Sajja et al. 2016; Sharma et al. 2007). Considering 
the ability of β-keto amphetamines to trigger neuronal oxidative stress (Budzynska et al. 
2015; Lopez-Arnau et al. 2015) and to raise the body temperature (Valente et al. 2014), the 
compromise of the BBB functions following use of cathinones might be anticipated. 
Overall, the psychostimulant and pharmacological effects of β-keto amphetamines 
are less potent than their amphetamine analogues. For instance, the IC50 values of 
methylone-induced release of NA, DA and 5-HT are over 2.5-fold higher than MDMA in rat 
brain synaptosomes (Baumann et al. 2012; Baumann et al. 2013a). For this reason, to attain 
equipotent effects, the recreational doses reported by methylone users are usually higher 
than those of MDMA (Simmler et al. 2013a). The lower effects of synthetic cathinones may 
also underlie the need for redosing, which is often seen with 4-MMC (Deluca et al. 2009b; 
Schifano et al. 2011).  
The presence of the β-keto group is known to increase the polarity of N-alkylated 
synthetic cathinone in comparison to their non-keto congeners, leading to a decline in their 
permeability and ability to cross the BBB and general bilipid membranes (Coppola and 
Mondola 2012a; Simmler et al. 2013a; Valente et al. 2014). In contrast, pyrovalerone 
derivatives have been suggested to easily cross the BBB due to their higher lipophilicity, 
which is conferred by the pyrrolidine ring-forming tertiary amine (Katz et al. 2014; Zaitsu et 
al. 2014). When comparing the BBB permeability of the most common cathinone and 
amphetamine derivatives in human brain cells expressing BBB transporters, Simmler et al. 
(2013a) found that MDPV, the compound with higher predicted lipophilicity, has the higher 
blood-to-brain and brain-to-blood permeability ratios. The lipophilic nature of MDPV enables 
extensive CNS stimulation, which helps explain the short onset of psychostimulant effects 
described by users for doses as low as 3 to 5 mg (Deluca et al. 2009a; Ross et al. 2012). 
Due to the significant difference found between apical-basolateral and basolateral-apical 
transport, active transport of MDPV across the BBB was proposed (Simmler et al. 2013a). 
In fact, MDPV was found to act as a substrate for a cocaine transporter present in the BBB, 
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and this carrier-mediated cocaine transport was demonstrated to be quantitatively much 
more important than its passive diffusion across the BBB (Chapy et al. 2014).  
Notwithstanding the obvious similarities with amphetamine derivatives and the 
likelihood of β-keto amphetamines to compromise the BBB, the putative mechanisms of 
induced dysfunction still require clarification. 
Metabolic bioactivation 
Studies on the metabolism of synthetic cathinones have shown that these 
substances undergo a series of phase I pathways, including reduction of the ketone group 
with formation of an alcohol, N-dealkylation, hydroxylation of the carbonyl chain, oxidation 
of aromatic and N-alkyl groups, and opening of the pyrrolidine and methylenedioxy rings 
(for detailed information, please refer to Valente et al. 2014).  
The pharmacokinetics of amphetamines has been thoroughly reviewed over the 
years (Carvalho et al. 2012; de la Torre et al. 2004a; de la Torre et al. 2004b; Lyles and 
Cadet 2003), and the metabolic activation of MDMA in particular plays a key role in both 
hepato- and neurotoxic potential of this substance (Capela et al. 2009; Capela et al. 2007; 
Carvalho et al. 2012; Carvalho et al. 2004a; Carvalho et al. 2010; Carvalho et al. 2004b; 
Lyles and Cadet 2003; Monks et al. 2004). MDMA presents two major pathways of hepatic 
metabolism, both mediated by cytochrome P450 (CYP450) isoenzymes, namely CYP2B6-
mediated N-demethylation with formation of 3,4-methylenedioxyamphetamine (MDA), and 
CYP2D6-mediated demethylenation of both MDMA and MDA, yielding the catechol 
metabolites N-methyl-α-methyldopamine (N-Me-α-MeDA) and α-methyldopamine (α-
MeDA) (Carvalho et al. 2012). Once formed in the liver, N-Me-α-MeDA and α-MeDA may 
enter the circulation and reach other organs, including the brain, where they exert their 
toxicity following further autoxidation with formation of highly reactive ortho-quinone 
intermediates, which may enter redox cycling with semiquinones with production of ROS 
and reactive nitrogen species (RNS), be further oxidized into toxic aminochromes like 
biogenic amines, or form GSH conjugates (Bindoli et al. 1989; Carvalho et al. 2012; Monks 
et al. 2004). Of note, MDMA-derived GSH conjugates proved to be more toxic than the 
parent compound (Barbosa et al. 2014; Capela et al. 2007; Carvalho et al. 2002b; 
Shenouda et al. 2009). 
Like MDMA, in vitro studies, typically conducted in human liver microsomes, suggest 
that O-demethylenation is a major metabolic pathway for methylenedioxy cathinone 
derivatives, including methylone and MDPV, being catalyzed mainly by CYP2C19, 2D6 and 
1A2 (Meyer et al. 2010a; Mueller and Rentsch 2012; Negreira et al. 2015; Pedersen et al. 
2013; Springer et al. 2005; Strano-Rossi et al. 2010). From this reaction are formed 
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catechols that are further metabolized via COMT, yielding methylcatechols, which may be 
conjugated to form the phase II glucuronidated and sulphated metabolites (Negreira et al. 
2015; Pedersen et al. 2013; Strano-Rossi et al. 2010). The analysis of urine specimens 
from β-keto amphetamines abusers and treated rats further confirmed the formation of 
catechols, methylcatechols and glucuronic acid conjugates (Bertol et al. 2014; Kamata et 
al. 2006; Meyer et al. 2010b). Of note, Meyer et al. (2014) showed the formation of GSH 
conjugates of five methylenedioxy cathinones, postulating conjugation at the aromatic ring. 
Despite the similarities to MDMA, there is a lack of evidence supporting the systemic 
formation of ortho-quinones from the metabolic activation of β-keto amphetamines. 
Nonetheless, a recent study by Wojcieszak et al. (2016) showed that the major metabolite 
of MDPV, catechol-MDPV, was significantly more toxic than the parent compound towards 
neuronal, hepatic and upper airway epithelium human cell lines, suggesting a major 
contribution of the catechol-metabolites to the neuro- and hepatotoxic effects of synthetic 
cathinones. 
Neuroinflammation and hyperthermia 
Neuroinflammation involving specific inflammatory factors and/or neuro-glial-
microglia pathways has been theorized as a neurotoxic mechanism of β-keto 
amphetamines (Blum et al. 2013). Evidences show that MDMA- and METH-induced 
neuroinflammation involves activation of glial cells, which in turn leads to the release of pro-
inflammatory factors and neuronal damage (Moratalla et al. 2015). Data on the 
neuroinflammatory effects of synthetic cathinones are scarce and somewhat inconsistent. 
For instance, Angoa-Perez et al. (2012) and Martinez-Clemente et al. (2014) found no signs 
of striatal or cortical astroglia or microglia activation in mice treated with 4-MMC in a binge-
like regimen, but some astrocyte reactivity was observed in the hippocampus. Similar 
effects were observed in methylone-treated mice (Lopez-Arnau et al. 2014a), whereas only 
some cortical astrocyte reactivity was detected in adolescent rats treated with this cathinone 
(Lopez-Arnau et al. 2014b). In contrast, neither 4-MMC alone, nor the combination with 
either METH or MDMA induced significant astroglial or microglial activation in mice 
hippocampus (Angoa-Perez et al. 2014). Methcathinone induced a significant increase in 
glial fibrillary acid protein (GFAP), the marker of astroglial activation, in mice striatum 
(Anneken et al. 2017). Interestingly, though neither methylone nor MDPV alone prompted 
astroglial activation in this model, methylone significantly potentiated METH-induced 
increase in GFAP density, while MDPV had the opposite effect on amphetamine, METH 
and MDMA-induced astrogliosis, reducing GFAP density to control levels (Anneken et al. 
2015). Importantly, astrogliosis, just like microglia activation, exacerbates 
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neuroinflammation via cytokine production (Brambilla et al. 2009),  and it has also been 
implicated in METH-induced neuroinflammation, particularly at high doses or chronic 
exposure (Friend and Keefe 2013; Narita et al. 2008; Sakoori and Murphy 2010; Zhang et 
al. 2015).  
Heat stress is closely related to the activation of glial cells and triggering of 
neuroinflammatory effects (Auvin et al. 2009; Bahniwal et al. 2011; Lee et al. 2015), and 
brain hyperthermia is known to exacerbate the harmful neuronal effects of amphetamines 
(Bowyer et al. 1994; Brown and Kiyatkin 2004; Kiyatkin et al. 2007; Malberg and Seiden 
1998). Sympathetic overstimulation, mediated predominantly α-adrenergic receptors, more 
importantly α1-adrenoceptor, are known to contribute to the hyperthermic effect of 
amphetamines (Bexis and Docherty 2008; Kikuchi-Utsumi et al. 2013; Matsumoto et al. 
2014). In the work of Simmler et al. (2013a), cathinone and the derivatives methcathinone, 
4-MMC and flephedrone, exhibited in vitro affinity towards α1-adrenoceptor. In humans,
robust increases in body temperature were reported during acute intoxication with 4-MMC
(Garrett and Sweeney 2010; Kasick et al. 2012; Lusthof et al. 2011; Zona et al. 2016),
methylone (Barrios et al. 2016; Pearson et al. 2012; Warrick et al. 2012; Zona et al. 2016)
and MDPV (Beck et al. 2015; Borek and Holstege 2012; Kesha et al. 2013; Mugele et al.
2012; Murray et al. 2012; Valsalan et al. 2017; Young et al.), and, as observed for MDMA
(Hysek et al. 2012; Sprague et al. 2005), the α- and β-adrenergic antagonist carvedilol
effectively blocked the hyperthermic effect of ‘bath salts’ containing methylone and 4-MMC
(Zona et al. 2016). However, in vivo animal studies addressing the effects of these
substances on body temperature are controversial, showing variations dependent on dose,
species, sex and experimental conditions, especially ambient temperature. For instance,
MDPV induces hyperthermia in adult male F344/N, LEW and Sprague-Dawley rats but not
in adolescent male Sprague-Dawley rats (King et al. 2014; Merluzzi et al. 2014). However,
Aarde et al. (2015) found a dose-dependent decrease in body temperature of MDPV- and
α-PVP-treated male Wistar rats. Adam et al. (2014)  showed that a 10 mg/kg dose of MDPV
had no effect on the core body temperature of mixed sex C57BL/6j mice, while Anneken et
al. (2015) found that 30 mg/kg of MDPV elicited a hyperthermia in female mice of the same
species at normal ambient temperature. In contrast, the same dose was shown to induce
hyperthermia on male NIH Swiss mice but only at warm ambient temperature (28ºC)
(Fantegrossi et al. 2013; Gannon et al. 2016). Also in male NIH Swiss mice, MDPV-induced
hyperthermic effects proved to be stereoselective, with the S(+) enantiomer being generally
more potent than R(-)-MDPV (Gannon et al. 2016). Data on 4-MMC and methylone is more
consistent, with a general dose-dependent production of hyperthermia in both rats and mice
(Angoa-Perez et al. 2013; Anneken et al. 2015; Baumann et al. 2012; den Hollander et al.
2013; Kiyatkin et al. 2015; Lopez-Arnau et al. 2014a; Martinez-Clemente et al. 2014; Piao
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et al. 2015), though some in vivo studies also show transient or sustained hypothermic 
responses following 4-MMC administration, as well as a dependence of ambient 
temperature and species in the thermoregulation by this derivative (den Hollander et al. 
2013; Lopez-Arnau et al. 2015; Miller et al. 2013; Shortall et al. 2013; Shortall et al. 2016) 
Of note, Kiyatkin et al. (2015) showed that both methylone and MDPV trigger in vivo dose-
dependent brain hyperthermia accompanied by peripheral vasoconstriction, which appears 
to be a critical mechanism underlying MDMA-induced neurodamage (Kiyatkin et al. 2014). 
Drug-induced hyperthermia was also related to the hepatotoxic potential of 
amphetamines (Carvalho et al. 2010; Matsumoto et al. 2014), and in vitro data further 
confirmed that the rise in temperature exacerbates the hepatotoxic effects of MDMA, METH 
and amphetamine (Carvalho et al. 1997; Carvalho et al. 2001b; Carvalho et al. 2002a; Dias 
da Silva et al. 2014; Halpin et al. 2013; Pontes et al. 2008a).  
Of note, the rise in body temperature per se is an aggressively deleterious condition 
to the liver and brain (Ando et al. 1994; Kiyatkin 2005; Santos-Marques et al. 2006; Sharma 
2006; Skibba et al. 1991), and hyperthermia is recognized as one of the most life-
threatening effects of amphetamines intoxications, leading to serious or even fatal 
complications such as rhabdomyolysis, disseminated intravascular coagulation and 
multiorgan system failure (Carvalho et al. 2012). Considering the thermoregulatory 
properties of β-keto amphetamines, further studies regarding the influence of hyperthermia 
on the toxic effects of these substances are essential for a comprehensive treatment 
approach of ‘bath salt’-related intoxications. 
Mitochondrial dysfunction and programmed cell death 
Mitochondria play vital roles in the maintenance of cell survival: these organelles are 
the main suppliers of energy in eukaryotic cells, generating adenosine triphosphate (ATP) 
through fatty acid β-oxidation and mainly oxidative phosphorylation (Nsiah-Sefaa and 
McKenzie 2016); they are a major source of ROS and RNS, which appear to act not just as 
harmful by-products of mitochondrial respiration but also as cell signaling modulators 
(Brookes et al. 2002); they are involved in programmed cell death through the opening of 
the mitochondrial permeability transition pore, release of cytochrome c, and subsequent 
initiation of mitochondria-dependent apoptotic pathway (Wang and Youle 2009). For all 
these reasons, mitochondria are primary targets of drugs of abuse and mitochondrial 
dysfunction is a central mechanism of drug-induced toxicity in several organs, including the 
liver and the brain (Dykens and Will 2008). 
The key role of mitochondria in the hepatic and neuronal toxicity of amphetamines 
has been thoroughly reviewed over the years, and appear to involve inactivation of key 
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mitochondrial enzymes, inhibition of mitochondrial electron transport chain’s complexes, 
uncoupling of oxidative phosphorylation, oxidative modifications in mitochondrial 
macromolecules, and upstream initiation of apoptotic cell death (Barbosa et al. 2015; Brown 
and Yamamoto 2003; Cadet et al. 2007; Carvalho et al. 2010).  
Thus far, information on β-keto amphetamines-induced mitochondrial dysfunction is 
scarce. In vitro evidences suggest that cathinone derivatives elicit a time- and 
concentration-dependent decline in mitochondrial activity, as demonstrated by Wojcieszak 
et al. (2016) in neuronal, hepatic and upper airway epithelium cells exposed to α-
pyrrolidinovalerothiophenone, α-pyrrolidinooctanophenone, MDPV and its catechol and 
methylcatechol metabolites. 4-MMC was shown to reduce the basal and induced maximal 
mitochondrial respiration in neuronal cells, producing a significantly larger decrease than 
METH (den Hollander et al. 2014). Interestingly, den Hollander et al. (2015) showed that 
the effect of cathinones on the mitochondrial respiration may be related to the formation of 
membrane insoluble break down products (methylbenzamides), with the methylbenzamides 
formed from methylone and 4-MMC inducing significant decrease in the basal respiration 
at conditions where the parent compounds had little to no effects. Methylone also elicited a 
significant concentration-dependent ATP depletion in isolated rat hepatocytes, which was 
followed by membrane blebbing and cell death, and a significant dissipation of the 
mitochondrial membrane potential (Δψm) (Nakagawa et al. 2009). The ability to induce 
apoptotic cell death was demonstrated for MDPV in neuronal cells, with a concentration-
dependent rise in DNA fragmentation (Rosas-Hernandez et al. 2016a), and in several 
regions of neonatal mouse brain, with significant increase in caspase 3 activation (Adam et 
al. 2014). More recently, Matsunaga et al. (2017) assessed the ability of several α-
pyrrolidinophenone derivatives to induce apoptosis in human aortic epithelial cells, showing 
a general increase in caspase 3 activation after 48 h of exposure. Furthermore, the neuronal 
cell death induced by 4-MMC was significantly reversed in cells overexpressing the anti-
apoptotic B-cell lymphoma 2 (Bcl-2) gene, supporting the contribution of apoptotic cell death 
to the neurotoxicity of this cathinone derivative (den Hollander et al. 2015). 
In addition to apoptosis, autophagy is another programmed cell death pathway by 
which cells dispose of damaged organelles and non-functional proteins, and that appears 
to be upregulated in response to stress or a toxic insult, ultimately leading to cell death, 
either by cellular atrophy and collapse of cellular functions (autophagic cell death), or 
through the activation of apoptotic or necrotic cell death (Galluzzi et al. 2008).   
The increase in autophagic activation triggered by METH and MDMA has been 
related to their neurotoxic effects, although the role of autophagy in the observed 
neurodegeneration remains a debatable matter, with evidences supporting the 
neuroprotective role of autophagy  (Castino et al. 2008; Lin et al. 2012; Mercer et al. 2017; 
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Pitaksalee et al. 2015), as well as the potentiation of neurotoxicity due to instigation of 
autophagic cell death (Li et al. 2016; Li et al. 2014). However, there are currently no studies 
addressing the ability of β-keto amphetamines to trigger autophagy, or its involvement in 
either neurotoxic or hepatotoxic effects of these substances.  
Oxidative stress 
Recent studies support the ability of β-keto amphetamines to trigger oxidative stress 
in different cell types, including neuronal cells, characterized by an overall increase in ROS 
and RNS production (Matsunaga et al. 2017; Rosas-Hernandez et al. 2016a; Rosas-
Hernandez et al. 2016b). However, the mechanisms underlying the elicited oxidative stress 
are not fully elucidated. 
Most of the previously described putative cellular mechanisms of hepato- and 
neurotoxicity of β-keto amphetamines may lead to an increase in intracellular oxidative 
stress, in comparable ways to amphetamines (Carvalho et al. 2012). 
For instance, catecholamine metabolism and non-enzymatic autoxidation lead to the 
production of highly reactive metabolites, as well as ROS and RNS that are capable of 
initiating oxidative damage (Costa et al. 2011; Eisenhofer et al. 2004; Miller et al. 1996). 
As aforementioned, a MDMA-like metabolic bioactivation may be hypothesized for 
methylenedioxy β-keto amphetamines, such as methylone and MDPV, with oxidation of 
their catechol metabolites, which were already validated both in vitro and in vivo (Kamata 
et al. 2006; Meyer et al. 2010a; Pedersen et al. 2013; Strano-Rossi et al. 2010), and 
formation of unstable ortho-quinones that enter redox cycling with their ortho-semiquinone 
radicals with consequent production of ROS and RNS (Capela et al. 2006).  
Microglial activation is known to underlie the neuroinflammatory effects of 
amphetamines (Carvalho et al. 2012; Halpin et al. 2014), but it also mediates the release of 
reactive species, including O2.- and nitric oxide (NO), that potentiate neuronal oxidative 
damage (Thomas et al. 2004). β-Keto amphetamines, on the other hand, appear to have 
little to no effect on microglia, but evidences suggest that they may trigger astrocyte 
activation (Anneken et al. 2017; Lopez-Arnau et al. 2014a; Lopez-Arnau et al. 2014b; 
Martinez-Clemente et al. 2014). Astrocytes are the most numerous and diverse specialized 
glial cells in the CNS, playing several roles in the preservation of CNS health, including the 
regulation of local blood flow and the maintenance of transmitter homeostasis required for 
a healthy synaptic transmission (Sofroniew and Vinters 2010). Among the list of detrimental 
effects following excessive astrocyte activation, also referred as reactive astrogliosis, 
stands out the generation of neurotoxic levels of reactive species, in particular NO, as a 
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result of the upregulation of the inducible form of NO synthase, contributing to delayed 
neuronal death (Swanson et al. 2004). 
Hyperthermia is also known to exacerbate the oxidative stress triggered by 
amphetamines in both liver and brain models (Barbosa et al. 2014; Carvalho et al. 2001b; 
Pontes et al. 2008b). As aforementioned, hyperthermia is a common complication following 
exposure to cathinones (Borek and Holstege 2012; Pearson et al. 2012) and, despite the 
lack of in vitro experimental evidences regarding the potential effects of the rise in body 
temperature on β-keto amphetamines-induced neuro- and hepatotoxicity, in vivo studies 
show that the effects of MDPV on locomotor stimulation are significantly affected by ambient 
temperature (Fantegrossi et al. 2013; Gannon et al. 2016). Importantly, hyperthermia per 
se triggers a prooxidant state, characterized by the depletion of the cellular antioxidant GSH 
and consequent rise in the oxidized form, glutathione disulfide (GSSG), potentiation of lipid 
peroxidation, and increased conversion of xanthine oxidase through proteolysis from the 
physiological type-D to type-O form, which generates O2.- and H2O2 by the reduction of 
oxygen during oxidation of xanthine or hypoxanthine (Kiyatkin 2005; Santos-Marques et al. 
2006; Sharma 2006; Skibba et al. 1991). 
There is a complex cellular crosstalk involving intracellular Ca2+, the mitochondria 
and ROS, in which the ROS generated as a result of an oxidative insult elicits Ca2+ overload 
in the mitochondria, triggering the stimulation of NO synthase and consequent generation 
of NO, which in turn inhibits the complex IV of the electron transport, leading to 
mitochondrial dysfunction and production of more ROS at complex III, thus propagating the 
oxidative damage (Brookes et al. 2004). The work of Votyakova and Reynolds (2001) 
showed that the majority of the ROS generation in rat brain mitochondria results from the 
inhibition of the electron transport at complex I, a mode of action that is also responsive to 
depolarization of the Δψm. For this reason, substances that interfere with mitochondrial 
respiration, either by increasing the Ca2+ levels, inhibiting the mitochondrial electron 
transport or disrupting the Δψm, may effectively lead to mitochondrial ROS generation. Of 
note, Nakagawa et al. (2009) showed that methylone significantly disrupts the Δψm in rat 
hepatocytes, leading to a depletion of ATP levels. However, there are few studies 
addressing the effects of synthetic cathinones on mitochondrial functions, and besides the 
suggestion of decreased mitochondrial activity in treated cells (den Hollander et al. 2014; 
den Hollander et al. 2015; Wojcieszak et al. 2016), little is known about the mechanisms 
underlying these effects or their relevance in mitochondrial ROS production and oxidative 
stress in general.  
An antioxidant deficiency can also result in oxidative stress (Davies 2000). There is 
mounting evidence that amphetamines trigger depletion of the antioxidant defense systems, 
which includes the drop of cellular GSH levels (Carvalho et al. 2002a; Pontes et al. 2008a), 
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downregulation of the antioxidant family of peroxiredoxins and upregulation of peroxiredoxin 
reducing systems (Chen et al. 2007), and disturbance in the activity and/or expression of 
several antioxidant enzymes such as catalase (Zhou et al. 2003), Cu-Zn superoxide 
dismutase (El-Tawil et al. 2011; Jayanthi et al. 1999), glutathione reductase (Carvalho et 
al. 2001a), glutathione peroxidase (Carvalho et al. 2002a; Jayanthi et al. 1998), and 
glutathione S-transferase (Pontes et al. 2008a). Accordingly, 4-MMC was also shown to 
induce oxidative stress in the brain of rats and mice, characterized by increased lipid 
peroxidation and variations in the expression of catalase, NO synthase, superoxide 
dismutase, and glutathione peroxidase (Budzynska et al. 2015; Ciudad-Roberts et al. 2016; 
Lopez-Arnau et al. 2015). 
In summary, aside from the pharmacological mechanisms of action of β-keto 
amphetamines, current knowledge on the cytotoxic mechanisms underlying the hepatotoxic 
and neurotoxic effects of these novel drugs of abuse is still scarce and requires further 
assessment. 
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Section II – Objectives 
Considering the prominent rise of NPS abuse worldwide, the information presented 
in the general introduction regarding the potential for adverse effects from β-keto 
amphetamines use, and the scarcity of experimental data on their cellular toxicity, the 
necessity of conducting a study addressing the mechanisms underlying the toxic effects of 
these psychostimulant substances became apparent. 
Of particular concern is the target-organ toxicity of β-keto amphetamines, namely 
the hepato- and neurotoxic effects, as clinical evidence suggests that both the liver and the 
CNS are major targets of these NPS. 
 β-Keto amphetamines share many resemblances to classical amphetamines, 
particularly with regards to chemical structure and pharmacological effects, and, thus, 
similar toxicological effects may also be anticipated. 
Hence, the present thesis aimed at improving the current knowledge on the cellular 
mechanisms underlying the toxicity of β-keto amphetamines by means of in vitro cell models 
suitable for the assessment of the cellular hepatic and neuronal effects of these prominent 
recreational drugs, hopefully contributing for the development of a comprehensive treatment 
approach of β-keto amphetamine-related intoxications. 
The specific purposes of this thesis were: 
1. To clarify the mechanisms underlying the hepatotoxicity of several commonly
abused β-keto amphetamine derivatives, including methylone, MDPV,
pentedrone and 4-MEC, using primary cultured rat hepatocytes and the
human hepatic cell line HepaRG, and compare them to the well-known
hepatotoxic amphetamine derivative, MDMA;
2. To assess the effects of hyperthermia on the observed hepatotoxicity of β-
keto amphetamines by comparison of effects on primary cultured rat
hepatocytes under normo- and hyperthermic conditions exposed to MDPV, a
derivative with documented clinical hyperthermic response;
3. To elucidate the cellular neurotoxic effects of methylone and MDPV in a
comparative study to MDMA, using undifferentiated and dopaminergic
neuronal SH-SY5Y cells, with special focus on oxidative stress, mitochondrial
dysfunction and cell death mechanisms;
4. To determine the role of autophagy in β-keto amphetamines-induced
neurotoxicity and its relationship with oxidative stress and apoptosis.
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Manuscript I. Characterization of hepatotoxicity mechanisms 
triggered by designer cathinone drugs (β-keto amphetamines) 
Reprinted from Toxicological Sciences 
153(1):89-102 (doi:10.1093/toxsci/kfw105). Copyright 
(2016) with kind permission of Oxford Journals. 
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ABSTRACT
The use of cathinone designer drugs in recreational settings has been associated with severe toxic effects, including liver
damage. The precise mechanisms by which cathinones induce hepatotoxicity and whether they act by common pathways
remain to be elucidated. Herein, we assessed the toxicity of the cathinones methylone, pentedrone, 3,4-
methylenedioxypyrovalerone (MDPV) and 4-methylethcathinone (4-MEC) in primary rat hepatocytes (PRH) and HepaRG
cells, and compared with that of 3,4-methylenedioxymethamphetamine (MDMA). MDPV and pentedrone were significantly
more toxic than MDMA, while methylone was the least cytotoxic compound. Importantly, PRH revealed to be the most
sensitive experimental model and was thus used to explore the mechanisms underlying the observed toxicity. All drugs
elicited the formation of reactive oxygen and nitrogen species (ROS and RNS), but more markedly for methylone,
pentedrone and 4-MEC. GSH depletion was also a common effect at the highest concentration tested, whereas only MDPV
and pentedrone caused a significant decrease in ATP levels. The antioxidants ascorbic acid or N-acetyl-L-cysteine partially
attenuated the observed cell death. All cathinones triggered significant caspase activation and apoptosis, which was
partially reversed by the caspase inhibitor Ac-LETD-CHO. In conclusion, the present data shows that (1) cathinones induce
in vitro hepatotoxic effects that vary in magnitude among the different analogues, (2) oxidative stress and mitochondrial
dysfunction play a role in cathinones-induced hepatic injury, and (3) apoptosis appears to be an important pathway of cell
death elicited by these novel drugs.
Key words: synthetic cathinones; b-keto amphetamines; hepatotoxicity; oxidative stress; apoptosis.
In the past few decades, classical illicit drugs have been gradu-
ally losing ground to new psychoactive substances (NPS), espe-
cially among young adult users in recreational settings (Burns
et al., 2014; Helander et al., 2014; Maxwell, 2014). Synthetic cathi-
nones, often deceivingly labelled as ‘bath salts’, are a major
family of NPS that encompasses a large number of psychoactive
substances deliberately designed to mimic the effects of con-
trolled drugs of abuse (Karila et al., 2015). According to the
European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), synthetic cathinones were the largest category of
NPS identified in Europe in 2014, with 31 new derivatives
reported for the first time that year (EMCDDA, 2015a). 3,4-
Methylenedioxymethcathinone (methylone), 3,4-methylene-
dioxypyrovalerone (MDPV), a-methylaminovalerophenone
(pentedrone) and 4-methylethcathinone (4-MEC) are four of the
most commonly used derivatives worldwide (Elliott and Evans,
VC The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
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2014; Moran and Seely, 2014). Together, these four derivatives
covered over 40% of all samples of synthetic cathinones seized
in Europe in 2013 (EMCDDA, 2015b), and were in the top five of
most consumed synthetic cathinones in the United States in
the same year (DEA, U.S 2014). Along with the paradigm shift in
recreational drug use, several reports of intoxication and deaths
related to the use of designer cathinone drugs have been de-
scribed in Maskell et al. (2011), Regunath et al. (2012), Ross et al.
(2011), and in particular with these 4 derivatives (Gil et al., 2013;
Murray et al., 2012; Pearson et al., 2012; Sykutera et al., 2015), rais-
ing a global health concern over the abuse of these NPS.
Chemically, synthetic cathinones are related to amphet-
amines, bearing a ketone group at the b-position of the side
chain, and are therefore often named b-keto amphetamines
(Prosser and Nelson, 2012). Functional group substitutions to
the core structure of the parent cathinone compound have
yielded a large number of NPS on the street and cyber drug mar-
kets (EMCDDA, 2015b), which can be separated into different
chemical families based on the substitutions made (Valente
et al., 2014). The most basic derivatives are the N-alkylated de-
rivatives, which may present alkyl substitutions in the a-carbon
of the side chain and in the benzyl ring. When a 3,4-methylene-
dioxy group is added to the benzyl ring, cathinones structurally
similar to 3,4-methylenedioxyamphetamines are produced
(Kelly, 2011). The pyrrolidinophenone-like family encompasses
derivatives containing a pyrrolidine substitution in the nitrogen
atom (Westphal et al., 2007), which can be further modified to
combine the pyrrolidine moiety and a 3,4-methylenedioxy ring
(Kelly, 2011), yielding more complex cathinones. Importantly,
the apparent boom in NPS creates a new challenge from a
chemical and biological point of view, as structures, solubility
and redox potential of the designer drugs differ between NPS
and the prototype drugs they are derived from (den Hollander
et al., 2014). Generally, the presence of the b-keto group in-
creases the polarity of cathinone derivatives, resulting in a de-
crease of their ability to cross lipid bilayer membranes, such as
the blood-brain barrier (BBB) (Simmler et al., 2013, 2014), which
consequently decreases the potency of synthetic cathinones
when compared with their related amphetamines. For this rea-
son, users often resort to higher doses or binge consumption of
cathinone derivatives to attain equipotent effects (Prosser and
Nelson, 2012). The polarity issue occurs mainly with the N-alky-
lated derivatives, but not so much with the pyrrolidine family of
cathinones, since the presence of the pyrrolidine ring greatly re-
duces the polarity of these compounds (Coppola and Mondola,
2012), resulting in a greater transport of derivatives such as
MDPV through the BBB.
Designer cathinone drugs exert their stimulant effects by
interacting with monoamine membrane transporters, namely
dopamine (DA), norepinephrine (NE), and serotonin (5-HT) trans-
porters (Baumann et al., 2012; Cozzi et al., 1999; Eshleman et al.,
2013; Kelly, 2011; Lopez-Arnau et al., 2012). However, considerable
differences have been found in the affinities towards these trans-
porters among the different substituted cathinones in vitro.
Methylone, like amphetamines (Sitte and Freissmuth, 2010), acts
as a substrate for monoamine transporters to induce reverse
transport of neurotransmitters, which consequently leads to in-
creased concentration of these biogenic amines in the synaptic
cleft, but with weaker potency than MDMA (Baumann et al.,
2012). Conversely, MDPV and pentedrone function as pure trans-
porter blockers, resembling cocaine, inhibiting the uptake of DA
and NE, with minimal effects on 5-HT uptake (Baumann et al.,
2013; Simmler, et al., 2014). 4-MEC presents a mixed mode of in-
teraction, with a potency of inhibition similar to cocaine, but also
a 5-HT release comparable to MDMA (Simmler, et al., 2014). As a
more dopaminergic and noradrenergic drug, MDPV induces
MDMA- and cocaine-like subjective effects, including increased
energy, but limited euphoria and only mild empathogenic effects
(Deluca et al., 2009), while methylone, 4-MEC and pentedrone
users report more MDMA-like stimulating effects, such as eupho-
ria, openness and increased sociability and sexual drive (Van
Hout, 2014; www.drugs-forum.com). Whereas variations on the
mode of action of synthetic cathinones appear to be determined
by their chemical structure (Simmler, et al., 2014), it remains to be
studied whether the mechanisms of toxicity elicited by this group
of NPS are also reliant on their structure. Common symptoms of
‘bath-salts’-induced intoxications are consistent with sympa-
thetic stimulation, including hypertension, hyperthermia, tachy-
cardia and seizures, and often result in end-organ effects and
death (Coppola and Mondola, 2012; Prosser and Nelson, 2012).
Since ingestion is one of the preferable routes of administration
for this group of NPS (Valente et al., 2014), the first-pass effect ren-
ders the liver more susceptible to toxic injury, as ascertained by
clinical evidences of cathinones-induced hepatic dysfunction
(Borek and Holstege, 2012; Carbone et al., 2013; Fro¨hlich et al.,
2011; Murray, et al., 2012; Pearson, et al., 2012) and organ accumu-
lation (Marinetti and Antonides, 2013; Sykutera, et al., 2015).
Therefore, the aim of this study was to investigate in vitro the ef-
fects and mechanisms underlying the hepatotoxicity of four de-
signer cathinone drugs belonging to different chemical families.
The structures and some physicochemical properties, namely
the partition coefficient (log P) and the acid dissociation constant
(pKa), of cathinones herein studied are presented in Table 1.
Methylone, which belongs to the group containing a 3,4-methyle-
nedioxy ring, only differs from MDMA by the presence of the b-
keto group, thus earning the common designation of bk-MDMA.
MDPV, from the 3,4-methylenedioxy-N-pyrrolidine family, is
characterized by a side chain alkylation (butylation), which is
also found in pentedrone. Pentedrone is included in the N-alky-
lated family, with a N-methyl group, as well as 4-MEC, which pre-
sents a methyl group in the benzyl ring, and a N-ethyl group.
Considering the structural similarity of cathinone derivatives and
MDMA, a comparative study was conducted. The specific objec-
tives of this study were to (1) evaluate the cytotoxic potential of
selected cathinones in primary rat hepatocytes (PRH) and
HepaRG cells, and compare it to MDMA, (2) provide further chem-
ical characterization by assessing the redox potential of cathi-
none derivatives, (3) elucidate the cellular mechanisms
underlying the observed hepatotoxicity, specifically the induction
of oxidative stress and the interference with mitochondrial func-
tion, and (4) characterize the cell death pathways involved in
liver damage elicited by these NPS.
MATERIALS ANDMETHODS
Chemicals
Collagenase from Clostridium histolyticum Type IA, Williams’ E
medium, dexamethasone, gentamicin, insulin solution from
bovine pancreas (10 mg/ml), hydrocortisone 21-hemisuccinate
sodium salt, thiazolyl blue tetrazolium bromide (MTT), sodium pyr-
uvate, b-nicotinamide adenine dinucleotide reduced disodium salt
hydrate (b-NADH), L-glutathione reduced (GSH) and L-glutathione
oxidized disodium salt (GSSG), b-nicotinamide adenine dinucleo-
tide 20-phosphate reduced tetrasodium salt hydrate (b-NADPH),
5,50-dithiobis(2-nitrobenzoic acid) (DTNB), 20,70-dichlorodihydro-
fluorescein (DCFH) and 20,70-dichlorodihydrofluorescein diacetate
(DCFH-DA), adenosine triphosphate (ATP), luciferase from Photinus
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pyralis (firefly) and D-luciferin sodium salt, N-acetyl-Asp-Glu-Val-
Asp-p-acetyl-Ile-Glu-Thr-Asp-p-nitroanilide (Ac-IETD-pNA), and
N-acetyl-Leu-Glu-His-Asp-p-nitroanilide (Ac-LEHD-pNA), N-acetyl-
Leu-Glu-Thr-Asp-aldehyde (Ac-LETD-CHO), N-acetyl-L-cysteine
(NAC), ascorbic acid (AA) and bovine serum albumin were pur-
chased from Sigma Aldrich (St Louis, Missouri). Heat-inactivated
fetal bovine serum (FBS), antibiotic mixture of penicillin/streptomy-
cin (10,000 U/ml/10,000 mg/ml), fungizone (250 mg/ml), and Hank’s
balanced salt solution (HBSS) were obtained from GIBCO Invitrogen
(Barcelona, Spain). All other chemicals of analytical grade were
purchased from Merck (Darmstadt, Germany). Hydrochloride salts
of methylone, MDPV, pentedrone and 4-MEC were purchased
online from the Sensearomatic website (http://sensearomatic.net,
currently unavailable), during March 2013. MDMA was extracted,
purified, and converted to the respective hydrochloride salt at
UCIBIO-REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy,
Porto, Portugal, from high purity MDMA tablets provided by the
Portuguese Criminal Police Department. The salts were fully char-
acterized by mass spectrometry, NMR and elemental analysis (data
not shown), and purity was>98%.
In Vitro Hepatotoxicity Cellular Models
HepaRG cell culture. HepaRG cell line was supplied by Life
Technologies Europe BV (Bleiswijk, the Netherlands) and
routinely maintained in complete Williams’ E medium, supple-
mented with 10% FBS, 100 U/ml/100 mg/ml penicillin/streptomy-
cin, 5 lg/ml insulin and 50lM hydrocortisone 21-hemisuccinate,
and incubated at 37C, with 5% CO2. Cells were subcultured over
6 passages (passages 9–14). When reaching confluence, 2%
DMSO was added to the culture medium to allow cell differen-
tiation hepatocyte-like cells into adult hepatocytes and biliary
epithelial cells. After a 2-week differentiation period, cells were
seeded in 96-well plates at high density (0.45 106 cells/cm2),
and incubated overnight at 37C, with 5% CO2, to allow cell
adhesion.
Isolation and primary culture of rat hepatocytes. Male Wistar Han
rats weighing 210–250 g were purchased from Charles-River
Laboratories (Barcelona, Spain). Surgical procedures were con-
ducted under isoflurane-induced anesthesia in an isolated sys-
tem, and carried out between 10.00 and 11.00 am. All
experiments were approved by the Ethics Committee of the
Faculty of Pharmacy, University of Porto.
Isolated rat hepatocytes were obtained through a collage-
nase perfusion, as previously described in Valente et al.
(forthcoming). Cell viability was assessed through the trypan
blue exclusion test and was always higher than 80%. A suspen-
sion of 0.5 106 viable cells/ml was cultured in 6- or 96-well
plates at approximately 0.1 106 cells/cm2, in Williams’ E
medium, supplemented with 10% FBS, 100 U/ml penicillin, 100
mg/ml streptomycin, 5 lg/ml insulin, 50 lM dexamethasone,
100 lg/ml gentamicin, and 2.5 lg/ml fungizone, and incubated
overnight at 37C, with 5% CO2, to allow cell adhesion.
Drug Treatments
Primary cultured hepatocytes and HepaRG cells were exposed
for 24 h to the four cathinones — methylone, MDPV, pentedrone
and 4-MEC — and MDMA, at a wide concentration range, from
0.05 to 10 or 20 mM, in order to obtain a complete
concentration-response curve in the MTT reduction assay. All
incubations with the test drugs were performed in serum-free
medium. For further assays, performed only in PRH, the five
compounds were tested at a narrower range that includes low-
effect to worst-case approach concentrations (0.2–1.6 mM). To
TABLE 1. Chemical Structures and Logarithmic Values of the Acid Dissociation Constant (pKa) and the Partition Coefficient (log P) of the
Studied Compounds
*pKa and log P values were calculated using MarvinSketch v.16.2.29.0 software (ChemAxon, Budapest, Hungary).
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evaluate the effect of cytochrome P450 2D6 isoenzyme (CYP2D6)
inhibitor quinidine, the antioxidants AA and NAC, or the cas-
pases inhibitor Ac-LETD-CHO, a pre-incubation of 1 h was per-
formed, followed by a co-incubation with MDMA or the
synthetic cathinones at 1.6 mM.
Characterization of the Reducing Properties of Synthetic Cathinones
The reducing power of cathinone derivatives and MDMA was
determined as described by Berker et al. (2007). Briefly, various
concentrations (0.05–50 mM) of each compound were mixed
with 0.2 M sodium phosphate buffer (pH 6.6) and 1% potassium
ferricyanide (w/v). The mixture was incubated at 50C for
20 min. After incubation, 10% tricloroacetic acid (w/v) was
added and the mixture was centrifuged for 8 min at 1000 rpm,
at 4C. The upper layer was mixed with equal volume of deion-
ised water and 0.1% of ferric chloride (w/v). Depending on the
reducing potential of each compound, the yellow color of the
initial solution changes to various shades of green due to the
formation of Prussian blue, KFe[Fe(CN)6], from the reduction of
the Fe3þ/ferricyanide complex to the ferrous form. Therefore,
the formation of Prussian blue at 700 nm provides a measure-
ment of the Fe2þconcentration in each solution. Results
were obtained from three independent experiments, run in
duplicate.
Cell Viability Assessment
MTT reduction and LDH leakage assays were performed as pre-
viously described (Valente et al., forthcoming). Data were
obtained from at least five independent experiments, per-
formed in triplicate, and normalized to no treatment and 1%
Triton X-100 controls.
Characterization of Hepatotoxicity Mechanisms Triggered by
Cathinone Derivatives
Intracellular ROS and RNS formation. Intracellular production of
reactive oxygen (ROS) and nitrogen (RNS) species was eval-
uated by the inclusion of the probe DCFH-DA (Valente et al.,
forthcoming). As determined by incubation of MDMA or cathi-
none derivatives for 24 h with DCFH, in the absence of cells, no
interference with the probe was noted at any tested concentra-
tion (data not shown). Results were obtained from six inde-
pendent experiments, performed in triplicate, and normalized
to cells with no treatment.
Intracellular GSH and GSSG levels. Total and oxidized glutathione
(GSSG) intracellular contents were determined by the DTNB-
GSSG reductase recycling assay (Valente et al., forthcoming).
GSH concentrations were calculated as follows: [GSH]¼ [total
glutathione] – 2*[GSSG]. GSH and GSSG levels were normalized
to total protein contents, as determined through the Lowry
method. Results were obtained from at least four independent
experiments, run in duplicate.
Intracellular ATP levels. Intracellular levels of ATP were quantified
through a bioluminescence assay based on the emission of light
from the reaction of ATP and luciferin, catalyzed by the enzyme
luciferase (Valente et al., forthcoming). No interference with the
probe was noted at any tested concentration, as determined by
measurement of the bioluminescence of MDMA or cathinone
derivatives solutions with luciferin-luciferase assay solution in
the absence of cells (data not shown). Results were obtained
from at least four independent experiments, run in duplicate.
ATP contents were normalized to total protein.
Characterization of Cell Death Pathways Triggered by Synthetic
Cathinones
Caspase 3, 8, and 9 activity. The activity of caspases 3, 8, and 9
was determined in the cytoplasmatic fractions of primary cul-
tured hepatocytes after a 24 h exposure to MDMA or the cathi-
none derivatives, as previously described (Valente et al.,
forthcoming). Results were obtained from five independent
experiments, run in duplicate. Protein contents on the cell
lysate were measured using the Bio-Rad RC DC protein assay kit
(Hercules, CA, USA), with albumin as the standard.
Hoechst 33342/propidium iodide fluorescent staining. Hepatocytes
undergoing apoptosis or necrosis were identified based on
nuclear morphological changes, using a cell-permeant nuclear
counterstain that emits blue fluorescence when bound to DNA,
Hoechst 33342, and a membrane impermeant nuclear dye that
emits red fluorescence only in dead cells, PI (Valente et al.,
forthcoming).
Statistical Analysis
Curves of normalized mortality values as a function of concen-
tration, obtained through the MTT reduction assay, were con-
structed and analyzed as described by Dias da Silva et al. (2014),
with a modified logit function applied as follows: Y¼ hmax/
(1þ exp ( h1 h2 log(x))), where hmax is the maximal observed
effect, x is the concentration of the test drug, h1 is the parameter
for the location, and h2 is the slope parameter. Statistical uncer-
tainties are expressed as 95% confidence intervals (CI).
Additionally, comparisons between curves (hmax, h1 and h2) were
performed using the extra sum-of-squares F-test. For further
assays, results are presented as mean6 standard error of the
mean (SEM). Normality of the data distribution was assessed by
the D’Agostino and Pearson omnibus normality test. Multiple com-
parisons within each compound (concentration as a variable) or
between each synthetic cathinone and MDMA were performed
through one-way ANOVA analysis, followed by Fisher’s LSD posthoc
test. Non-linear curve fitting and all statistical calculations were
performed using GraphPad Prism 6 (version 6.01) for Windows. P-
values lower than .05 were considered statistically significant.
RESULTS
PRH Is a More Suitable In VitroModel than HepaRG to Study the
Hepatotoxicity Elicited by Synthetic Cathinones
The hepatotoxic potential of methylone, MDPV, pentedrone and
4-MEC was assessed in PRH and HepaRG cells through the MTT
reduction assay. Figure 1 presents the concentration–response
curves for each drug in the two used in vitro models. A summary
of the calculated half maximal effective concentrations (EC50)
of each compound, and other parameters from the nonlinear
regression fit are provided in Supplementary Table S1. HepaRG
cells proved to be significantly more resistant to the toxicity eli-
cited by all five drugs, with curve fits substantially shifted to the
right of PRH ones (P < .0001). For all four cathinones, but not
MDMA, HepaRG cells presented steeper curves, with signifi-
cantly higher slopes (P < .01 vs. PRH, when curves were com-
pared for h2), which is representative of a higher variation of
mortality within smaller concentration ranges in this in vitro
model.
In order to determine whether the discrepant results
between the two hepatic cellular models were due to differen-
ces in their intrinsic metabolic capacities, an additional study
was conducted in the presence of quinidine, a CYP2D6 inhibitor.
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As depicted in Table 2, quinidine partially, but significantly,
reversed cell death induced by cathinone derivatives in PRH,
with a significant increase in MTT reduction for 1.6 mM methyl-
one, MDPV, and pentedrone (P < .0001). No significant differen-
ces were found between HepaRG cells exposed to the
cathinones in the presence or absence of the CYP2D6 inhibitor
(data not shown).
Due to the higher sensitivity of PRH to the cytotoxicity eli-
cited by the tested cathinones, all further toxicological evalua-
tions were carried out in this cell model.
Synthetic Cathinones Elicit Hepatotoxicity in Vitro in a
concentration-Dependent Manner, with Variable Potency among
Derivatives
Exposure of cells to synthetic cathinones resulted in
concentration-dependent hepatotoxicity. However, cathinone
derivatives displayed different toxic potencies, as follows:
pentedroneMDPV> 4-MEC>methylone. Methylone was the
least cytotoxic drug in both cell models, with EC50 values of
1.262 and 5.623 mM in PRH and HepaRG cells, respectively.
MDPV and pentedrone were the most toxic compounds in
HepaRG cells (EC50 of 2.432 and 3.405 mM) and PRH (EC50
of 0.756 and 0.656 mM, respectively). For both models, these
two cathinones were even more hepatotoxic than MDMA (EC50
of 3.854 and 1.070 mM in HepaRG and PRH, respectively; P < .05).
The toxic potential of 4-MEC was similar to MDMA in HepaRG
cells (EC50 of 3.905 mM), but significantly higher in the primary
culture (EC50 of 0.835 mM; P < .01).
In order to validate MTT reduction data obtained for PRH
model, LDH leakage was assessed, as an unbiased test and indi-
cator of cell membrane integrity, under equal experimental con-
ditions. Results obtained from the LDH leakage assay are
presented in Figure 2. In accordance to the MTT reduction data,
a concentration-dependent increase in extracellular LDH was
observed for all compounds. At 1.6 mM, after a 24 h exposure
period, MDPV induced an increase on LDH leakage significantly
FIG. 1. Nonlinear regression models for the cell death induced by MDMA, methylone, MDPV, pentedrone, and 4-MEC in PRH and HepaRG cells, as evaluated by the MTT
reduction assay after 24 h exposure. The mean effects were fitted to the logit function. Dotted lines represent the 95% confidence band of each fit. Results were obtained
from at least four independent experiments, performed in triplicate.
TOXICOLOGICAL SCIENCES, 2016 | 5
65
higher than MDMA (56.0163.61% for MDPV vs. 34.786 2.82% for
MDMA, P < .0001). At this concentration, 4-MEC, pentedrone
and methylone were, in this order, significantly less effective
than MDMA (28.3562.92, 27.8662.28, and 20.6862.70%,
respectively).
Synthetic Cathinones Have a Strong Reducing Potential
The reducing power assay is often used to evaluate the overall
capability of a compound to donate an electron, as compounds
with higher reducing power have superior electron-donor abil-
ity (Kohen and Nyska, 2002). As depicted in Figure 3, all four
cathinones presented a concentration-dependent reducing
potential, in the following order of potency: pentedrone
 4-MEC>methylone>MDPV. To attain a reducing power of 0.5
(Abs¼ 0.500), the concentrations of cathinones required were
4.16160.009, 4.23060.010, 6.04760.026, and 40.45160.700 mM
for pentedrone, 4-MEC, methylone and MDPV, respectively.
MDMA showed an almost negligible reducing power, with an
absorbance of 0.04260.001 for the highest concentration tested,
50 mM.
Synthetic Cathinones Trigger Oxidative Stress in PRH, and Cell
Death Is Partially Reversed by Antioxidants
In order to determine the role of oxidative stress in cathinones-
induced hepatotoxicity, the formation of ROS and RNS and the
intracellular levels of GSH and GSSG were measured in PRH
exposed to the cathinone derivatives for 24 h. Our data show
that all four cathinone derivatives were capable of stimulating
the production of ROS and RNS (Fig. 4). MDMA and MDPV were
the least effective compounds, eliciting identical increase of
ROS and RNS, only significant at the higher concentration tested
(1.236 0.04 and 1.2460.07 fold increase over control, P < .0001).
Methylone, 4-MEC and pentedrone induced a significant
increase of ROS and RNS production, already observable at a
concentration as low as 0.4 mM (1.106 0.02, 1.146 0.03, and
1.1760.02-fold increase over control, respectively, P < .05). At
1.6 mM, ROS and RNS production for pentedrone was exten-
sively greater when compared with control (1.5660.07 fold
increase over control, P < .0001) and to MDMA at the same con-
centration. As depicted in Figure 5A, and in accordance to the
prior results, pentedrone was also the most effective compound
in decreasing the intracellular levels of GSH (23.7462.19
at 1.6 mM vs. 43.896 4.24 nmol/mg of protein in control cells,
P < .0001), which is a primary cellular antioxidant. However, the
GSH depletion induced by pentedrone was not accompanied by
corresponding increases in GSSG levels (Fig. 5B). For the other 4
drugs, a general decrease in GSH levels was followed by an
increase in the oxidized form, in an apparent concentration-
dependent manner. Nonetheless, no significant differences
were observed in the GSH intracellular concentration between
any of the synthetic cathinones and MDMA.
To further define the role of oxidative stress in cathinones-
induced cell death, two well-described antioxidants were tested
in combination with the drugs at 1.6 mM, the concentration at
FIG. 2. Extracellular LDH quantification, 24 h after exposure of PHR to MDMA, methylone, MDPV, pentedrone, and 4-MEC. Results were obtained from 6 independent
experiments, performed in triplicate. *P < .05, ** P < .01, *** P < .001, **** P < .0001 versus control. # P < .05, ## P < .01, #### P <.0001 versus MDMA.
FIG. 3. Nonlinear regression models for the reducing power of MDMA, methyl-
one, MDPV, pentedrone, and 4-MEC. The mean effects were fitted to the logit
function. Dotted lines represent the 95% confidence band of each fit. Results
were obtained from three independent experiments, performed in duplicate.
TABLE 2. Cell viability, as evaluated by the MTT reduction assay after a 24 h exposure of PHR to MDMA, methylone, MDPV, pentedrone and
4-MEC individually (1.6 mM), or in combination with 10 mM quinidine, 1 mM AA, 1mM NAC, or 100 mM Ac-LETD-CHO
Compound Individual þ 10 mM quinidine þ 1 mM AA þ 1 mM NAC þ 100 mM Ac-LETD-CHO
MDMA 26.47 6 1.96 30.79 6 2.41 39.82 6 1.51**** 33.57 6 3.06* 34.296 1.26*
Methylone 38.70 6 1.58 55.44 6 1.81**** 45.33 6 1.87* 45.76 6 1.88** 45.706 2.44**
MDPV 4.92 6 0.45 10.36 6 0.86**** 12.47 6 1.17**** 5.51 6 0.92 11.856 0.69****
Pentedrone 8.43 6 0.62 19.46 6 2.10**** 17.77 6 1.37**** 13.44 6 1.40** 18.866 1.75****
4-MEC 17.72 6 1.04 20.84 6 2.46 23.48 6 1.93* 18.25 6 1.82 26.926 3.07***
Results are presented as mean 6 SEM. *P < 0.05; **P < .01; ***P < .001; ****P < .0001 versus individual compounds.
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which all drugs induce significant increase in ROS and RNS gen-
eration and depletion of GSH levels. Results are presented in
Table 2. Individually, 1 mM AA and NAC did not show toxicity
towards PRH (data not shown). Incubation with AA significantly
reversed the cytotoxicity induced by all four synthetic cathi-
nones and MDMA (P < .05). This antioxidant effect was more
effective with MDMA, pentedrone and MDPV, with a gain of
about 13, 9, and 8% in cell viability (P < .0001 vs. individual com-
pounds at 1.6 mM), respectively. On the other hand, NAC parti-
ally attenuated MDMA, methylone and pentedrone-induced cell
death, with a decrease in cell death of about 7% for MDMA and
methylone, and 5% for pentedrone (P < .05 vs. individual com-
pounds at 1.6 mM). Despite a slight increase in cell viability in
PRH exposed to MDPV and 4-MEC in the presence of NAC, this
protective effect did not reach statistical significance.
Synthetic Cathinones Disrupt the Hepatocellular
Energetic Status
Mitochondria participate in several vital cellular functions,
including ATP generation as a source of energy for cells. As
depicted in Figure 6, after 24 h of exposure, MDMA, MDPV, and
pentedrone were able to significantly reduce ATP intracellular
levels at the highest concentration tested, 1.6 mM (P < .05). No
significant effects were observed with methylone or 4-MEC at
any concentrations. MDPV was the most effective drug, induc-
ing a decrease of almost 60% on ATP levels, from 20.6561.95
in control cells to 8.5561.67 nmol/mg of protein at 1.6 mM
(P < .001). At the same concentration, pentedrone and MDMA
induced a decline of about 40% of ATP levels. Nonetheless, no
significant differences were observed among 1.6 mM
FIG. 4. ROS and RNS production in PHR exposed to MDMA, methylone, MDPV, pentedrone, and 4-MEC, for 24 h. Results were obtained from five independent experi-
ments, performed in triplicate. * P < .05, ** P < .01, *** P < .001, **** P < .0001 versus control. # P < .05, ## P < .01, ### P < .001, #### P < .0001 versus MDMA.
FIG. 5. Intracellular levels of (A) GSH and (B) GSSG in PHR exposed MDMA, methylone, MDPV, pentedrone and 4-MEC, for 24 h. Results were obtained from five inde-
pendent experiments, performed in duplicate. * P < .05, ** P < .01, *** P < .001, **** P < .0001 versus control. # P < .05, ## P < .01, #### P < .0001 versus MDMA.
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pentedrone, MDPV and MDMA. Of note, at lower concentrations
(0.2 and 0.4 mM) an increase in ATP production was observed
for pentedrone (P < .05 vs. control).
Synthetic Cathinones Induce Apoptotic Cell Death, Which Is Partially
Reversed by a Caspase Inhibitor
To determine whether synthetic cathinones-induced hepatotoxic-
ity involves programed cell death, the activation of caspase 3 was
evaluated as a main event leading to apoptosis. In order to estab-
lish the involvement of extrinsic and/or intrinsic pathways, cas-
pases 8 and 9 activities were further analyzed. All four cathinone
derivatives induced the activation of the effector caspase, caspase
3, in a concentration-dependent manner (Fig. 7A). For methylone
and 4-MEC, this activation was only significant at the higher con-
centration tested, with an increase of about 60% over control cells
(P < .0001), but no significant differences were found when com-
pared with MDMA. Although MDMA significantly activated cas-
pase 3 already at 0.4 mM (130.89611.54%, P < .05 vs. control cells),
pentedrone and MDPV were the most effective compounds at
the higher concentration, with an activation of 254.03623.45 and
213.60613.85%, respectively, at 1.6 mM (P < .0001 vs. control cells),
which was significantly greater than that observed with MDMA
at the same concentration (177.51620.06%, P < .05). Similar
tendency was observed for caspases 8 and 9 (Figs. 7B and C), with
a more pronounced activation with pentedrone and MDPV. At
1.6 mM, these two derivatives led to an activation of 207.80618.22
and 165.3765.60% of caspase 8, and 249.14615.83 and
190.4267.04% of caspase 9 (P < .0001 vs. control cells, P < .05 vs.
1.6 mM MDMA). Results are consistent with the activation of both
intrinsic (caspase 9) and extrinsic (caspase 8) apoptotic pathways.
Thus, the protective potential of Ac-LETD-CHO, a caspase inhibitor
known to exert inhibitory effects on caspases 8 and 9, was eval-
uated. When tested individually, 100 mM Ac-LETD-CHO presented
no cytotoxicity (data not shown). The combination of the caspase
inhibitor with each compound induced a modest but significant
increase of cell viability of about 7–10% when compared with the
individual drugs at 1.6 mM (P< .05).
The triggering of apoptosis was also demonstrated with
Hoechst 33342/PI staining, with evident changes in the chroma-
tin morphology of cells exposed to the synthetic cathinones
(Supplementary Figure S1). In control cells, nuclei appear fairly
round, with regular contours, and large in size. With
the increase in concentration of the drugs, it is evident a
reduction of the nuclei size, distinctive of chromatin condensa-
tion (eg, 1.6 mM pentedrone compared with control cells), and
the presence of pyknotic nuclei, characteristic of early (without
PI label, green arrows) and late (with PI label, orange arrows)
apoptotic events. In accordance with our data on caspase 3 acti-
vation, apoptotic events in MDMA-exposed cells were apparent
already at 0.4 mM (Supplementary Figure S1). Nonetheless, a
general concentration-dependent increase of apoptotic cells
was observed for all compounds, though less evident with
methylone. Necrotic cells (large PI-labeled nuclei, red arrows)
were more evident at the two highest concentrations tested (0.8
and 1.6 mM).
DISCUSSION
Little is currently known about the potential harms arising from
the use of this new generation of cathinone-derived designer
drugs. Due to chemical similarity to long-studied amphet-
amines (particularly MDMA) and the use as alternative for these
drugs, similar pharmacodynamics and toxicological mecha-
nisms for b-keto amphetamine-derived designer drugs could be
postulated. Thus, there is a great need to study these cathinone
derivatives at a fundamental level by comparing their potencies
with related amphetamines in order to make risk assessments.
In our study, all four synthetic cathinones showed significantly
different toxicological potencies in both PRH and HepaRG cells.
Methylone was the least cytotoxic substance in both hepatic
in vitro models, significantly less potent than its non-keto ana-
logue, MDMA, whereas MDPV and pentedrone were more
potent than MDMA. 4-MEC was also more toxic than MDMA in
PRH, but no significant differences were observed between
these two compounds in HepaRG. These results may be partially
explained by chemical properties and structures of the com-
pounds in study. Methylone (bk-MDMA) presents a lower log
P value (1.08) when compared with its related amphetamine
MDMA (1.98), which indicates lower lipophilicity as expected
from the presence of the b-keto group. On the other hand, the
presence of the pyrrolidine ring in cathinones like MDPV greatly
reduces their polarity (Coppola and Mondola, 2012), resulting in
a greater diffusion of this derivative through cell membranes. In
fact, MDPV has the highest log P value (2.63) of all cathinones in
study, being even higher than MDMA, which is in conformity
with the significantly higher increase in toxicity, as evidenced
by the LDH leakage assay (Figure 2). Data on extracellular LDH
also supports the concentration-dependent pattern observed
with the MTT reduction assay. However, the magnitude of loss
of integrity of the plasma membrane, as determined by the LDH
leakage assay, was lower than the decrease of mitochondrial
function, given by the MTT reduction assay. This result was
somehow expected since mitochondrial dysfunction often pre-
cedes membrane damage, thus explaining the greater sensitiv-
ity of the MTT assay.
FIG. 6. Intracellular levels of ATP in PHR exposed to MDMA, methylone, MDPV, pentedrone, and 4-MEC, for 24 h. Results were obtained from 5 independent experi-
ments, performed in duplicate. * P < .05, ** P < .01, *** P < .001 versus control. # P < .05, #### P < .0001 versus MDMA.
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The hypothesis of a chemical contribution to the observed
cytotoxic effects was further evaluated through the measure-
ment of the redox potential of the cathinone derivatives.
As depicted in Figure 3, all four cathinones presented
concentration-dependent reducing power. Conversely, MDMA
displayed virtually no reducing ability. Accordingly, with a pKa
value of 10.14 (Table 1), MDMA is the stronger base, which means
that under physiologic pH (7.4) it is mostly found in the proto-
nated form, and thus detains low electron-donor capacity. When
comparing MDMA and its b-keto analogue, the combination of
lower pKa (7.96) and the ability to undergo keto-enol tautomeri-
zation (Coppola and Mondola, 2012) may contribute to the higher
reducing power of methylone. This is also valid for 4-MEC and
pentedrone. On the other hand, despite being the weaker base
under study (pKa value of 7.31), MDPV presents a relatively low
reducing potential, which may be a consequence of molecular
stabilization by the presence of the pyrrolidine group (Leffler
et al., 2014). Our results are in accordance with data from the
work of den Hollander et al. (2014), which showed significant dif-
ferences on redox reactivity among several b-keto and non-keto
amphetamines, using a tetrazolium redox indicator.
Results show substantial differences between the two cellu-
lar models regarding the susceptibility to drug-induced cytotox-
icity. HepaRG cells were significantly less sensitive to the
toxicity elicited by cathinone derivatives, with EC50 values
about 3 to 5 times higher than those observed in PRH
(Supplementary Table S1). Under specific culture conditions,
the human hepatoma HepaRG cells represent a highly differen-
tiated and metabolically competent liver cell model, capable of
expressing both phase I and II drug-metabolizing enzymes as
observed in vivo (Guillouzo et al., 2007). For this reason, this
model has been used as a suitable alternative to human hepato-
cytes for the study of well-known hepatotoxic compounds
(Antherieu et al., 2011; McGill et al., 2011; Sharanek et al., 2014).
FIG 7. Percentage of increase in caspases (A) 3, (B) 8, and (C) 9 activity in PHR exposed to MDMA, methylone, MDPV, pentedrone and 4-MEC, for 24 h. Results were
obtained from four independent experiments, performed in duplicate. * P < .05, ** P < .01, *** P < .001, **** P < .0001 versus control. # P < .05, ## P < .01, ### P < .001, #### P <
.0001 versus MDMA.
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However, despite the general advantages of using an immortal-
ized cell line, such as the ease of manipulation, the ability to be
cryopreserved and the reduced data variability, the expression
of cytochrome P450 enzymes in HepaRG cells is, for most isoen-
zymes, significantly lower than that observed in freshly isolated
human hepatocytes (Aninat et al., 2006), which greatly affects
the translation of results into the in vivo situation. This is partic-
ularly critical for compounds with CYP2D6-dependent metabo-
lism, since this hepatoma cell line was derived from a CYP2D6
poor metabolizer patient (Guillouzo, et al., 2007). In fact, recent
evidence suggests that CYP2D6 is the main responsible enzyme
for the in vitro phase I metabolism of synthetic cathinones
(Negreira et al., 2015; Pedersen et al., 2013a, b), which may
explain the higher resistance of HepaRG to the synthetic
cathinones-induced cytotoxicity. This lower sensitivity of the
hepatoma cell line was also observed with MDMA, for which
CYP2D6-mediated bioactivation into hepatotoxic metabolites is
fully accepted (Carmo et al., 2006; Carvalho et al., 2012). To ascer-
tain whether the CYP2D6 metabolism could explain the higher
susceptibility of PRH, both cell models were co-incubated with
the cathinones and the CYP2D6 inhibitor, quinidine. A signifi-
cant reversion in cell death was observed in PRH for methylone,
MDPV and pentedrone, while, as expected, no effect was seen in
HepaRG cells. Taken together, these findings indicate that PRH
is a more suitable in vitro model for toxicological studies on syn-
thetic cathinones.
The synthetic cathinones under study triggered oxidative
stress as evidenced by enhanced generation of ROS and RNS
(Figure 4), and decreases in intracellular GSH levels (Figure 5A).
Methylone, 4-MEC and pentedrone were the most potent drugs
regarding the formation of ROS and RNS, whereas MDPV and
MDMA were only effective at the highest concentration tested.
Interestingly, our results show that cathinones-induced ROS and
RNS formation appears to be correlated with their reducing
potential (electron donor capacity), as derivatives with higher
reducing power (methylone, pentedrone, and 4-MEC) elicit
greater ROS and RNS production. It is possible that increased
reducing power may lead to greater redox cycling of the cathi-
none metabolites, thereby promoting greater ROS generation,
lipid peroxidation, and protein adduction. However, further stud-
ies are required to ascertain the contribution of redox properties
of the studied drugs to the respective toxicological effects. It is
also acknowledged that oxidative stress arises from the disrup-
tion of the mitochondrial respiratory chain, contributing to an
increase in intracellular ROS and RNS formation (Brookes et al.,
2004). Importantly, recent studies have revealed that mephe-
drone and methylone induce mitochondrial respiratory dysfunc-
tion in neuronal cells (den Hollander, et al., 2014, 2015), which is
also a recognized mechanism underlying amphetamines-
induced toxicity (Carvalho et al., 2012). Furthermore, MDMA is
known to undergo extensive hepatic cytochrome P450-mediated
bioactivation, with formation of catechols and further oxidation
to o-quinones, which are highly reactive molecules that may
enter redox cycling and lead to the production of ROS and RNS
(Carvalho et al., 2010). Since the formation of catechols through
o-demethylenation was shown to be one of the main metabolic
pathways for methylone and MDPV (Pedersen et al., 2013a;
Strano-Rossi et al., 2010), it could be anticipated that a similar bio-
activation pathway takes place with cathinone derivatives con-
taining the methylenodioxy ring. Nonetheless, further work is
needed to elucidate the exact contribution of these mechanisms
to the augmented formation of ROS/RNS induced by cathinones.
GSH is a major endogenous antioxidant defense, being
responsible for numerous functions while protecting the liver
against drug-induced damage (Chen et al., 2013). Since one of
these functions is the direct scavenging of superoxide anion
and hydroxyl radical, GSH depletion is a foreseeable outcome
from the increase in ROS and RNS production. Accordingly, all
four cathinones induced a significant decrease in GSH intracel-
lular levels at the higher concentration tested (Figure 5A).
Pentedrone was the most effective compound, but no signifi-
cant increase in GSSG levels was observed after 24 h. The in vitro
formation of glutathionyl adducts with the demethylenated
metabolites of methylenedioxy b-keto amphetamines, includ-
ing MDPV and methylone, was recently demonstrated (Meyer
et al., 2014). However, there is no evidence supporting the ability
of cathinones lacking the methylenedioxy ring, such as pente-
drone and 4-MEC, to undergo metabolic pathways that result in
the formation of conjugates with GSH. For this reason, the
absence of a significant increase in GSSG intracellular levels for
pentedrone may be due to an ATP-dependent export of the
formed GSSG into the extracellular space (Leier et al., 1996). The
formation of ROS and RNS and the GSH depletion are well-
acknowledged toxicological pathways of MDMA-induced hepa-
totoxicity (Carvalho et al., 2010), but little is known on the ability
of synthetic cathinones to induce oxidative stress. However,
some recent studies demonstrated that the cathinone deriva-
tive 4-methylmethcathinone (mephedrone) elicits oxidative
stress in the brain of rats and mice, characterized by increased
lipid peroxidation and altered enzymatic antioxidant systems
(Budzynska et al., 2015; Ciudad-Roberts et al., 2016; Lopez-Arnau
et al., 2015).
Since oxidative stress appears to underlie the observed hep-
atotoxicity, it is expected that antioxidants prevent or partially
revert the cell death induced by the cathinones. In fact, in our
study, 1 mM AA significantly reversed cell death induced by
MDMA and all four cathinones, but more pronouncedly for
MDMA and its b-keto analogue, while protection with 1 mM
NAC was significant only for MDMA, methylone and pentedrone
(Table 2). Accordingly, our group has previously demonstrated
the protective effects of AA and NAC against the hepatotoxicity
elicited by the main MDMA catecholic metabolite, N-methyl-
a-methyldopamine (Carvalho et al., 2004), as well as the neuro-
protection of NAC against the cytotoxicity induced by this
metabolite and the GSH conjugate, 5-GSH-a-methyldopamine
(Capela et al., 2006). The protective effect of AA is widely
acknowledged, and relies on its ability to scavenge ROS and RNS
and to regenerate other antioxidants, such as a-tocopherol
(Maxwell, 1995). NAC exerts antioxidant effects by acting either
directly, as a ROS and RNS scavenger, or indirectly, as a source
of cysteine, the precursor for the rate-limiting step of the syn-
thesis of glutathione (Firuzi et al., 2011). This latter function is
important when the liver is depleted of GSH, becoming more
vulnerable to oxidative damage, which is the case of the syn-
thetic cathinones in this study. Although MDPV is one of the
most hepatotoxic compounds, triggering significant depletion
of GSH intracellular levels at 1.6 mM, NAC failed to exhibit cyto-
protection in the presence of this substance at this concentra-
tion. A plausible explanation for these results would be the
formation of cytotoxic thioether conjugates of MDPV with NAC
and GSH, as it is known to occur with MDMA (Jones et al., 2005),
but further studies with MDPV conjugates are required to verify
this hypothesis. Since 1.6 mM 4-MEC did not lead to a depletion
of GSH or an increase in ROS and RNS production as great as
pentedrone, the induction of these oxidative stress pathways
may be less preponderant in 4-MEC-induced hepatotoxicity at
the conditions tested, thereby explaining the lack of protective
effect by NAC.
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Used by cells to execute energy-requiring processes, ATP is
the primary energy currency, and since mitochondria are the
main source of ATP, mitochondrial ATP generation is essential
for the maintenance of cellular integrity (Brookes et al., 2004). Our
results show that MDPV and pentedrone, as well as MDMA, eli-
cited a significant decline in ATP synthesis after 24 h (Figure 6).
This decrease occurred at a concentration where the GSH deple-
tion and the formation of ROS and RNS were significantly
increased, especially for pentedrone, suggesting that oxidative
stress may be involved in mitochondrial dysfunction. However,
despite the decrease in GSH levels observed for methylone and
4-MEC, the mitochondrial damage appears to be insufficient to
hamper ATP synthesis with these two derivatives, at least at the
range of concentrations tested. The involvement of mitochondria
in amphetamines-induced toxicity has been thoroughly reviewed
(Barbosa et al., 2015; Carvalho et al., 2012). In response to oxidative
injury, the mitochondria undergo extensive changes, including
the permeabilization of the mitochondrial membrane, with
release of pro-apoptotic proteins into the cytosol, such as cyto-
chrome c (Brookes et al., 2004). Once in the cytosol, cytochrome c
initiates the complex signaling cascade that characterizes the
intrinsic mechanisms of apoptosis, with activation of caspase 9
and downstream executioner caspases 3 and 7 that, in turn,
cleave intracellular substrates, causing the morphological and
biochemical changes that ultimately end in cell death (Tait and
Green, 2010; Tsujimoto, 2003). Our data show that all cathinones
prompt apoptosis, with activation of both caspases 3 and 9 (Figs.
7A and C). The activation of extrinsic apoptosis was also eval-
uated through the measurement of caspase 8 activation. This
extrinsic pathway is mitochondrion-independent, and it is initi-
ated by the binding of xenobiotics to death receptors located in
the surface of cell membrane, with subsequent activation of cas-
pase 8, and further activation of the executioner caspases, or
indirect activation of the intrinsic apoptotic pathway (McIlwain
et al., 2013). As seen in Figure 7B, all five compounds elicited the
activation of caspase 8 in an identical pattern to that observed for
caspases 3 and 9. Methylone and 4-MEC were the least effective
compounds, which may be expected from the putative inferior
potency to induce mitochondrial dysfunction. MDPV and pente-
drone, the most hepatotoxic drugs in study, and the most potent
compounds concerning ATP depletion and oxidative stress stim-
ulation, respectively, were the most effective triggers of apopto-
sis, as well. Hoechst 33342/PI staining further supports these
findings, with an apparent increase in apoptotic events (green
and orange arrows) in a concentration dependent manner
(Supplementary Figure S1). This increase was less evident for
methylone, which is also the least hepatotoxic drug in study. The
presence of necrotic events (red arrows) was also noted at higher
concentrations. It is important to note that necrosis is a degrada-
tive process that may occur as a primary event of cell death or
secondary to apoptosis. Based on our findings showing the
absence of necrotic events at lower concentrations of the studied
drugs, it seems that the observed LDH release in cells exposed to
low concentrations is more likely due to secondary necrosis from
late apoptosis. Additionally, the decrease in MTT reduction, a
marker of mitochondrial dysfunction, under the same experi-
mental conditions, further supports apoptosis as a main pathway
of cell death. For this reason, it was expected that caspase inhibi-
tion would detain protective properties against cathinones-
induced toxicity. In fact, 100 mM Ac-LETD-CHO, a caspase 8 and 9
inhibitor, significantly reduced the cell death elicited by all cathi-
nones (Table 2). MDPV was previously shown to prompt apopto-
sis in neonatal mouse brain after acute administration (Adam
et al., 2014), whereas the overexpression of the anti-apoptotic Bcl-
2 protein partially prevented the cytotoxicity elicited by mephe-
drone in neuronal cells (den Hollander et al., 2015).
One major limitation of this study is the use of relatively high
concentrations of synthetic cathinones when compared with the
micromolar levels found in blood samples from ‘bath salts’-
related intoxications (Gil et al., 2013; Kesha et al., 2013; Pearson et
al., 2012; Sykutera et al., 2015). Nonetheless, due to the toxicoki-
netics, and especially drug distribution and tissue accumulation,
it should be noted that the drug concentration to which the liver
is actually exposed may be much higher than that found in the
blood, to similarly to what was determined for MDMA (Garcıa-
Repetto et al., 2003). In fact, it was recently shown that pente-
drone and MDPV reach liver-to-blood ratios up to 11 and 23,
respectively (Marinetti and Antonides, 2013; Sykutera et al.,
2015). Furthermore, it is important to stress that the present
work involves a comparative mechanistic study, and the
obtained data should be regarded as a means of improving the
understanding of the cellular mechanisms that may be involved
in the in vivo effects of synthetic cathinones.
In conclusion, the present work provided evidence of the hepa-
totoxicity of cathinone derivatives in in vitro models, whose mech-
anisms may help to understand liver damage reported in
humans. Variations in magnitude among the different analogues
may be attributable to their chemical properties, including lipophi-
licity and reducing power, as more lipophilic compounds present
greater hepatotoxic potential, and more powerful reducing cathi-
nones elicit enhanced formation of reactive species. Furthermore,
this study demonstrated for the first time a common mechanism
for cathinones-induced hepatic injury involving oxidative stress
and mitochondrial dysfunction. Finally, apoptosis appears to be
the main pathway of cell death elicited by these novel drugs, with
activation of both intrinsic and extrinsic mechanisms.
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depletion, as one of the first signs of toxicity, observed already 
at low concentrations of MDPV, with negligible changes on 
GSSG levels, followed by accumulation of ROS and RNS, 
depletion of ATP contents and increases in intracellular Ca2+ 
concentrations. Additionally, activation of caspases 3, 8, and 
9 and apoptotic nuclear morphological changes were found in 
primary rat hepatocytes exposed to MDPV, indicating that this 
cathinone derivative activates both intrinsic and extrinsic apop-
totic death pathways. The cytotoxic potential of MDPV and all 
the studied endpoints were markedly aggravated under hyper-
thermic conditions (40.5 °C). In conclusion, these data suggest 
that MDPV toxicity in primary rat hepatocytes is mediated by 
oxidative stress, subsequent to GSH depletion and increased 
ROS and RNS accumulation, mitochondrial dysfunction, and 
impairment of Ca2+ homeostasis. Furthermore, the rise in 
body temperature subsequent to MDPV abuse greatly exacer-
bates its hepatotoxic potential.
Keywords MDPV · Synthetic cathinones · 
Hepatotoxicity · Hyperthermia · Oxidative stress
Abbreviations
MDPV  3,4-Methylenedioxypyrovalerone
MDMA  3,4-Methylenedioxymethamphetamine
GSH  Reduced glutathione
GSSG  Oxidized glutathione
ROS  Reactive oxygen species
RNS  Reactive nitrogen species
ATP  Adenosine triphosphate
Introduction
Synthetic cathinones are a broad group of novel psycho-
stimulant substances, commonly known as ‘bath salts’, 
Abstract Synthetic cathinones have emerged in recreational 
drug markets as legal alternatives for classical amphetamines. 
Though currently banned in several countries, 3,4-methylen-
edioxypyrovalerone (MDPV) is one of the most commonly 
abused cathinone derivatives worldwide. We have recently 
reported the potential of MDPV to induce hepatocellular 
damage, but the underlying mechanisms responsible for such 
toxicity remain to be elucidated. Similar to amphetamines, 
a prominent toxic effect of acute intoxications by MDPV is 
hyperthermia. Therefore, the present in vitro study aimed to 
provide insights into cellular mechanisms involved in MDPV-
induced hepatotoxicity and also evaluate the contribution of 
hyperthermia to the observed toxic effects. Primary cultures of 
rat hepatocytes were exposed to 0.2–1.6 mM MDPV for 48 h, 
at 37 or 40.5 °C, simulating the rise in body temperature that 
follows MDPV intake. Cell viability was measured through 
the MTT reduction and LDH leakage assays. Oxidative stress 
endpoints and cell death pathways were evaluated, namely 
the production of reactive oxygen and nitrogen species (ROS 
and RNS), intracellular levels of reduced (GSH) and oxidized 
(GSSG) glutathione, adenosine triphosphate (ATP) and free 
calcium (Ca2+), as well as the activities of caspases 3, 8 and 
9, and nuclear morphological changes with Hoechst 33342/
PI double staining. At 37 °C, MDPV induced a concentration-
dependent loss of cell viability that was accompanied by GSH 
 * Maria João Valente 
mjoao.pcv@gmail.com
 * Márcia Carvalho
mcarv@ufp.edu.pt
1 Laboratory of Toxicology, Faculty of Pharmacy, UCIBIO@
REQUIMTE, Porto, Portugal
2 FP-ENAS, CEBIMED, Fundação Ensino e Cultura Fernando 
Pessoa, Porto, Portugal
77
Arch Toxicol
1 3
that originally appeared in the recreational drug mar-
kets as legal alternatives to classical illicit drugs, namely 
amphetamines and cocaine (for a comprehensive review 
on synthetic cathinones, please see Valente et al. 2014) 
Although recently regulated in several countries, cathi-
none derivatives are expanding into the illicit markets and, 
therefore, remain widely accessible in Internet Web sites 
and can also be purchased through street dealers (Ger-
man et al. 2014; Johnson and Johnson 2014). This group 
of substances comprises structural derivatives of cathi-
none, a phenylalkylamine alkaloid naturally present in 
the khat plant (Catha edulis) (Valente et al. 2014). Cathi-
none is structurally related to amphetamine, differing only 
by the presence of a ketone group in the β-position of the 
alkylamine side chain (Fig. 1). For this reason, cathinone 
derivatives are often termed β-keto amphetamines. Based 
on the close chemical similarities, cathinone and cathinone-
derived designer drugs share many of the pharmacological 
and behavioral characteristics commonly associated with 
the amphetamine psychostimulants, including increased 
locomotor activity (Aarde et al. 2013; Gatch et al. 2013; 
Jones et al. 2014; Lopez-Arnau et al. 2012), thermoregu-
latory disruption (Lopez-Arnau et al. 2015; Miller et al. 
2013; Shortall et al. 2013) and the ability to produce dis-
criminative stimulus effects (Fantegrossi et al. 2013; Gatch 
et al. 2013; Varner et al. 2013). From over seventy synthetic 
cathinone derivatives identified so far, 3,4-methylenedi-
oxypyrovalerone (MDPV) has received notoriety as a major 
component of ‘bath salts’ products (EMCDDA-Europol 
2014; EMCDDA 2015; Zuba and Byrska 2013), and is one 
of the most commonly abused derivatives worldwide by 
virtue of its amphetamine- and cocaine-like effects (John-
son and Johnson 2014; Murray et al. 2012). Structurally, 
MDPV contains both a 3,4-methylenedioxy ring attached 
to the phenyl group similar to the well-known 3,4-meth-
ylenedioxymethamphetamine (MDMA, ‘ecstasy’), and 
a pyrrolidine ring in the side chain making it close to the 
psychostimulant pyrovalerone (Fig. 1). Not surprisingly, 
MDPV induces MDMA-like subjective effects, including 
increased energy, mild empathogenic effects and socia-
bility, and increased mental stimulation and sexual drive 
(Coppola and Mondola 2012a; Deluca et al. 2009; Kesha 
et al. 2013).
Information on the toxicological properties of these 
emerging drugs of abuse is limited, but several cases of 
‘bath salts’-related intoxication and deaths have been 
reported over the last years (James et al. 2011; Murray 
et al. 2012; Wood et al. 2010). Most symptoms are consist-
ent with sympathetic stimulation, including tachycardia, 
vasoconstriction, hypertension, hyperthermia, diaphoresis, 
mydriasis, respiratory distress, muscle tremor and spasms, 
muscle weakness, rhabdomyolysis, and seizures. Sev-
eral other effects have been associated with intoxication 
by synthetic cathinones, including chest pain, myocardial 
infarction, stroke, disseminated intravascular coagulation, 
hepatic dysfunction, acute kidney injury, cerebral edema, 
coma, cardiovascular collapse, and death (Borek and Hol-
stege 2012; Carhart-Harris et al. 2011; Coppola and Mon-
dola 2012a, b; Fröhlich et al. 2011; Mugele et al. 2012).
The liver is a major target for many drugs of abuse, such 
as amphetamines and cocaine (Andreu et al. 1998; James 
et al. 2011; Kamijo et al. 2002; Kanel et al. 1990). Clini-
cal evidence has shown that the liver is also a target of 
MDPV toxicity (Borek and Holstege 2012; Fröhlich et al. 
2011; Murray et al. 2012). Based on the close chemical 
and pharmacological similarities shared by amphetamines 
and β-keto amphetamines, we hypothesized that cathinone 
derivatives would cause hepatotoxicity like their ampheta-
mine counterparts. In line with this, our group has recently 
demonstrated the in vitro hepatotoxic potential of four of 
the most prevalent synthetic cathinones, namely methylone, 
MDPV, 4-methylethcathinone (4-MEC) and pentedrone 
(Araujo et al. 2015), with potencies similar to MDMA. 
However, specific mechanisms and pathways involved 
are completely unknown. Various factors may contribute 
to MDPV-induced liver toxicity, including hyperthermia. 
Fig. 1  Chemical structures 
of amphetamine, MDMA, 
cathinone, pyrovalerone and 
MDPV. MDMA 3,4-methyl-
enedioxymethamphetamine, 
MDPV 3,4-methylenedioxypy-
rovalerone (color figure online)
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The impairment of thermoregulation elicited by MDPV 
has also been reported, with significant increases in human 
body temperature up to values ranging between 39.5 and 
41.7 °C (Borek and Holstege 2012; Fröhlich et al. 2011; 
Kesha et al. 2013; Mugele et al. 2012; Murray et al. 2012). 
It must be stressed that hyperthermia per se is a pro-oxidant 
aggressive condition (Skibba et al. 1991; Wills et al. 1976), 
which may render liver cells more vulnerable to oxidants. 
Accordingly, our group has previously shown that hyper-
thermia acts synergistically with MDMA-induced toxic-
ity toward freshly isolated mouse hepatocytes (Carvalho 
et al. 2001) and primary cultured rat hepatocytes (Pon-
tes et al. 2008), but it remains to be investigated whether 
hyperthermia also exacerbates MDPV toxic responses 
in vitro. Therefore, the goal of the present study was to pro-
vide insights into the mechanisms involved in the toxicity 
elicited by MDPV in primary cultures of rat hepatocytes 
under normothermic and hyperthermic conditions (37 and 
40.5 °C, respectively). The specific objectives of this study 
were to (1) evaluate the cytotoxic effect of MDPV in pri-
mary rat hepatocytes; (2) elucidate the biochemical mecha-
nisms underlying the cellular injury, namely the generation 
of ROS and RNS, the interference of MDPV in the homeo-
stasis of glutathione and calcium, and with mitochondrial 
function; (3) characterize the nature of cell death in MDPV-
exposed rat hepatocytes; and (4) investigate the role of 
hyperthermia in MDPV hepatotoxicity.
Materials and methods
Chemicals
Hank’s balanced salt solution (HBSS), heat-inactivated 
fetal bovine serum (FBS), antibiotic mixture of penicil-
lin/streptomycin (10,000 U/mL/10,000 µg/mL) and fun-
gizone (250 µg/mL) were obtained from GIBCO Invitro-
gen (Barcelona, Spain). Collagenase from Clostridium 
histolyticum Type IA, bovine serum albumin (BSA), 
4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid 
(HEPES), ethylene glycol-bis-(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA), dithiothreitol (DTT), 
ethylenediaminetetraacetic acid (EDTA), Williams’ E 
Medium, dexamethasone, gentamicin sulfate salt, insu-
lin solution from bovine pancreas (10 mg/mL), thia-
zolyl blue tetrazolium bromide (MTT), sodium pyruvate, 
β-nicotinamide adenine dinucleotide reduced disodium 
salt hydrate (β-NADH), 2′,7′-dichlorodihydrofluorescein 
(DCFH) and 2′,7′-dichlorodihydrofluorescein diacetate 
(DCFH-DA), L-glutathione reduced (GSH) and L-glu-
tathione oxidized disodium salt (GSSG), β-nicotinamide 
adenine dinucleotide 2′-phosphate reduced tetrasodium 
salt hydrate (β-NADPH), 5,5′-dithiobis(2-nitrobenzoic 
acid) (DTNB), adenosine triphosphate (ATP), luciferase 
from Photinus pyralis (firefly) and D-luciferin sodium salt, 
N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-
pNA, caspase 3 substrate), N-acetyl-Ile-Glu-Thr-Asp-
p-nitroanilide (Ac-IETD-pNA, caspase 8 substrate), and 
N-acetyl-Leu-Glu-His-Asp-p-nitroanilide (Ac-LEHD-
pNA, caspase 9 substrate) were purchased from Sigma-
Aldrich (St. Louis, MO). Fluo-3 AM, FluoroPure™ grade 
was obtained from Molecular Probes (Eugene, OR, USA). 
All other chemicals, of analytical grade, were purchased 
from Merck (Darmstadt, Germany). MDPV hydrochlo-
ride was purchased online from the Sensearomatic web-
site (http://sensearomatic.net, currently unavailable), dur-
ing March 2013. The salt was fully characterized by mass 
spectrometry, Nuclear Magnetic Resonance (NMR), and 
elemental analysis, and purity was greater than 98 %.
Isolation and primary culture of rat hepatocytes
Rat hepatocytes were isolated from male Wistar Han rats 
(200–250 g) purchased from Charles-River Laboratories 
(Barcelona, Spain). All experiments were approved by the 
local ethics committee for the welfare of experimental ani-
mals and performed in accordance with national legisla-
tion. Surgical procedures were conducted under anesthesia 
by inhalation of isoflurane, in an isolated system, and car-
ried out between 10.00 and 11.00 a.m. Cells were isolated 
through a collagenase perfusion, as previously described 
by our group (Pontes et al. 2008). Briefly, a cannula was 
inserted in the hepatic portal vein, and the liver was per-
fused initially with Hank’s washing buffer containing BSA 
and the chelating agent EGTA, followed by a solution of 
collagenase supplemented by its co-factor calcium. The 
liver capsule was then gently disrupted in order to release 
isolated liver cells into a Krebs–Henseleit buffer. The cell 
suspension was subsequently purified through three cycles 
of low-speed centrifugations (300 rpm, for 2 min). The final 
suspension was then incubated with penicillin/streptomycin 
(500 U/mL/500 μg/mL), at 4 °C, for 30 min. Cell viabil-
ity was estimated by the trypan blue exclusion test and was 
always higher than 80 %. A suspension of 500,000 viable 
cells/mL was cultured in 6- or 96-well plates at approxi-
mately 100,000 cells/cm2, in William’s E medium, supple-
mented with 10 % FBS, 100 U/mL/100 µg/mL penicillin/
streptomycin, 5 μg/mL insulin, 50 μM dexamethasone, 
100 μg/mL gentamicin and 2.5 μg/mL fungizone, and 
incubated overnight at 37 °C, with 5 % CO2, to allow cell 
adhesion.
Cell viability assays
Hepatocytes were seeded in 96-well plates and exposed to 
MDPV at a concentration range that includes low-effect 
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to worst-case approach concentrations (0.2–1.6 mM) in 
serum-free medium, under normothermic (37 °C) and 
hyperthermic (40.5 °C) conditions. Cell viability was eval-
uated after 48 h through the MTT reduction assay and con-
firmed by the LDH leakage assay, as previously described 
(Araujo et al. 2015; Barbosa et al. 2014), with minor 
modifications. For the MTT reduction assay, cells were 
incubated with a solution of 0.5 mg/mL MTT for 80 min, 
and the formazan crystals formed through mitochon-
drial succinate dehydrogenase were dissolved in DMSO 
and detected at 550 nm in a 96-well plate reader (Power-
WaveX; Bio-Tek, Winooski, VT, USA). For measurement 
of the amount of LDH released into the culture medium, 
the plates were centrifuged for 10 min at 250g, and 50 μL 
of the incubation medium (dilutions prepared in phosphate 
buffer: 50 mM KH2PO4, pH 7.4) were collected from each 
well in duplicates into new 96-well plates, to which 200 μL 
of a 0.21 mM β-NADH solution were added. The kinetic 
oxidation of β-NADH into β-NAD+ after adding 25 μL of 
22.7 mM sodium pyruvate was monitored at 340 nm in a 
96-well absorbance plate reader. Data were normalized to a 
no-effect (no treatment) and a maximum-effect (lysed with 
1 % Triton X-100) controls.
Characterization of hepatotoxicity mechanisms 
triggered by MDPV
Measurement of intracellular GSH and GSSG levels
Total glutathione (tGSH) and oxidized glutathione (GSSG) 
contents were determined through the DTNB-GSSG reduc-
tase recycling assay (Carvalho et al. 2004). For this purpose, 
hepatocytes were seeded in 6-well plates and exposed to 
MDPV, at 37 °C or 40.5 °C. After a 48 h incubation period, 
cells were rinsed with HBSS without calcium and magne-
sium, scrapped and precipitated with 5 % perchloric acid 
for 20 min, at 4 °C. Suspensions were centrifuged at 6000g, 
for 5 min, at 4 °C, and the supernatant was then neutralized 
with 0.76 M KHCO3, on ice. The samples were spinned at 
13,000 rpm, and 100 μL of the supernatants were added to a 
96-well plate, followed by 65 μL of a freshly prepared rea-
gent solution of 71.5 mM phosphate buffer with 0.63 mM 
EDTA containing 0.7 mM NADPH and 4 mM DTNB. Sam-
ples were incubated for 15 min at 30 °C in a thermomax 
96-well plate reader, and 40 μL of 10 U/mL glutathione 
reductase was then rapidly added to all samples. The con-
sequent formation of 5-thio-2-nitrobenzoic acid (TNB) 
was followed for 2 min at 415 nm and compared with a 
GSH standard curve prepared in 5 % HClO4. For GSSG 
quantification, precipitated samples were incubated with 
2-vinylpyridine for 1 h, at 4 °C, with continuous agitation, 
in order to derivatizate GSH. GSSG was then quantified 
as described for tGSH. All data were normalized to total 
protein content of each sample, measured by the Lowry 
method, using standard stock solutions of BSA. GSH levels 
were calculated by subtracting GSSG content from tGSH 
values as follows: GSH = tGSH − (2 × GSSG).
Measurement of intracellular reactive oxygen and nitrogen 
species
Intracellular generation of reactive oxygen (ROS) and 
nitrogen (RNS) species was monitored via DCFH-DA 
fluorescence assay as previously described (da Silva et al. 
2014). DCFH-DA is a cell-permeable fluorogenic probe 
that readily diffuses into the cells, where it is deacetylated 
by cellular esterases, and the resultant non-fluorescent 
DCFH is further oxidized by ROS and RNS to the highly 
fluorescent 2′,7′-dichlorofluorescein (DCF). For this assay, 
after overnight cell adhesion in 96-well plates, hepatocytes 
were pre-incubated with 10 μM DCFH-DA, at 37 °C, 
protected from light. After 30 min, cells were rinsed with 
HBSS without calcium and magnesium and incubated with 
0.2–1.6 mM MDPV for 48 h, at 37 or 40.5 °C. The fluores-
cence was then recorded on a microplate reader (Synergy 
HTX Multi-Mode Reader; Bio-Tek, Winooski, VT, USA), 
set to 485 nm excitation and 530 m emission. Results were 
normalized to negative controls (no treatment) and calcu-
lated as fold increase over control. No interference with 
the probe was noted at any tested concentration of MDPV, 
as determined by incubation for 48 h with DCFH in the 
absence of cells (data not shown).
Measurement of intracellular ATP levels
The ATP bioluminescence assay is based on the emission 
of light from the reaction of ATP and luciferin, catalyzed 
by luciferase and was performed as previously described 
(Valente et al. 2012). After exposure to MDPV, cells were 
rinsed and treated as described above for tGSH measure-
ment. After neutralization, samples were spinned, and 
100 μL of the supernatants were added to 96-well opaque 
plates with 100 μL of luciferin–luciferase assay solu-
tion [final concentrations: 0.15 mM luciferin, 30,000 light 
units luciferase, 50 mM glycine, 10 mM MgSO4, 1 mM 
Tris, 0.55 mM EDTA, 1 % BSA (pH 7.6)]. ATP calibration 
curve was obtained with standard stock solutions of ATP 
prepared in 5 % HClO4. Results were normalized to total 
protein, measured by the Lowry method.
Quantification of intracellular free calcium (Ca2+) levels 
by flow cytometry
Fluo3-AM is a sensitive fluorochrome that is enzymati-
cally hydrolyzed by cellular esterases to give Fluo3, which 
exhibits an increase in fluorescence upon binding with 
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calcium. For this assay, cells from six-well plates exposed 
to 0.2–1.6 mM MDPV for 48 h were collected after trypsi-
nization with 0.05 % trypsin/EDTA, centrifuged (250g, 
5 min, 4 °C), and rinsed with HBSS without calcium and 
magnesium. After further centrifugation, the supernatant 
was discarded and samples were incubated for 30 min, 
with continuous agitation, at 37 °C, with 50 μL of a 10 μM 
Fluo3-AM solution prepared in serum-free Williams’ E 
Medium without phenol red. Following incubation, the 
cells were washed and resuspended with HBSS with cal-
cium and magnesium and kept on ice until further analysis. 
Samples were analyzed in a BD Accuri™ C6 flow cytom-
eter (BD Biosciences, CA, USA), with the FCS Express™ 
analysis software. The green fluorescence of Fluo3 was 
detected through a 533/30 nm filter (FL1 detector). The 
DNA of non-viable cells was stained with 5 µg/mL propid-
ium iodide (PI), which has a maximum fluorescence emis-
sion at 617 nm, and the green fluorescence from PI positive 
cells was excluded from the analysis. At least 20,000 viable 
cells were analyzed per sample. There was no contribu-
tion of autofluorescence, as determined by the analysis of 
treated cells in the absence of Fluo3-AM (data not shown). 
Data were normalized to controls without treatment.
Characterization of death pathways triggered 
by MDPV
Measurement of caspase 3, 8 and 9 activity
The activities of caspase 3, 8 and 9 were determined in 
cytoplasmatic fractions of hepatocytes after exposure 
to 0.2–1.6 mM MDPV for 48 h, as previously described 
(Capela et al. 2007), with adaptations. This assay was 
based on the hydrolysis of the peptide substrates for each 
caspase, namely Ac-DEVD-pNA, Ac-IETD-pNA and Ac-
LEHD-pNA, for caspase 3, 8 and 9, respectively. This 
reaction results in the release of the p-nitroaniline moiety, 
with peak absorbance at 405 nm. For each condition, three 
wells of a 6-well plate were rinsed with HBSS without 
calcium and magnesium, and pellets were collected into 
new tubes with 225 μL of lysis buffer [final concentra-
tions: 50 mM HEPES, 1 mM DTT, 0.1 mM EDTA, 0.1 % 
CHAPS (pH 7.4)]. Samples were incubated for 5 min 
on ice, centrifuged (16,000g, 10 min, 4 °C), and the cell 
lysate transferred into new tubes. Two hundred microlit-
ers of assay buffer [final concentrations: 100 mM NaCl, 
50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10 % glyc-
erol, 0.1 % CHAPS (pH 7.5)] were added to 50 μL of 
lysate in 96-well plates, followed by 5 μL of colorimetric 
substrate (16 μM Ac-DEVD-pNA, 200 μM Ac-IETD-pNA 
or 200 μM Ac-LEHD-pNA). After 24 h at 37 °C, absorb-
ance was determined at 405 nm in a 96-well absorbance 
plate reader. Protein content in cell lysate was measured 
using the Bio-Rad RC DC protein assay kit (Hercules, CA, 
USA), with BSA as the standard.
Hoechst 33342/propidium iodide fluorescent staining
Apoptotic hepatocytes were identified based on chromatin 
morphology, as previously described (Valente et al. 2012), 
using Hoechst 33342, a cell-permeant nuclear counterstain 
that emits blue fluorescence when bound to DNA, and PI, a 
membrane impermeant nuclear dye that emits red fluores-
cence only in dead cells. Briefly, primary rat hepatocytes 
were seeded into six-well plates and exposed to MDPV 
(0.2–1.6 mM) for 48 h, at 37 or 40.5 °C. After washing 
with HBSS without calcium and magnesium, cells were 
incubated with 50 µM PI for 15 min, rinsed again, and 
fixed with a 4 % solution of p-formaldehyde for 20 min. 
After washing, cells were incubated with a 5 µg/mL Hoe-
chst 33342 solution for 5 min and observed under a fluores-
cent microscope.
Statistical analysis
Data were obtained from at least five independent experi-
ments, performed in duplicate or triplicate, and are pre-
sented as mean ± standard error of the mean (SEM). Sta-
tistical analysis was performed using the GraphPad Prism 
6 (version 6.01) for Windows. Multiple comparisons within 
the two variables (concentration and temperature) were 
performed through one-way ANOVA analysis, followed by 
Fisher’s LSD post hoc test. Significance was accepted for 
p < 0.05.
Results
MDPV induces cell death in a concentration‑dependent 
manner, exacerbated in hyperthermic conditions
The data presented in Fig. 2 show a concentration-depend-
ent increase in cytotoxicity, as determined by the MTT 
reduction assay, in primary rat hepatocytes exposed to 
MDPV at 37 °C. This effect was significant (p < 0.01 vs. 
control), even at the lowest concentration tested (0.2 mM). 
Since MDPV is a ketone, and thus, a possible redox elec-
tron donor that may interfere with redox-based tests like 
the MTT assay (den Hollander et al. 2014), we additionally 
performed the interference-free and unbiased LDH leak-
age assay, under the same experimental conditions, and the 
obtained results are shown in Fig. 3. Data from this assay 
corroborate the results from the MTT test, showing cell 
death in identical magnitude and significance, which sug-
gests that there is no substantial reduction of the tetrazo-
lium dye by MDPV under our in vitro conditions.
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Noteworthy, a rise in incubation temperature from 37 to 
40.5 °C greatly exacerbated cell death induced by MDPV, 
for all concentration range (p < 0.0001 vs. normothermia). 
For instance, as observed in the MTT assay, cell death 
induced by 0.2 mM MDPV increased from 11.1 ± 2.9 % in 
normothermic conditions up to 31.4 ± 5.9 % in hyperther-
mic conditions.
MDPV triggers a marked GSH depletion and ROS 
and RNS formation in primary rat hepatocytes, 
exacerbated in hyperthermic conditions
Since oxidative stress is a well-known mechanism involved 
in the hepatotoxicity of non-keto amphetamines (Carvalho 
et al. 2012), we started to investigate whether this mecha-
nism is also shared by MDPV. Glutathione provides a major 
cell antioxidant defense against reactive species formation 
and ensuing oxidative damage. Therefore, the intracellular 
content of GSH and GSSG was measured after exposure of 
primary rat hepatocytes to MDPV (0.2–1.6 mM), at 37 and 
40.5 °C. As depicted in Fig. 4a, at 37 °C, MDPV caused a 
significant concentration-dependent decline in GSH levels, 
with a decrease from 39.1 ± 3.2 nmol/mg of protein in con-
trol cells to 15.4 ± 2.9 nmol/mg of protein in cells treated 
with 1.6 mM MDPV. GSH depletion was clearly more 
accentuated under hyperthermic conditions. In fact, the 
highest concentration studied (1.6 mM) caused an almost 
complete depletion of GSH levels (0.4 ± 0.1 nmol/mg of 
protein) at 40.5 °C (p < 0.0001 vs. control and normother-
mia). An important finding was that, under normothermic 
conditions, the GSH depletion induced by MDPV was not 
accompanied by glutathione oxidation (Fig. 4b). How-
ever, it is noteworthy that hyperthermia, by itself, elicited 
a significant decline in basal GSH levels of control cells of 
approximately 36 % (p < 0.0001), as well as an increase of 
nearly 100 % in GSSG levels (p < 0.05).
The involvement of oxidative stress in MDPV-induced 
toxicity was further assessed through the measurement of 
ROS and RNS generation at the same conditions. The lev-
els of reactive species following 48 h exposure with MDPV 
at normothermic and hyperthermic conditions are shown 
in the Fig. 5. At 37 °C, MDPV increased the formation of 
reactive species after exposure to the highest concentra-
tion studied (1.6 mM), with a 1.50 ± 0.04-fold increase 
over control cells (p < 0.0001 vs. control). At 40.5 °C, the 
levels of ROS and RNS were prominently increased in a 
concentration-dependent manner following incubation with 
MDPV, with a 1.14 ± 0.03, 1.29 ± 0.03 and 1.65 ± 0.06-
fold increase in cells treated with 0.4, 0.8 and 1.6 mM 
MDPV, respectively.
Fig. 2  Effects of MDPV on 
MTT reduction in primary cul-
tured rat hepatocytes. Hepato-
cytes were exposed for 48 h, at 
37 or 40.5 °C, to 0.2–1.6 mM 
MDPV. Results are presented as 
mean ± SEM from at least five 
independent experiments, per-
formed in triplicate. **p < 0.01, 
****p < 0.0001 versus control. 
#p < 0.05, ####p < 0.0001 versus 
normothermia
Fig. 3  Effects of MDPV on 
LDH leakage in primary cul-
tured rat hepatocytes. Hepato-
cytes were exposed for 48 h, at 
37 or 40.5 °C, to 0.2–1.6 mM 
MDPV. Results are presented 
as mean ± SEM from six 
independent experiments, per-
formed in triplicate. **p < 0.01, 
****p < 0.0001 versus control. 
####p < 0.0001 versus normo-
thermia
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MDPV hampers the hepatocellular energetic status 
and Ca2+ homeostasis, especially at high concentrations 
and in hyperthermic conditions
To better understand the potential mechanisms involved 
in MDPV-induced toxicity in primary rat hepatocytes, we 
investigated whether mitochondrial bioenergetic function 
or calcium homeostasis are affected. Figure 6 depicts the 
intracellular levels of ATP in MDPV-treated cells at both 
incubation temperatures herein studied (37 and 40.5 °C). 
At 37 °C, it was observed a pronounced decline (from 
23.6 ± 4.2 to 8.3 ± 1.6 nmol/mg of protein) in intracellular 
ATP levels in cells exposed to 1.6 mM MDPV (p < 0.001 
vs. control), with no significant changes detected at lower 
concentrations. The increase in incubation temperature to 
40.5 °C prompted an abrupt energy depletion in hepato-
cytes treated with 0.8 mM and 1.6 mM MDPV (from 
22.7 ± 1.9 in control cells to 1.8 ± 0.3 and 0.3 ± 0.1 nmol/
mg, respectively), and to a less extent with 0.4 mM MDPV. 
Moreover, as shown in Fig. 7, MDPV at these two highest 
concentrations also affects the intracellular Ca2+ homeosta-
sis, whereas no significant changes were noticed at lower 
concentrations. No statistically significant differences were 
detected between normo- and hyperthermic conditions.
Fig. 4  Effects of MDPV on a 
GSH and b GSSG levels in pri-
mary cultured rat hepatocytes. 
Hepatocytes were exposed 
for 48 h, at 37 or 40.5 °C, to 
0.2–1.6 mM MDPV. Results are 
presented as mean ± SEM from 
at least five independent experi-
ments, performed in triplicate. 
Please note that different scales 
on the y-axis are used in a and 
b. *p < 0.05, ***p < 0.001, 
****p < 0.0001 versus control. 
#p < 0.05, ####p < 0.0001 versus 
normothermia
Fig. 5  Effects of MDPV 
on ROS and RNS produc-
tion in primary cultured rat 
hepatocytes. Hepatocytes 
were exposed for 48 h, at 37 
or 40.5 °C, to 0.2–1.6 mM 
MDPV. Results are presented 
as mean ± SEM from six 
independent experiments, per-
formed in triplicate. **p < 0.01, 
****p < 0.0001 versus control. 
##p < 0.01, ###p < 0.001, 
####p < 0.0001 versus normo-
thermia
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MDPV induces primarily apoptotic cell 
death in normothermia, but shifts to necrosis 
under hyperthermic conditions
To determine whether MDPV-induced hepatotoxicity 
involves the initiation of apoptotic cell death mechanisms, 
two different methodological approaches were followed: (1) 
fluorescence microscopy analysis after staining with Hoechst 
33342/PI and (2) measurement of caspase 3, 8 and 9 activity. 
Nuclear morphological changes of MDPV-treated primary 
rat hepatocytes were examined using Hoechst 33342, a mem-
brane permeable blue dye for DNA labeling, and PI, a fluo-
rescent red dye that intercalates into double-stranded nucleic 
acid of late apoptotic or necrotic cells. Figure 8 shows repre-
sentative Hoechst 33342/PI fluorescence photomicrographs 
of cultured cells treated with and without MDPV at two 
different incubation temperatures. In control cells, at 37 °C, 
nuclei appeared with regular contours and were round and 
large in size, whereas, at 40.5 °C, it was possible to identify 
early apoptotic events (pyknotic nuclei formation without 
PI label, green arrows). In MDPV-treated cells, under nor-
mothermic conditions, the pyknotic nuclei were visible even 
at the lowest MDPV concentration tested, as well as late 
apoptotic cells (red condensed nuclei). On the other hand, 
necrotic cells (red large nuclei) were only observable in 0.8 
and 1.6 mM MDPV-exposed cells. In contrast, a rise in incu-
bation temperature to 40.5 °C clearly favoured necrosis in 
hepatocytes treated with MDPV, as red large nuclei are seen 
under exposure to concentrations as low as 0.2 mM.
Since caspase activation is one of the main events lead-
ing to apoptosis, we additionally confirmed apoptotic cell 
death by evaluating the activation of caspases 8 (extrinsic 
pathway), 9 (intrinsic pathway), and 3 (effector caspase) at 
37 and 40.5 °C. As can be seen in Fig. 9, at 37 °C, 1.6 mM 
MDPV significantly increased caspase 3, 8 and 9 activities 
in primary rat hepatocytes about 118, 55 and 54 % over con-
trol values, respectively (p < 0.0001 vs. control). Noteworthy, 
the increase in incubation temperature to 40.5 °C triggers 
caspase activation at lower concentrations. Under hyperther-
mia, a peak in caspase activation was achieved at 0.8 mM 
MDPV, with increases up to 156, 64 and 50 % over control 
values (p < 0.0001 vs. control), and further reduced at 1.6 mM 
MDPV to values near to controls for caspase 8 and 9 (p > 0.05 
vs. control, p < 0.001 vs. normothermia), respectively.
Discussion
MDPV structure is closely related to amphetamines that are 
known to be hepatotoxic in humans (Carvalho et al. 2012). 
Fig. 6  Effects of MDPV on 
ATP levels in primary cultured 
rat hepatocytes. Hepatocytes 
were exposed for 48 h, at 37 
or 40.5 °C, to 0.2–1.6 mM 
MDPV. Results are presented 
as mean ± SEM from at 
least five independent experi-
ments, performed in duplicate. 
***p < 0.001, ****p < 0.0001 
versus control. #p < 0.05, 
####p < 0.0001 versus normo-
thermia
Fig. 7  Effects of MDPV on 
intracellular Ca2+ levels in pri-
mary cultured rat hepatocytes. 
Hepatocytes were exposed 
for 48 h, at 37 or 40.5 °C, to 
0.2–1.6 mM MDPV. Results are 
presented as mean ± SEM from 
at least five independent experi-
ments, performed in dupli-
cate. *p < 0.05, **p < 0.01, 
***p < 0.001 versus control
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Fig. 8  Representative fluo-
rescence microscopy images 
of Hoechst 33342/PI staining. 
Hepatocytes were exposed 
for 48 h, at (left) 37 or (right) 
40.5 °C, to a 0, b 0.2, c 0.4, d 
0.8 or e 1.6 mM MDPV. Green 
arrows indicate early apoptotic 
cells, orange arrows indicate 
late apoptotic cells and red 
arrows indicate necrotic cells. 
Original magnification, ×200
(color figure online)
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Therefore, toxicological studies of cathinone designer 
drugs toward liver cells are of particular interest. In this 
study, we first tested and confirmed the ability of the syn-
thetic cathinone MDPV to induce cytotoxicity in primary 
rat hepatocytes and contributed to the elucidation of the 
mechanisms involved in MDPV-induced hepatocellular 
injury at normothermia and hyperthermia. We showed that 
MDPV-induced cell death in a concentration- and temper-
ature-dependent manner, through two different cytotoxic-
ity tests, namely by inhibiting the reduction of MTT and 
promoting LDH leakage (Figs. 2, 3, respectively). These 
findings are consistent with our previous study showing 
the hepatotoxic potential of four of the most widely abused 
cathinone derivatives, including MDPV (Araujo et al. 
2015).
Several mechanisms induced by drugs of abuse may lead 
to liver damage. Among them, oxidative stress is thought to 
play a major role in the hepatocellular damage consequent 
to the abuse of amphetamines (Beitia et al. 2000; Carvalho 
et al. 2010). Due to structural similarities to their non-keto 
congeners, we hypothesize that synthetic cathinones may 
undergo similar mechanisms of toxicity. In fact, our results 
suggest that MDPV and/or its intermediate metabolites, 
similarly to MDMA (Cerretani et al. 2011), cause oxida-
tive stress in the liver, as evidenced by substantial deple-
tion in the intracellular levels of GSH (Fig. 4a), which is 
an endogenous antioxidant known to play a crucial role in 
cell survival, and increased formation of ROS and NOS 
(Fig. 5). Importantly, we found that MDPV-induced GSH 
depletion was not accompanied by an increase in GSSG 
levels. This result might be explained by ATP-dependent 
export of the formed GSSG into the extracellular space 
(Leier et al. 1996). However, in this experiment, GSH 
depletion seems to be primarily related to the formation 
of conjugates of MDPV with GSH, rather than a direct 
effect of reactive species, since the rise in ROS and RNS 
production was only observed in cells exposed to MDPV 
at high concentrations, where a severe GSH depletion in 
the cytosolic GSH pool had already occurred. In accord-
ance, metabolic activation to a reactive metabolite capable 
of conjugating with GSH has been recently demonstrated 
for MDPV in vitro using human liver microsomes (Meyer 
et al. 2014; Strano-Rossi et al. 2010), and in vivo in rats 
and humans (Meyer et al. 2010) and, most certainly, occurs 
in our in vitro model. Therefore, MDPV metabolism and 
the ensuing depletion of intracellular GSH levels lowers the 
capacity of the cells to scavenge reactive species, enhanc-
ing oxidative stress, disturb cellular function and, ulti-
mately, may lead to cell death.
Moreover, it must be highlighted that hepatic metabo-
lism of amphetamines that contain a 3,4-methylenedioxy 
ring is an important source of ROS and other chemically 
Fig. 9  Effects of MDPV on the activities of caspases 3, 8 and 9 in 
primary cultured rat hepatocytes. Hepatocytes were exposed for 48 h, 
at 37 or 40.5 °C, to 0.2–1.6 mM MDPV. Results are presented as 
mean ± SEM from at least five independent experiments, performed 
in duplicate. **p < 0.01,  ****p < 0.0001 versus control. #p < 0.05, 
###p < 0.001, ####p < 0.0001 versus normothermia
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reactive compounds (Carvalho et al. 2010, 2012). This 
methylenedioxy group is also present in MDPV but, pres-
ently, it is not clear if any MDPV metabolites formed in 
cells are capable to undergo oxidation into reactive ortho-
quinones that enter redox cycling with subsequent produc-
tion of ROS and RNS, as has been thoroughly described 
for MDMA (Carvalho et al. 2010). Therefore, it is still 
unknown whether the generation of reactive species in 
hepatocytes exposed to MDPV depends either on distur-
bance of the mitochondrial respiratory chain (well-known 
as the major cellular source of ROS generation) or MDPV 
metabolism, or even a combination of both.
There is a complex cross-talk between oxidative stress, 
Ca2+ homeostasis and mitochondrial function. As the main 
organelles responsible for ATP production, mitochondria 
are the core of cell energy supply and participate actively 
in the sequestration of free Ca2+ (Brookes et al. 2004). 
Our results showed that MDPV, at a high concentration 
(1.6 mM), triggered a drastic ATP depletion (Fig. 6). The 
lack of ATP might lead to a less efficient calcium control 
and mitochondrial electron chain regulation, as can be seen 
with the increase in intracellular Ca2+ content in primary 
rat hepatocytes treated with 1.6 mM MDPV for 48 h at 
37 °C (Fig. 7), thus indicating that the mitochondrial func-
tion and calcium homeostasis are severely impaired by 
MDPV at high concentrations. This decreases in ATP lev-
els occurred at a concentration where GSH depletion was 
almost complete, with overproduction of ROS and RNS, 
suggesting that oxidative stress may be involved in the dis-
turbance of mitochondrial functions. On the other hand, it 
is possible that MDPV and/or its metabolites may inhibit 
the mitochondrial function by directly interacting with 
mitochondrial proteins. Further studies are necessary to 
determine the mechanisms of mitochondrial impairment 
induced by MDPV.
As center of cell death control, mitochondria undergo 
extensive membrane integrity and permeability changes 
prior to cell death itself (Tait and Green 2010). The mito-
chondrial permeability transition pore (MPTP), a large 
nonspecific conductance channel assembled from proteins 
in the inner and outer mitochondrial membranes, appears 
to play a key role in triggering of an intrinsic apoptotic 
pathway, and Ca2+ is also in control of the process of 
MPTP opening (Brookes et al. 2004; Halestrap 2009). In 
fact, Baumgartner et al. (2009) showed that the elevation 
of mitochondrial Ca2+ is the decisive factor in determin-
ing whether cells undergo oxidative stress-induced apop-
tosis. When there is an overload of Ca2+ in the mitochon-
drial matrix, the MPTP opens and allows free passage of 
ions and solutes under 1500 Da across the mitochondrial 
inner membrane. This effect has two outcomes: entering 
of protons that lead to uncoupling of the oxidative phos-
phorylation, and consequent impairment of ATP synthesis 
(Halestrap 2006, 2009); and swelling of the mitochondria 
matrix, with subsequent rupture of the outer membrane, 
and nonspecific release of pro-apoptotic proteins into the 
cytosol, including cytochrome c (Tait and Green 2010). 
Alternatively, permeabilization of the outer mitochondrial 
membrane can be achieved by pore formation by pro-
apoptotic Bcl-2 family proteins (Bax and Bak) (Tsujimoto 
2003). Once in the cytosol, cytochrome c triggers a com-
plex signaling cascade that ultimately ends in cell death 
through apoptosis, with activation of caspase 9, which fur-
ther cleaves and activates the executioner caspases 3 and 
7 that, in turn, cleave intracellular substrates, causing the 
morphological and biochemical changes observed in the 
process of apoptosis. These caspases may also enter the 
mitochondrial intermembrane space, disrupting the res-
piratory chain, consequently leading to a decline in ATP 
synthesis and increase in ROS production, which further 
amplifies apoptosis (McIlwain et al. 2013; Tait and Green 
2010). Besides this intrinsic pathway, xenobiotics may also 
induce mitochondria-independent apoptotic pathways. This 
extrinsic process is initiated by the binding of ligands to 
death receptors located in the cell membrane, leading to the 
activation of caspase 8, which directly initiates apoptosis 
by activating the executioner caspases, or indirectly activat-
ing the intrinsic apoptotic pathway (McIlwain et al. 2013).
In the present study, it was demonstrated that MDPV-
treated primary rat hepatocytes stained with Hoechst 
33342/PI, in the absence of heat stress (at 37 °C), prefer-
entially exhibited death with apoptotic characteristics, with 
an increase in early apoptotic cells, evident at concentra-
tions as low as 0.2 mM (Fig. 8). Typical nuclear morphol-
ogy changes of cells undergoing apoptosis, such as con-
densation and fragmentation of nuclei chromatin, were 
observed in cells exposed to MDPV at lower concentra-
tions, while necrotic events were only evident at the highest 
concentrations (0.8 and 1.6 mM). This result is indicative 
of a bimodal cell death, with apoptosis at lower concen-
trations and necrosis at higher concentrations. As previ-
ously referred in the LDH data (Fig. 3), the supernatants 
of hepatocytes exposed to MDPV (0.2–1.6 mM) contained 
significantly higher amounts of LDH all over the experi-
mental period, indicating a loss of integrity of the plasma 
membrane. It is important to stress at this point that the 
LDH release assay does not distinguish between primary 
necrosis and secondary necrosis as a consequence of apop-
totic cell death. Based on our findings, any detected LDH 
release in cells exposed to low concentrations of MDPV is 
more likely due to secondary necrosis from late apoptotic 
cells, as no signs of primary necrosis were observed in cells 
exposed to lower concentrations of the tested drug. More-
over, decreases in MTT reduction, a marker of mitochon-
drial dysfunction, under the same experimental conditions, 
further supports an apoptotic cell death mechanism.
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Additionally, our data on caspase activity, under normo-
thermic conditions, is in agreement with the induction of 
apoptosis, though only statistically significant at the high-
est concentration of MDPV tested. After a 48 h period 
of incubation, MDPV was able to induce both intrinsic 
(caspase 9) and extrinsic (caspase 8) apoptotic pathways 
in primary cultures of rat hepatocytes, which was accom-
panied by a significant activation of the end-line effector 
caspase common to both pathways, caspase 3. The occur-
rence of apoptotic events in the liver was also demonstrated 
in rats administered with MDMA (Cerretani et al. 2011) 
and recently described in neonatal mouse brain following 
MDPV administration (Adam et al. 2014).
Hyperthermia is a toxicological effect that has been 
associated with the abuse of different cathinone derivatives, 
particularly MDPV (Borek and Holstege 2012; Kesha et al. 
2013; Penders et al. 2012). Although it was already dem-
onstrated that hyperthermia potentiates the toxicity induced 
by amphetamines in several study models including pri-
mary hepatocytes (Carvalho et al. 1997, 2001; Pontes et al. 
2008), neuronal cells (Capela et al. 2006) and skeletal 
muscle (Duarte et al. 1999), it remained unknown whether 
hyperthermia also increases hepatotoxic responses of the 
bk-amphetamines analogues. The present study provides 
irrefutable evidence of the potentiation of MDPV toxic-
ity by hyperthermia as a dramatic decrease in cell viability 
(Figs. 2, 3), as well as an intensification of all tested oxi-
dative stress endpoints were observed in cells exposed to 
the drug at 40.5 °C. Hyperthermic conditions heightened 
MDPV-induced depletion of GSH and formation of ROS 
and RNS (Figs. 4a, 5, respectively). It is worth to note that 
the observed potentiation of MDPV-induced GSH deple-
tion by hyperthermia was not due to an increase of GSSG 
formation. There is compelling evidence in the literature 
that hyperthermia, per se, stimulates a pro-oxidant state in 
the liver, with the depletion of GSH as a probable initiat-
ing event (Skibba et al. 1989, 1991). In accordance, our 
data showed a decline of intracellular GSH levels in control 
hepatocytes at 40.5 °C (Fig. 4a), as well as a significant rise 
in GSSG levels (Fig. 4b). This loss of antioxidant defenses 
may be in the origin of the intensification of MDPV toxic 
effects under hyperthermia. The rise in temperature also 
increased mitochondrial energetic impairment in cells 
exposed to high MDPV concentrations, leading to a nearly 
complete ATP depletion (Fig. 6), followed by increased 
intracellular calcium concentrations (Fig. 7).
Moreover, our data suggest that the increment of 3.5 °C 
increased cell vulnerability toward necrosis, which advo-
cates a change in the mode of cell death, with the increase 
in temperature, from apoptosis at physiological tempera-
ture, to necrosis under hyperthermic conditions. These find-
ings are in agreement with the ATP levels found in cells. 
In fact, since apoptosis is an energy-consuming process, 
requiring sufficient ATP to occur, the profound ATP deple-
tion attained in cells treated with MDPV (0.4–1.6 mM) 
at 40.5 °C forces the cell death mechanisms to shift from 
apoptosis to necrosis. Our results show that hyperther-
mia hastened activation of apoptotic cell death in MDPV-
exposed cells, as evidenced by caspase activation at lower 
concentrations (Fig. 9), as well as triggered primary 
necrotic cell death in rat hepatocytes (Fig. 8). These data 
are corroborated by the observed decline in caspase activity 
in cells exposed to 1.6 mM MDPV at 40.5 °C, at a con-
centration where ATP levels are virtually nonexistent and 
necrosis ensues. The favouring of a necrotic cell death 
mechanism over apoptosis under hyperthermic conditions 
was also described in primary cultured rat hepatocytes 
(Pontes et al. 2008) and HepG2 cells exposed to MDMA 
(da Silva et al. 2013). Considering that the higher temper-
ature used in our experiment (40.5 °C) matches the body 
temperatures that recreational abusers may attain after 
MDPV consumption (Borek and Holstege 2012; Fröhlich 
et al. 2011; Kesha et al. 2013; Mugele et al. 2012; Mur-
ray et al. 2012), our results suggests that MDPV-induced 
thermoregulation impairment most certainly contributes to 
increased liver damage.
Finally, it could be argued that the observed hepatotoxic 
effects occur at relatively high concentrations of the tested 
drug when compared to the low micromolar concentrations 
commonly found in MDPV users or in blood of fatal intox-
ication victims (Kesha et al. 2013; Marinetti and Antonides 
2013; Murray et al. 2012; Wyman et al. 2013). However, 
similar to other drugs like MDMA, whose levels were 
found to be up to 18 times higher in the liver (De Letter 
et al. 2006; Garcıa-Repetto et al. 2003), the drug concen-
trations to which hepatocytes are actually exposed may be 
much higher than those found in blood. Moreover, it must 
be noted that we used the same concentration range typi-
cally used in in vitro toxicity studies with amphetamine-
type drugs (Beitia et al. 1999; Capela et al. 2006; Carvalho 
et al. 2004; da Silva et al. 2014; Downey et al. 2014; Pon-
tes et al. 2008). The results from these experiments should 
be viewed as a way of gaining a better understanding of 
mechanisms that may be involved in the in vivo effects of 
MDPV.
Concluding remarks
The data presented in this study strongly suggest that 
MDPV toxicity in primary cultured rat hepatocytes is 
mediated by oxidative stress, subsequent to marked GSH 
depletion, followed by a triangle of events that includes 
increased ROS and RNS accumulation, mitochondrial dys-
function and perturbation of intracellular Ca2+ homeostasis, 
ultimately leading to apoptotic (for lower concentrations) 
88
Arch Toxicol 
1 3
and necrotic (for higher concentrations) cell death. Both 
intrinsic (caspase 9 activation) and extrinsic (caspase 8 acti-
vation) apoptotic pathways are stimulated, with subsequent 
activation of the common effector caspase 3. Furthermore, 
our results clearly indicate that hyperthermia boosts the 
oxidative stress induced by MDPV in primary rat hepato-
cytes that ultimately leads to extensive cell death mainly by 
necrosis. These results suggest that the rise in body tem-
perature after MDPV intake most certainly contributes to 
the hepatotoxicity that has been reported in humans. Also 
of great importance, we evidenced the similarities between 
the toxic events elicited by the MDPV and amphetamines 
such as MDMA, thus suggesting a correspondence in the 
mechanism of toxicity of these drugs.
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ABSTRACT: Synthetic cathinones (β-keto amphetamines) act as
potent CNS stimulants similarly to classical amphetamines, which raise
concerns about their potential neurotoxic eﬀects. The present in vitro
study aimed to explore and compare the mechanisms underlying the
neurotoxicity of two commonly abused cathinone derivatives, 3,4-
methylenedioxymethcathinone (methylone) and 3,4-methylenediox-
ypyrovalerone (MDPV), with those of 3,4-methylenedioxymetham-
phetamine (MDMA), using undiﬀerentiated and diﬀerentiated SH-
SY5Y cells. Following a 24 h exposure period, methylone and MDPV
induced loss of cell viability in a concentration-dependent manner, in
the following order of potency: MDPV ≈ MDMA > methylone.
Dopaminergic diﬀerentiated cells evidenced higher sensitivity to the
neurotoxic eﬀects of both cathinones and MDMA than the
undiﬀerentiated ones, but this eﬀect was not inhibited by the DAT
inhibitor GBR 12909. Intracellular oxidative stress mediated by methylone and MDPV was demonstrated by the increase in
reactive oxygen and nitrogen species (ROS and RNS) production, depletion of intracellular reduced glutathione and increased
oxidized glutathione levels. All three drugs elicited mitochondrial impairment, characterized by the mitochondrial membrane
potential (Δψm) dissipation and intracellular ATP depletion. Apoptosis was found to be a common mechanism of cell death
induced by methylone and MDPV, with evident chromatin condensation and formation of pyknotic nuclei, and activation of
caspases 3, 8, and 9. In conclusion, the present data shows that oxidative stress and mitochondrial dysfunction play a role in
cathinones-induced neuronal damage, ultimately leading to cell death by apoptosis.
KEYWORDS: β-Keto amphetamines, synthetic cathinones, neurotoxicity, oxidative stress, mitochondrial impairment, apoptosis
■ INTRODUCTION
Synthetic cathinones emerged this century as a novel class of
recreational designer drugs and have grown to be popular drugs
of abuse worldwide, with special incidence among young
adults.1 These substances, also known as β-keto amphetamines,
are chemically related to classical amphetamines, bearing a
ketone group at the β-position of the side chain,2 and act
essentially as stimulants of the central nervous system (CNS).3
Synthetic cathinones are currently the second largest group of
new psychoactive substances (NPS) monitored globally,4,5 with
103 diﬀerent derivatives identiﬁed so far.5 Methylone and 3,4-
methylenedioxypyrovalerone (MDPV) are two of the most
commonly abused derivatives worldwide,6 and belong to
diﬀerent chemical subgroups of cathinones: methylone is the
β-keto analogue of 3,4-methylenedioxymethamphetamine
(MDMA), whereas MDPV is a pyrrolidinophenone analogue,
containing a pyrrolidine group besides the 3,4-methylenedioxy
ring.7 Similarly to long-standing drugs of abuse such as
amphetamines and cocaine, the psychostimulant eﬀects of β-
keto amphetamines arise from their interaction with mono-
amine membrane transporters, leading to increased levels of
catecholamines in the synaptic cleft and consequent sym-
pathetic overstimulation.2 However, the type of interaction and
aﬃnity toward the diﬀerent transporters vary among deriva-
tives.8 In fact, methylone acts as a nonselective substrate for
monoamine transporters, like MDMA and methamphetamine,
although with inferior potency,9 whereas MDPV functions as a
pure transporter blocker, like cocaine, strongly inhibiting the
uptake of dopamine (DA) and norepinephrine (NE), but with
minimal eﬀects on serotonin (5-HT) transporter.10 Subjective
eﬀects diﬀer among derivatives. Methylone induces MDMA-
like stimulating eﬀects, such as euphoria, increased energy and
openness, mood lift and empathogenic feelings.11 On the other
hand, due to its aﬃnity toward DA and NE transporters (DAT
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and NET), MDPV induces more cocaine-like subjective eﬀects,
including increased alertness and sexual stimulation, but limited
euphoria and only mild, if any, empathogenic eﬀects.12,13
Higher doses and long-term abuse of these substances lead to
unwanted psychological eﬀects, including anxiety and panic
attacks, hallucinations and psychosis.14
Neurotoxic eﬀects of non-keto amphetamines have been
thoroughly reported, and the main mechanisms by which these
substances induce neuronal damage include neuroinﬂamma-
tion, excitotoxicity, oxidative stress and mitochondrial dam-
age.15−17 In vitro studies regarding the ability of cathinone
derivatives to induce oxidative stress and mitochondrial
dysfunction have recently been published, providing some
light on the mechanisms possibly involved in β-keto amphet-
amines cytotoxicity in hepatic18−21 and brain cells.21−25
However, studies at a cellular level on the mechanisms of
synthetic cathinones-induced neurotoxicity are still scarce and
require clariﬁcation. Therefore, in the present work, we
assessed the neurotoxic potential of methylone and MDPV in
cultured human dopaminergic cells and investigated the
mechanisms related to oxidative stress, mitochondrial dysfunc-
tion, and type of cell death.
■ RESULTS AND DISCUSSION
Dopaminergic Phenotype Renders SH-SY5Y Cells
More Susceptible to the Cytotoxicity of β-Keto Amphet-
amines. Though the undiﬀerentiated SH-SY5Y cell line
expresses several dopaminergic markers, diﬀerentiated SH-
SY5Y cells are more similar to primary neurons, with a mature
neuron-like phenotype.26 The desired phenotype determines
the diﬀerentiation method. Generally, amphetamines and β-
keto amphetamines present a strong aﬃnity toward DAT,
though with diﬀerent potencies of binding and transporter-
mediated release and/or uptake of monoamines. For instance,
although the DAT binding aﬃnity of methylone was shown to
be 2.4-times higher than that of MDMA,27 the potency of
actual DAT-mediated release induced by this β-keto amphet-
amine appears to be much lower than its non-keto analogue.9,27
On the other hand, MDPV, which presents substantial
membrane permeability and is actively transported through
the blood-brain barrier (BBB), was shown to have a binding
aﬃnity to DAT 650-times higher than MDMA27 and strongly
inhibits DAT-mediated DA reuptake, with an eﬀectiveness 51-
times over cocaine10 and 548-times over MDMA.27 Consider-
ing this strong interaction of β-keto amphetamines with DAT,
RA-TPA exposure was the selected method for the present
study, which prompts cell diﬀerentiation into a more
dopaminergic phenotype.28 In order to evaluate the relevance
of diﬀerentiation to the neurotoxicity elicited by the β-keto
amphetamines, the neurotoxic potential of MDMA, methylone
and MDPV was measured through the MTT reduction assay in
both undiﬀerentiated and RA-TPA diﬀerentiated cells after a 24
h exposure. Figure 1 presents the concentration−response
curves for each drug in the two in vitro models, as well as the
estimated EC50 for each compound. With curve ﬁts signiﬁcantly
shifted to the right, undiﬀerentiated SH-SY5Y cells proved to
be more resistant to drug-induced cell death (p < 0.0001).
Previous work by our group29 and others30,31 provided
evidence that RA-TPA diﬀerentiation elicits the rise in the
expression of dopaminergic markers, including DAT and
Figure 1. Nonlinear regression models for the cell death induced by MDMA, methylone and MDPV in undiﬀerentiated and dopaminergic SH-SY5Y
cells, as evaluated by the MTT reduction assay after 24 h exposure. The mean eﬀects were ﬁtted to the logit function. Dotted lines represent the 95%
conﬁdence band of each ﬁt. Results were obtained from four independent experiments, performed in triplicate. Table: estimated EC50 values for each
compound in both cell models. ****p < 0.0001 vs MDMA. ####p < 0.0001 vs dopaminergic cells.
ACS Chemical Neuroscience Research Article
DOI: 10.1021/acschemneuro.6b00421
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
B
96
tyrosine hydroxylase, the rate-limiting enzyme of catecholamine
biosynthesis. In order to determine if the increase in DAT
expression could explain the higher susceptibility of diﬀer-
entiated cells to MDMA, methylone and MDPV-induced
neurotoxicity, an additional study was conducted in the
presence of GBR 12909, a selective DAT inhibitor. However,
no protective eﬀect of the DAT inhibitor was observed, even
for the DAT substrates MDMA and methylone (Figure S1).
These results suggest that, even though the neurotoxic proﬁle
of β-keto amphetamines may vary with the phenotype
expressed by the neurons, their toxicity is independent of
DAT-mediated uptake, possibly relying on the diﬀusion across
the membrane.27 In line with these results, our group also
demonstrated that the cytotoxicity induced by MDMA for 48 h,
in the same diﬀerentiated SH-SY5Y cells, is not signiﬁcantly
aﬀected by the pre- and coexposure to the DAT inhibitor GBR
12909.32 Work from den Hollander et al.23 also showed no
protective eﬀect of this DAT inhibitor in methylone-induced
LDH leakage in SH-SY5Y cells, though it signiﬁcantly and
completely reversed the cytotoxicity elicited by its membrane
insoluble breakdown product 3,4-methylenedioxy-N-methyl-
benzamide, whose uptake occurs exclusively through DAT,
corroborating the DAT-independent methylone-induced neu-
rotoxicity. Whether the higher sensitivity of dopaminergic SH-
SY5Y cells to the cytotoxicity elicited by both cathinones and
MDMA may be related to diﬀerent intrinsic metabolic
capacities or redox cycle with DA is not known and requires
future investigation.
Since all substances under study are strong dopaminergic
drugs9,10 and RA-TPA diﬀerentiation renders cells more
sensitive to the cytotoxicity elicited by both cathinones and
MDMA, all further toxicological evaluations were carried out in
this cell model.
β-Keto Amphetamines Induce Neuronal Cell Death in
a Concentration-Dependent Manner. As presented in
Figure 1, exposure to the β-keto amphetamines resulted in
concentration-dependent neuronal death, indicated by the
decrease in MTT reduction, a marker of mitochondrial
dysfunction. When comparing EC50 values estimated for this
assay, MDPV and MDMA showed comparable potency in this
in vitro model (EC50 of 1.506 and 1.536 mM, respectively),
while methylone was signiﬁcantly less potent than its non-keto
analogue (EC50 of 2.493 mM, p < 0.0001 vs MDMA). This
decrease in mitochondrial function was followed by a loss in
membrane integrity, as determined through the LDH leakage
assay (Figure 2). The LDH leakage assay proved to be less
sensitive than the MTT reduction assay in determining cell
viability, presenting signiﬁcantly higher EC50 values than the
latter (see embedded tables in Figures 1 and 2). In fact,
mitochondrial dysfunction often precedes membrane damage,
and the greater sensitivity of the MTT reduction assay over the
LDH leakage measurement was already demonstrated in the
past.33 In accordance with our results, a recent study by
Wojcieszak et al.21 showed that MDPV did not trigger LDH
leakage in undiﬀerentiated SH-SY5Y cells at concentrations that
already exhibited signiﬁcant decrease in MTT reduction.
Nevertheless, the order of drug potency determined by the
LDH leakage assay was similar to that of MTT reduction assay:
MDPV ≈ MDMA > methylone (p < 0.0001 vs MDPV and
MDMA). Our group has recently showed comparable diﬀer-
ences in potency of these three compounds in primary rat
hepatocytes.19 Structural diﬀerences among the tested drugs
may underlie the diﬀerence in potency herein found. An overall
increase in polarity and, consequently, a decline in lipophilicity
and ability to cross phospholipidic bilayers is expectable from
the presence of the β-keto group in the structure of synthetic
cathinones.27 Conversely, the pyrrolidine group present in
derivatives such as MDPV greatly decreases their polarity,12
counteracting the eﬀect of the β-keto group.
Oxidative Stress as a Mechanism of β-Keto Amphet-
amines-Induced Neurotoxicity. The intracellular formation
of ROS and RNS and levels of GSH and GSSG were measured
in dopaminergic SH-SY5Y cells with the purpose of evaluating
the inﬂuence of oxidative stress in the observed β-keto
amphetamines-induced neurotoxicity. Contrarily to MDMA,
which was unable to trigger the production of ROS and RNS at
the conditions herein tested, methylone and MDPV induced a
signiﬁcant and concentration-dependent increase in reactive
species formation after a 24 h exposure (Figure 3). This
production was more evident for methylone, for which the
EC60 induced a 1.23 ± 0.02-fold increase over control cells (p <
0.0001 vs control; p < 0.01 vs EC30 methylone). Our group
recently showed that synthetic cathinones, contrarily to
MDMA, present a great reducing potential,19 which may justify
our results in neuronal cells. We have hypothesized that a
higher reducing potential may render the compounds more
liable to enter redox cycling, thus promoting greater ROS
generation. Nevertheless, further studies are required to
ascertain this hypothesis in a cellular model. In accordance
with our results, Rosas-Hernandez et al.24 recently showed the
ability of MDPV to trigger the formation of reactive species in
Figure 2. Nonlinear regression models for LDH leakage induced by
MDMA, methylone and MDPV in dopaminergic SH-SY5Y cells after
24 h exposure. The mean eﬀects were ﬁtted to the logit function.
Dotted lines represent the 95% conﬁdence band of each ﬁt. Results
were obtained from four independent experiments, performed in
triplicate. Table: estimated EC50 values for each compound in both cell
models. ****p < 0.0001 vs MDMA.
Figure 3. ROS and RNS production in dopaminergic SH-SY5Y cells
exposed to EC30 and EC60 MDMA, methylone and MDPV for 24 h.
Results were obtained from four independent experiments, performed
in triplicate. **p < 0.01, ****p < 0.0001 vs control. ##p < 0.01 vs EC30.
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undiﬀerentiated SH-SY5Y cells. When comparing MDPV and
MDMA with regards to ROS production, Rosas-Hernandez et
al.25 also determined that this β-keto amphetamine is more
potent than the non-keto amphetamine in an in vitro BBB
model. Oxidative stress has been extensively implicated in the
neurotoxicity of amphetamines, and it is characterized by a rise
in ROS and RNS formation through several possible
mechanisms, namely, oxidative deamination of catecholamines
by monoamine oxidase, mitochondrial dysfunction, metabolism
of the methylenedioxy ring, excitotoxicity, microglial activation,
depletion of antioxidant systems and hyperthermia.16,34,35
However, although evidence show that methamphetamine
increases the formation of ROS in SH-SY5Y cells at millimolar
levels,36−38 to the extent of our knowledge, neuronal MDMA-
induced ROS production was never shown in this in vitro
model. In fact, after 24 h exposure to MDMA (≤400 μM), our
group found no signs of neuronal oxidative stress,32,39,40 and
only after 48 h was it possible to observe a signiﬁcant decrease
in GSH intracellular levels of MDMA-treated SH-SY5Y cells.40
Evidences show that methylone and MDPV undergo metabolic
pathways analogous to MDMA, including the formation of
catechols.41,42 The further oxidation of cathecols into highly
reactive ortho-quinones that enter redox cycling is a well-known
pathway for MDMA-induced ROS generation,34 and may be
also anticipated for synthetic cathinones containing a
methylenedioxy ring, like methylone and MDPV. Moreover,
the conversion of unsequestered DA into reactive quinones and
radicals has been shown to contribute to methamphetamine-
induced neurotoxicity,43 and similar oxidative eﬀects may be
expected from the DA accumulation in the presynaptic cleft
triggered by methylone and MDPV.9,10 Additionally, the rise in
intracellular ROS and RNS formation as a consequence of the
disruption of the mitochondrial respiratory chain is also
acknowledged,44 and recent studies support the ability of
synthetic cathinones to impair mitochondrial respiratory
function in vitro,19,20,22,23 including the present work (as
Figure 4. Intracellular levels of (A) GSH and (B) GSSG in dopaminergic SH-SY5Y cells exposed to EC30 and EC60 MDMA, methylone, and MDPV
for 24 h. Results were obtained from three independent experiments, performed in triplicate. ***p < 0.001, ****p < 0.0001 vs control. ####p <
0.0001 vs EC30.
Figure 5. Representative cytometer plots displaying (A, C, and E) the distribution of events in FL2 vs FL1 and (B, D, and F) event counting and
distribution in FL1 for (A and B) control cells, (C and D) 200 μM CCCP, and (E and F) EC30 MDPV. (G) Percentage of depolarized events in
dopaminergic SH-SY5Y cells exposed to EC30 and EC60 MDMA, methylone and MDPV for 24 h. 200 μM CCCP was used as a positive control.
Results were obtained from ﬁve independent experiments, performed in triplicate. ****p < 0.0001 vs control. #p < 0.05, ##p < 0.01 vs EC30.
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shown below). The increase in ROS and RNS formation was
followed by a signiﬁcant GSH depletion, the primary cellular
antioxidant barrier, at the EC60 of both β-keto amphetamines
(Figure 4A), with a mean decrease of 23.0 ± 2.8 and 29.1 ±
3.8% for methylone and MDPV, respectively (p < 0.0001 vs
control). For MDMA, GSH depletion was more pronounced,
with a decrease of 44.7 ± 7.3% over control (p < 0.0001). This
decrease in GSH levels was accompanied by a signiﬁcant
increased GSSG formation (Figure 4B), the oxidized form of
GSH. The observed decline in GSH and increase in GSSG
formation are likely consequences of the triggering of ROS and
RNS generation. Interestingly, we observed GSH depletion for
all three compounds at the EC60, though no signiﬁcant ROS
and RNS production was found for EC60 of MDMA. In
addition to its function as a direct superoxide anion and
hydroxyl radical scavenger, GSH is also capable of conjugating
with ortho-quinones to form glutathionyl adducts, which is a
well described mechanism for amphetamines, including
MDMA,34 and may also justify the observed GSH depletion.
Importantly, the formation of GSH conjugates was recently
demonstrated in vitro for methylenedioxy β-keto amphetamines
including MDPV and methylone.45
β-Keto Amphetamines Impair Mitochondrial Function
in Dopaminergic Neuronal Cells. Mitochondrial oxidative
phosphorylation is the main pathway for ATP synthesis, and is
primarily stimulated by the mitochondrial uptake of free
calcium, which in turn is driven by the Δψm.44 Therefore, a
disruption of Δψm may lead to mitochondrial dysfunction and
disturb the intracellular energetic status. As depicted in Figure
5, methylone and MDPV, like MDMA, were shown to induce
substantial mitochondrial depolarization. In fact, the Δψm
dissipation was similar for all three substances, with signiﬁcant
increases already observed at the EC30, from 11.6 ± 0.6% of
depolarized events in control cells to 43.2 ± 2.1, 40.5 ± 1.9 and
43.1 ± 1.6% in cells treated with MDMA, methylone and
MDPV, respectively (p < 0.0001). The Δψm dissipation has
been associated with the neurotoxicity of amphetamine and
methamphetamine,46−48 hepatotoxicity of MDMA and meth-
ylone,18 and khat-induced cell death of primary normal human
oral cells.49 This eﬀect on Δψm was followed by a signiﬁcant
and concentration-dependent ATP depletion (Figure 6), with
mean reductions of 66.1 ± 2.1, 27.0 ± 1.6 and 49.8 ± 3.3% as
compared to control for EC60 MDMA, methylone and MDPV,
respectively (p < 0.0001 vs control; p < 0.01 vs EC30).
Importantly, the decrease in GSH levels occurred at the highest
concentration tested, whereas ATP depletion and/or mitochon-
drial membrane depolarization were already signiﬁcant at EC30,
suggesting that mitochondrial dysfunction may be involved in
the observed oxidative stress, as it was thoroughly reviewed for
amphetamines-induced neurotoxicity.15
β-Keto Amphetamines Induce Apoptotic Neuronal
Cell Death in a Concentration-Dependent Manner.
Subsequently to oxidative damage, mitochondria may undergo
profound changes, with opening of the mitochondrial
permeability transition pore (PTP), which leads to membrane
depolarization (Δψm dissipation), that in turn signals the
translocation of the pro-apoptotic factor Bax to the
mitochondria, causing cytochrome c release through the PTP
and initiating an apoptotic signaling cascade that includes the
activation of caspase 9 and the eﬀector caspase 3.44,50,51
Accordingly, a signiﬁcant rise in caspases 3 and 9 activity was
observed for both β-keto amphetamines, in a concentration-
dependent manner (Figures 7A and C). For the EC60,
methylone presented an increase of 336.9 ± 20.1 and 170.8
± 14.0% of caspase 3 and 9 activity over control (p < 0.0001),
respectively, while for MDPV this increment was slightly
higher: 346.2 ± 29.9 and 184.1 ± 10.5% of activity over control
(p < 0.0001). For both β-keto compounds, but not MDMA, it
was also observed a signiﬁcant activation of caspase 8 (Figure
7B), with similar values for EC60 methylone and MDPV: 153.3
± 14.3 and 156.6 ± 13.5% of activity over control (p < 0.001).
The activation of caspase 8 independently portrays the
mitochondria-independent pathway of apoptosis, as a con-
sequence of the binding of the drugs to cell surface death
receptors, leading to further activation of the eﬀector caspases,
and/or indirect activation of the mitochondria-dependent
pathway.52 The activation of both intrinsic and extrinsic
apoptotic mechanism was also reported for methylone and
MDPV in primary rat hepatocytes19 and for MDMA in
neuronal in vivo and in vitro models.53,54
Apoptosis is characterized by a series of typical morpho-
logical features such as cell shrinkage, chromatin condensation,
nuclear fragmentation and plasma membrane blebbing.55
Experimental evidence has revealed nuclear morphological
changes associated with neuronal cell death induced by
amphetamine derivatives, following mitochondria swelling,
release of pro-apoptotic factors, activation of caspases and
DNA fragmentation.56−60 Here we also demonstrated, through
Hoechst 33342/PI double staining, the triggering of apoptosis
in dopaminergic SH-SY5Y cells exposed to the β-keto
amphetamines, with evident changes in the morphology of
chromatin (Figure 8). In nontreated cells, large blue nuclei
appear with regular contours, while exposure to the drugs leads
to chromatin condensation characterized by a reduction of the
nuclei size (e.g., EC60 MDPV compared to control cells), and
presence of pyknotic nuclei, distinctive of early apoptosis
(without PI label, green arrows) and late apoptosis (with PI
label, yellow arrows). For the tested conditions, cells appear to
be in advanced stages of apoptosis, with a general prevalence of
late apoptotic events. Necrotic cells (large PI-labeled nuclei, red
arrows) were scarce. Nuclear morphology data further supports
the neuronal β-keto amphetamines-induced activation of
apoptosis, with an evident increase of apoptotic events in a
concentration dependent manner.
Importantly, the concentrations herein studied are consid-
erably higher than the micromolar levels found in blood
samples from β-keto amphetamines-related intoxications,61,62 as
well as the brain distribution levels determined in postmortem
samples.63 Nonetheless, the concentrations are in the range of
Figure 6. Intracellular levels of ATP in dopaminergic SH-SY5Y cells
exposed to EC30 and EC60 MDMA, methylone, and MDPV for 24 h.
Results were obtained from three independent experiments, performed
in triplicate. ****p < 0.0001 vs control. ####p < 0.0001 vs EC30.
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those used in other in vitro studies of this nature18,23 and the
obtained data should be considered as an insight into the
cellular mechanisms that may be involved in the in vivo eﬀects
of these NPS. It is also important to stress that the metabolic
pathways of β-keto amphetamines might lead to the formation
of highly neurotoxic metabolites, which, individually or in
mixture, may induce deleterious eﬀects signiﬁcantly more
pronounced than the parent compound, through similar
mechanisms but at substantially lower concentrations, as it
was recently demonstrated by our group for MDMA and its
metabolites.29 Additionally, further studies on the neurotoxicity
of β-keto amphetamines at in vivo relevant concentrations are
currently underway.
■ CONCLUSIONS
The continuous growth in the use of cathinone designer drugs
as alternative drugs of abuse poses signiﬁcant public health
challenges. The current work provided evidence of the in vitro
neurotoxic potential of two commonly abused β-keto amphet-
amines. A common pathway of neurotoxicity was found for
methylone and MDPV, which involved oxidative stress,
characterized by ROS and RNS production and GSH depletion,
and mitochondrial dysfunction, with Δψm dissipation and ATP
depletion, ultimately leading to cell death by apoptosis, with
activation of both mitochondria-dependent and -independent
pathways. Better knowledge of these mechanisms may help to
outline therapeutic approaches to avoid or attenuate the known
adverse outcome of synthetic cathinones abuse.
■ METHODS
Chemicals. Hydrochloride salts of methylone and MDPV were
purchased online from the Sensearomatic Web site (currently
unavailable) during March 2013. MDMA was extracted, puriﬁed,
and converted to the respective hydrochloride salt at UCIBIO-
REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, Porto,
Portugal, from high purity MDMA tablets provided by the Portuguese
Criminal Police Department. The salts were fully characterized by
mass spectrometry, NMR, and elemental analysis, and purity was
greater than 98%. Dulbecco’s modiﬁed Eagle’s medium (DMEM) with
4.5 g/L glucose, retinoic acid (RA), 12-o-tetradecanoylphorbol 13-
acetate (TPA), thiazolyl blue tetrazolium bromide (MTT), sodium
pyruvate, β-nicotinamide adenine dinucleotide reduced disodium salt
hydrate (β-NADH), L-glutathione reduced (GSH) and L-glutathione
oxidized disodium salt (GSSG), β-nicotinamide adenine dinucleotide
2′-phosphate reduced tetrasodium salt hydrate (β-NADPH), 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB), 2′,7′-dichlorodihydroﬂuor-
escein diacetate (DCFH-DA), adenosine triphosphate (ATP),
luciferase from Photinus pyralis (ﬁreﬂy) and D-luciferin sodium salt,
bisbenzimide H 33342 trihydrochloride (Hoechst 33342), propidium
iodide (PI), and bovine serum albumin (BSA) were purchased from
Sigma-Aldrich (St. Louis, MO). Heat-inactivated fetal bovine serum
(FBS), antibiotic mixture of penicillin/streptomycin (10 000 U/mL/
10 000 μg/mL), MEM Non-Essential Amino Acids (NEAA) 100×,
and Hank’s balanced salt solution (HBSS) were obtained from
GIBCO Invitrogen (Barcelona, Spain). 1-(2-[Bis(4-ﬂuorophenyl)-
methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909) hydro-
chloride was provided by Cayman Chemical (Ann Arbor, MI).
5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazoylcarbocyanine io-
dide (JC-1 dye) and 2-[2-(3-chlorophenyl)hydrazinylyidene]-
propanedinitrile (CCCP) were supplied by Thermo Fisher Scientiﬁc
(Waltham, MA) and Abcam (Cambridge, U.K.), respectively. All other
chemicals of analytical grade were purchased from Merck (Darmstadt,
Germany).
Cell Culture Conditions. The SH-SY5Y cell line is a human
neuroblastoma cell line that retain neuronlike properties, thus being
widely used as neuronal model.64 SH-SY5Y cells were supplied by
ATCC (American Tissue Culture Collection, Manassas, VA), and
routinely maintained in complete DMEM medium, supplemented with
10% FBS, 1% MEM NEAA, and 1% penicillin/streptomycin, at 37 °C
in a humidiﬁed atmosphere of 5% CO2. Subcultures were performed
weekly by trypsinization, and the assays were conducted over 8
Figure 7. Caspase (A) 3, (B) 8, and (C) 9 activity in dopaminergic SH-SY5Y cells exposed to EC30 and EC60 MDMA, methylone and MDPV for 24
h. Results were obtained from four independent experiments, performed in duplicate. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs
control. #p < 0.05 vs EC30.
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passages (passages 32−39) to avoid phenotypic changes. Upon
plating, cells were cultured at a density of 2.5 × 104 cells/cm2 and
diﬀerentiated into a dopaminergic phenotype prior to the incubation
with compounds. SH-SY5Y cell diﬀerentiation was induced with 10
nM RA for 72 h, followed by 10 nM RA and 80 nM TPA for 72 h
more. For viability assays conducted in undiﬀerentiated cultures, cells
were plated at 2.5 × 104 cells/cm2 without diﬀerentiation factors, cell
media was renewed after 72 h, and the drug treatments took place 72 h
later.
Experimental Procedures. All drug treatments were performed
in complete medium to avoid apoptotic cell death by serum
deprivation.65 In order to obtain a complete cytotoxicity concen-
tration−response curve, undiﬀerentiated and RA-TPA diﬀerentiated
SH-SY5Y cells were exposed for 24 h to MDMA, methylone or MDPV
at a wide concentration range, from 0.01 to 12 or 20 mM, and cell
viability was indirectly evaluated through the MTT reduction assay,
which provides an assessment of mitochondrial function. For RA-TPA
diﬀerentiated cells, the integrity of the plasma membrane was also
assessed by measuring the cellular leakage of the cytosolic enzyme
lactate dehydrogenase (LDH) at the same concentration range.
Further experiments were conducted only in RA-TPA diﬀerentiated
cells, including ROS and RNS production, determination of GSH and
GSSG levels, measurement of the mitochondrial membrane potential
(Δψm) and ATP intracellular levels, determination of caspases 3, 8,
and 9 activities, and Hoechst 33342/PI double staining for ﬂuorescent
microscopy. Cells were exposed to the drugs for 24 h, at the EC30 and
EC60 estimated from the concentration−response curves obtained
from the MTT reduction assay for this cell model. The determined
concentrations for MDMA, methylone and MDPV were, in that order,
as follows: EC30 of 1.253, 1.962, and 1.165 mM; EC60 of 1.693, 2.797,
and 1.703 mM. In experiments where the eﬀect of the selective DAT
inhibitor GBR 12909 was tested, the cells were pretreated for 30 min
with 1 μM GBR 12909 and then coincubated for 24 h with the drugs
at the EC30 and EC60.
Cell Viability Assays. Cell viability was assessed using the MTT
reduction assay, which measures the mitochondrial function, as
previously described29 with minor modiﬁcations. Brieﬂy, after 24 h of
exposure, cells were incubated with a 0.5 mg/mL MTT solution for 30
min, after which the formazan crystals formed through mitochondrial
succinate dehydrogenase were dissolved in DMSO and quantiﬁed at
550 nm in a 96-well plate reader (PowerWaveX; Bio-Tek, Winooski,
VT). The LDH leakage was also assessed in RA-TPA diﬀerentiated
cells, as described before.20 The half maximal eﬀective concentration
(EC50) of each compound was estimated for both data sets.
ROS and RNS Generation. The intracellular ROS and RNS
generation was monitored by means of the DCFH-DA probe, as
previously described.20 Data was obtained from four independent
experiments, run in triplicate, and normalized to cells with no
treatment.
Intracellular GSH and GSSG Levels. Total glutathione (tGSH)
and GSSG levels were determined by the DTNB−GSSG reductase
recycling assay, as described before.66 GSH levels were calculated by
subtracting GSSG content from tGSH values as follows: GSH = tGSH
− (2 × GSSG). Data were obtained from three independent
experiments, run in triplicate, and normalized to total protein.
Mitochondrial Membrane Potential. The Δψm reﬂects the
functional status of mitochondria within the cells. Changes in Δψm
were evaluated through the uptake of the JC-1 dye into the
mitochondria. JC-1 is a lipophilic cationic dye that selectively enters
the mitochondria proportionately to the membrane potential. Color
emission shifts reversibly from red to green upon membrane
depolarization. Brieﬂy, cells were trypsinized, centrifuged at 400g for
3 min and pellets were resuspended in a 5 μg/mL JC-1 solution and
incubated at 37 °C for 20 min. Cells were then rinsed and resuspended
in PBS for further analysis using a BD Accuri C6 ﬂow cytometer (BD
Biosciences, San Jose, CA). Both polarized (red ﬂuorescence) and
depolarized cells (green ﬂuorescence) were detected on the FL2 (585
nm) and FL1 (533 nm) channels. A minimum of 20 000 events per
sample was acquired for analysis. A 200 μM solution of CCCP, a
potent mitochondrial oxidative phosphorylation uncoupler, was used
as positive control of depolarization. Results were obtained from ﬁve
independent experiments run in triplicate.
Intracellular ATP Levels. Intracellular contents of ATP were
measured as previously described,39 through a bioluminescence assay
based on the emission of light from the reaction of ATP and luciferin,
catalyzed by the enzyme luciferase. Data were obtained from three
independent experiments, run in triplicate, and normalized to total
protein.
Caspases 3, 8, and 9 Activities. The activity of caspases 3, 8, and
9 was determined in the cytoplasmatic fractions, through a
colorimetric assay using substrates for each caspase, as previously
described.20 Results were obtained from four independent experi-
ments, run in duplicate, and normalized to total protein contents on
the cell lysate.
Nuclear Morphological Modiﬁcations. The activation of
nuclear morphological alterations by MDMA, methylone and MDPV
in SH-SY5Y cells was determined using Hoechst 33342, a cell-
permeant nuclear counterstain emitting blue ﬂuorescence when bound
to DNA, and PI, a membrane impermeant nuclear dye that emits red
ﬂuorescence in dead cells, as previously described.20
Statistical Analysis. Curves of normalized mortality values as a
function of concentration, obtained through the MTT reduction and
the LDH leakage assays, were constructed and analyzed as previously
described,19 with a modiﬁed logit function applied as follows: Y =
Figure 8. Representative ﬂuorescence microscopy images of Hoechst
33342/PI double staining of (A) control dopaminergic SH-SY5Y cells,
and cells exposed to EC30 and EC60 (B and C) MDMA, (D and E)
methylone, and (F and G) MDPV for 24 h. Green arrows indicate
early apoptotic cells (blue condensed nuclei), yellow arrows indicate
late apoptotic cells (red condensed nuclei), and red arrows indicate
necrotic cells (large red nuclei). Original magniﬁcation ×200.
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θmax/(1 + exp (−θ1 − θ2 log(x))), where θmax is the maximal observed
eﬀect, x is the concentration of the test drug, θ1 is the parameter for
the location, and θ2 is the slope parameter. Statistical uncertainties are
expressed as 95% conﬁdence intervals. For other assessments, results
are presented as mean ± standard error of the mean (SEM).
Normality of the data distribution was assessed by the D’Agostino &
Pearson omnibus normality test. Multiple comparisons within each
compound (concentration as a variable) or between each synthetic
cathinone and MDMA were performed through one-way ANOVA
analysis, followed by Fisher’s LSD post hoc test. Nonlinear curve
ﬁtting and all statistical calculations were performed using GraphPad
Prism 6 (version 6.01) for Windows. P-values lower than 0.05 were
considered statistically signiﬁcant.
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Abstract 
Autophagy has an essential role in neuronal homeostasis and its dysregulation 
has been recently linked to neurotoxic effects of a growing list of psychoactive drugs, 
including amphetamines. However, the role of autophagy in β-keto amphetamine (β-KA) 
designer drugs-induced neurotoxicity has hitherto not been investigated. In the present 
study, we show that two commonly abused cathinone derivatives, namely 3,4-
methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone 
(MDPV), elicited morphological changes consistent with autophagy and 
neurodegeneration, including formation of autophagic vacuoles and neurite retraction. 
Methylone and MDPV prompted the formation of acidic vesicular organelles (AVOs) and 
lead to increased expression of the autophagy-associated protein LC3-II in a 
concentration- and time-dependent manner. Electron microscopy confirmed the 
presence of autophagosomes with typical double-membranes and autolysosomes in SH-
SY5Y cells exposed to both β-KA. The autophagic flux was further confirmed using 
bafilomycin A1, a known inhibitor of the late phase of autophagy. Moreover, we showed 
that autophagy markers were activated before the triggering of cell death and caspase-3 
activation, suggesting that β-keto amphetamines-induced autophagy precedes apoptotic 
cell death. To address the role of oxidative stress in autophagy induction, we also 
investigated the effects of antioxidant treatment with N-acetyl-L-cysteine (NAC) on 
autophagy and apoptotic markers altered by these drugs. NAC significantly attenuated 
methylone- and MDPV-induced cell death, by completely inhibiting the generation of 
ROS and RNS, and hampering both apoptotic and autophagic activity, suggesting that 
oxidative stress plays an important role in mediating autophagy and apoptosis elicited by 
these drugs. 
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Introduction 
 
β-Keto amphetamines (β-KA), also known as synthetic cathinones, emerged 
recently in the recreational setting as a new class of psychoactive substances with 
structural and pharmacological properties resembling those of well-known 
amphetamines (Valente et al. 2014; Zaitsu et al. 2011). With over a hundred β-KA 
derivatives detected so far (EMCDDA-Europol 2016), 3,4-methylenedioxymethcathinone 
(methylone) and 3,4-methylenedioxypyrovalerone (MDPV) are among the most widely 
consumed ones. Like amphetamines or cocaine, methylone and MDPV inhibit the uptake 
of biogenic amines at the central nervous system, acting respectively as substrate or 
inhibitor of dopamine, noradrenaline and serotonin transporters, and leading to the 
accumulation of these catecholamines in the synaptic cleft and subsequent 
overstimulation of the sympathetic system (Baumann et al. 2012; Baumann et al. 2013; 
Prosser and Nelson 2012).  
Apart from their effects on the monoaminergic systems, little is known about the 
potential detrimental effects of β-KA to the brain. However, in view of the obvious 
similarities to long-studied neurotoxic drugs of abuse, the increasing abuse of β-KA 
raises concerns about potential neurotoxic effects. The first studies addressing the in 
vitro neurotoxicity of β-KA emerged in the past few years (den Hollander et al. 2014; den 
Hollander et al. 2015; Rosas-Hernandez et al. 2016a; Rosas-Hernandez et al. 2016b; 
Valente et al. 2017; Wojcieszak et al. 2016) indicating that neuronal death occurs 
through apoptosis and necrosis. Notwithstanding, several lines of evidence support that 
another form of programmed cell death, namely autophagic cell death, may play an 
important role in human neurodegenerative diseases (Jaeger and Wyss-Coray 2009). 
More recently, a growing number of psychoactive substances were also shown to induce 
autophagy, including cocaine (Cao et al. 2016; Guo et al. 2015; Periyasamy et al. 2016), 
MDMA (Li et al. 2016; Li et al. 2014; Mercer et al. 2017), methamphetamine 
(Chandramani Shivalingappa et al. 2012; Kanthasamy et al. 2006; Larsen et al. 2002; Li 
et al. 2012), cannabinoids (Salazar et al. 2009), morphine (Zhao et al. 2010), and 
ethanol (Chen et al. 2012; von Haefen et al. 2011). 
Autophagy upregulation was shown to be involved in the neurotoxicity triggered 
by amphetamine derivatives, though the role of autophagic activation in the observed 
neurodegeneration remains a controversial matter. For instance, the autophagic inhibitor 
3-methyladenine significantly attenuated MDMA-induced autophagic activation, while 
ameliorating MDMA-triggered neurite damage and neuronal death in both primary 
cultured cortical and serotonergic neurons (Li et al. 2016; Li et al. 2014). In contrast, 
Mercer et al. (2017) found that the potentiation of autophagy by rilmenidine, a known 
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autophagy activator, also had beneficial effects against MDMA-elicited 
neurodegeneration in serotonergic neurons, supporting a neuroprotective role for 
autophagy. Methamphetamine was shown to induce autophagy in dopaminergic cells by 
modulating regulatory factors common to apoptotic and autophagic pathways (Nopparat 
et al. 2010), and this autophagic upregulation was further determined to precede 
apoptotic activation (Kanthasamy et al. 2006). Moreover, the antioxidant agents N-
acetyl-L-cysteine, L-ascorbate, taurine and melatonin exhibited significant protective 
effects against the neurotoxic effects of methamphetamine by downregulating both cell 
death pathways (Chandramani Shivalingappa et al. 2012; Huang et al. 2017; 
Kongsuphol et al. 2009; Li et al. 2012; Nopparat et al. 2010). 
Regarding the β-KA, recent studies showed that they promote the production of 
reactive oxygen species, which have been proposed to act as upstream modulators of 
autophagy induction (Li et al. 2015). However, whether autophagy is activated by these 
drugs or its role in β-KA-induced neurotoxicity remains unknown. For this reason, the 
present study aimed at evaluating the occurrence and contribution of autophagy to 
neurotoxicity in dopaminergic SH-SY5Y cells challenged with methylone and MDPV. Our 
results provide evidence of autophagy activation by methylone and MDPV in 
dopaminergic SH-SY5Y cells. Moreover, NAC treatment ameliorated both methylone- 
and MDPV-induced autophagy and decreased the associated toxicity, suggesting that 
oxidative stress participates in the control of autophagy in response to β-KA in SH-SY5Y 
cells. 
Materials and Methods 
Chemicals 
Methylone and MDPV hydrochloride salts were purchased online (website 
currently unavailable), during March 2013. Chemical purity and identity of these 
compounds were verified by mass spectrometry, NMR and elemental analysis. All 
analytical data were consistent with the assigned structures with over 98% purity for both 
cathinone derivatives. Dulbecco’s Modified Eagle’s Medium (DMEM) - high glucose, 
thiazolyl blue tetrazolium bromide (MTT), 2′,7′-dichlorodihydrofluorescein diacetate 
(DCFH-DA), N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNA), acridine orange 
(AO), N-acetyl-L-cysteine (NAC), monoclonal anti-α-tubulin antibody, retinoic acid (RA), 
12-O-tetradecanoylphorbol 13-acetate (TPA), bafilomycin A1 (Baf A1) from
Streptomyces griseus and bovine serum albumin (BSA) were purchased from Sigma
Aldrich (St. Louis, MO, USA). Heat-inactivated fetal bovine serum (FBS), antibiotic
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mixture of penicillin/streptomycin (10,000 U/mL / 10,000 µg/mL), MEM Non-Essential 
Amino Acids 100 X, trypsin-EDTA and Hank’s balanced salt solution (HBSS) were 
obtained from Thermofisher Scientific (Waltham, MA, USA). Rabbit polyclonal anti-
LC3A/B antibody was supplied by Cell Signaling Technology® (Danvers, MA, USA). 
Amersham™ ECL™ Western Blotting reagent pack containing secondary anti-mouse 
and anti-rabbit HRP conjugate antibodies was purchased from GE Healthcare Life 
Sciences (Marlborough, MA, USA). All other chemicals of analytical grade were 
purchased from Merck (Darmstadt, Germany) or Sigma Aldrich (St. Louis, MO, USA).  
 
Cell culture and differentiation 
 
The epithelial SH-SY5Y human neuroblastoma derived cell line was supplied by 
ATCC® (American Tissue Culture Collection, Manassas, VA), and routinely maintained 
in complete DMEM medium, supplemented with 10% FBS, 100 U/mL penicillin, 100 
µg/mL streptomycin and MEM Non-Essential Amino Acids, at 37ºC, in a humidified 
atmosphere of 5 % CO2. Cells were subcultured over 7 passages (passages 31 to 37), 
and cultured at a density of 25.000 cells/cm2. Upon plating, cell differentiation into a 
dopaminergic phenotype was induced using 10 nM RA for 72 h, followed by 10 nM RA 
and 80 nM TPA for 72 h more. 
 
Experimental design 
 
Exposure to the test drugs took place after complete cell differentiation and was 
performed in complete medium to avoid the induction of autophagic cell death by serum 
starvation (Macleod et al. 2001; Xu et al. 2013). Complete cytotoxicity concentration-
response curves for differentiated SH-SY5Y cells exposed for 24 h to methylone and 
MDPV were previously determined through the MTT reduction assay (Valente et al. 
2017). For the present experiments, the β-KA drugs were tested at the effective 
concentrations (ECs) 10, 30 and 60, i.e., the concentrations that induce 10, 30 and 60% 
of viability loss, respectively, as estimated from the concentration-response curves. The 
determined ECs for methylone and MDPV were, in that order, as follows: EC10 of 1.342 
and 0.773; EC30 of 1.962 and 1.165 mM; EC60 of 2.797 and 1.693 mM. Depending on the 
experiment, cells were exposed to the drugs for 2, 6 and/or 24 h. For the assessment of 
the combination of each drug with the autophagy inhibitor Baf A1, cells were co-treated 
for 24 h with EC60 methylone or MDPV and 40 nM Baf A1, whereas for the antioxidant 
NAC, cells were pretreated for 30 min with 5 mM NAC before adding the drugs at EC60 
for 24 h more. 
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Phase contrast microscopy  
 
To detect possible morphological modifications due to the exposure to methylone 
or MDPV, cells were rinsed with HBSS after incubation with the compounds, and 
observed under an inverted microscope Nikon Eclipse TS100F (Nikon, Amsterdam, 
Netherlands), at an original magnification of 200×. 
 
Fluorescence microscopy with acridine orange staining 
 
Following exposure to methylone or MDPV, cells were incubated with 0.5 µg/mL 
AO for 20 min, at 37 ºC, to detect AVOs formation. AO is a lysosomotropic dye that emits 
green/yellow/orange/red fluorescence in a pH-dependent manner. At neutral pH, AO is a 
hydrophobic green molecule, while within acidic organelles it becomes protonated and 
form aggregates that emit bright yellow to red fluorescence. Following incubation with 
AO, cells were rinsed three times with HBSS and observed under an inverted 
fluorescence microscope Nikon Eclipse Ti (Nikon, Amsterdam, Netherlands), at an 
original magnification of 200×. 
 
Flow cytometry with acridine orange staining 
 
In order to quantify the drug-induced formation of AVOs, cells exposed to the 
drugs were collected with trypsin-EDTA, rinsed with HBSS and incubated with 0.5 µg/mg 
AO for 20 min, at 37 ºC, with agitation. Cells were then rinsed three times with HBSS by 
centrifugation at 400g for 3 min, and resuspended in HBSS for further analysis in a BD 
Accuri™ C6 flow cytometer (BD Biosciences, San Jose, CA, USA), using two channel 
(FL3/FL1) detection set on a linear scale. Briefly, the nucleus and cytoplasm of acridine 
orange-stained cells emit green fluorescence (FL1, 533 nm), whereas AVOs emits red 
fluorescence (FL3, 675 nm). Thus, the increase in intensity of red fluorescence (AO+ 
events), is proportional to the volume of AVOs. A minimum of 20,000 events per sample 
was acquired for analysis. Results are from four independent experiments, run in 
triplicate. Data were analyzed using BD Accuri™ software.  
 
Transmission electron microscopy 
 
To determine the nature of the observed vacuoles in phase contrast microscopy, 
cells exposed to methylone or MDPV were analyzed through transmission electron 
microscopy (TEM). For this purpose, about 5.0 x 106 cells were collected by 
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trypsinization, rinsed with HBSS, and centrifuged at 130g for 3 min. The pellets were 
then immersed in a solution of 2.5 % gluteraldehyde in 0.1 M cacodylate buffer, pH 7.2, 
for two hours. After rinsing with cacodylate buffer, tissue specimens were post-fixed in 
2% osmium tetroxide and rinsed again prior to dehydration with graded ethanol and 
further embedding in Epon™. The samples were then stored for two days at 60 ºC to 
promote resin polymerization. Ultrathin (100 nm) sections, contrasted with uranylacetate 
and lead citrate, were prepared on cupper grids (300 Mesh) for TEM analysis at 80 
kVolts in a JEOL USA JEM-1400 Transmission Electron Microscope (JEOL USA, Inc., 
Peabody, MA, USA).  
 
LC3 Western Blotting analysis 
 
Drug-induced LC3 turnover was detected through Western Blotting. For this 
purpose, after treatment, cells were rinsed, lysed in cold lysis buffer (20 mM Tris HCl; 
150 mM NaCl; 0.3% Triton X-100; 5 mM EDTA; pH 7.5) containing protease inhibitor 
cocktail, for 30 min at 4 ºC, and collected with a Teflon cell scrapper. Samples were then 
vortexed, sonicated and centrifuged at 15 000g for10 min. The supernatants were 
collected into new vials and the total protein content was determined using a Bio-Rad 
DC™ Protein Assay kit. A total of 100 µg of protein of each sample was subjected to 
15% acrylamide/bis-acrylamide SDS-PAGE gels. After electrophoresis, the proteins were 
transferred to nitrocellulose membranes, and the immunodetection was performed using 
a rabbit polyclonal anti-LC3A/B antibody (1:250), and the secondary anti-rabbit HRP 
conjugate antibody (1:2000). α-Tubulin was detected as a protein loading control, using a 
primary monoclonal anti-α-tubulin antibody (1:500) and a secondary anti-mouse HRP 
conjugate antibody (1:2000). Immunoreactive bands were visualized using the 
chemiluminescent Clarity™ Western ECL substrate and analyzed in a Bio-Rad 
ChemiDoc™ XRS+ System with Image Lab™ Software (Hercules, CA, USA). Results 
are from at least three independent experiments. 
 
Cell viability assays 
 
The viability of cells exposed to the different individual compounds or to the 
combination of each one with NAC was determined indirectly through the MTT reduction, 
performed as previously described (Valente et al. 2017). Data was obtained from five 
independent experiments, run in triplicate, and normalized to non-treated (100 % MTT 
reduction) and 1% triton X-100-treated cells (0 % MTT reduction). 
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ROS and RNS production 
 
The intracellular levels of ROS and RNS were determined using the DCFH-DA 
fluorescent probe, as previously described (Valente et al. 2016b), with minor 
modifications. Briefly, after differentiation, cells were incubated with a 100 µM DCFH-DA 
solution in complete medium. After 30 min, the supernatant was discarded and cells 
were exposed to the drugs. For ROS and RNS measurement in the presence of NAC, 
cells were simultaneously pretreated for 30 min with 100 µM DCFH-DA and 5 mM NAC, 
and then exposed for 24 h with NAC alone or in combination with the drugs. Results 
were obtained from five independent experiments, performed in triplicate, and 
normalized to non-treated cells. 
 
Caspase-3 activity 
 
The cytoplasmic caspase-3 activity was measured as a marker of apoptotic 
activity, using a colorimetric substrate for this effector caspase, as previously described 
(Valente et al. 2016b). Data are from five independent experiments, run in duplicate, and 
normalized to total protein concentration in cell lysates. 
 
Statistical analysis  
 
Results are presented as mean ± standard error of the mean (SEM). Normality of 
the data distribution was assessed by the D'Agostino & Pearson omnibus normality test. 
Multiple comparisons within each compound (concentration or time as a variable) or 
between treatments were performed through one-way ANOVA analysis, followed by 
Fisher´s LSD post hoc test. All statistical calculations were performed using GraphPad 
Prism 6 (version 6.01) for Windows. P-values lower than 0.05 were considered 
statistically significant. 
 
Results 
 
β-keto amphetamines trigger autophagy in dopaminergic SH-SY5Y cells in a time- and 
concentration-dependent manner 
 
Hitherto, there were no reports of the autophagy induction by β-KA on neuronal 
cells. In this study, we employed differentiated SH-SY5Y cells as an in vitro model of 
human dopaminergic neurons to evaluate the possible involvement of autophagy in 
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methylone- and MDPV-induced neurotoxic effects. The autophagy activation was 
investigated at different time points (2, 6 and 24 h) after initial exposure of cell to 
methylone or MDPV and with different drug concentrations (EC10, EC30 and EC60, i.e., 
effective concentrations causing respectively 10%, 30% and 60% loss of cell viability 
after 24 h exposure). 
We first examined the morphological changes in treated cells by phase contrast 
microscopy. As shown in Fig. 1, a marked increase in cytoplasmic vacuolization was 
already visible in methylone-treated cells after 2 h exposure (Fig. 1D), which was not 
seen in control cells (Fig. 1A), suggesting the occurrence of autophagy. Similar results 
were obtained in MDPV-treated cells (data not shown). Vacuole formation was 
accompanied by neurite retraction, being these alterations more pronounced with time of 
incubation (Figs 1D to 1F) and drug concentration (data not shown). 
 
Figure 1 
 
To clarify the nature of these vacuoles, we next studied the presence of AVOs by 
fluorescence microscopy and flow cytometry. The volume of cellular acidic compartment 
has been reported as a marker of autophagy that can be visualized after cell staining 
with acridine orange (AO) (Paglin et al. 2001). As shown in Fig. 2, control cells showed 
minimal acidic fluorescence (Fig. 2B). In contrast, cells exposed to EC60 MDPV for 6 h 
present bright yellow/orange/red fluorescence within vesicles, whereas the nucleus and 
cytoplasm exhibit green fluorescence (Fig. 2D). Interestingly, immunofluorescence 
images demonstrated that AVOs appear not only in the cell body of the neurons (red 
arrow), but also in neurites (yellow arrow).  
Red fluorescent events were also quantified through flow cytometry. The results 
show that methylone and MDPV induced AVOs formation in SH-SY5Y cells in a time- 
and concentration-dependent manner (Fig.s 2E and 2F). When comparing effects of the 
same drug concentration (EC30) but at different time points (Fig. 2E), both methylone and 
MDPV elicited a significant increase of AO+ events already after 2 h of exposure, with 
13.8 ± 2.4 and 10.8 ± 0.7 % AO+ events, respectively (p<0.001 vs. control). Both drugs 
significantly increased the AVOs formation already at the lowest concentration tested 
(Fig. 2F), with over 20 % of AO+ events for EC10 methylone or MDPV compared to the 3 
% detected in control cells (p<0.0001).  
 
Figure 2 
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To further determine the effect of β-KA on autophagy activity, we analyzed the 
expression of autophagy protein LC3 by western blotting analysis. Upon autophagy 
activation, the cytosolic form of the LC3, or LC3-I, is cleaved, conjugated with 
phosphatidylethanolamine to form LC3-II, and this form is inserted into autophagosome 
membranes (Tanida et al. 2008). Thus, the cytosolic turnover of LC3-I to LC3-II, here 
graphically represented as the LC3-II/LC3-I ratio, is a hallmark of autophagy and 
correlates with autophagosome formation. The expression of LC3 proteins, as well as 
the ratios of LC3-II/LC3-I, at different concentrations and exposure times are depicted in 
Fig. 3. The LC3-II band, virtually absent in control cells, is evident in drug-treated cells 
(Fig. 3A). We observed an increase in LC3-II expression in cells exposed to the β-KA in 
a time- and concentration-dependent manner, being this effect more pronounced for 
methylone. The results showed that treatment with EC30 methylone for 2, 6 and 24 h 
increased the LC3-II/LC3-I ratio 14-, 15- and 25-fold over control values (p<0.05), 
respectively (Fig. 3A). For cells treated for 24 h with EC60 methylone or MDPV, the rises 
in LC3 turnover were significant for both substances, with a 47-fold increase for 
methylone (p<0.0001 vs. control) and 13-fold increase for MDPV (p<0.01 vs. control) 
(Fig. 3B). 
The observed rise in LC3-II levels may be associated to either the increase of 
autophagosome formation in the early stage or the defective degradation in the late 
stage, which results in the accumulation of autophagic vacuoles. Therefore, to clarify the 
role of autophagosome accumulation, we employed Baf A1 to affect the autophagic flux 
and monitored LC3-I to LC3-II turnover.  Baf A1 inhibits the fusion between 
autophagosomes and lysosomes (Yamamoto et al. 1998) and, thus, if autophagic flux is 
occurring, the level of LC3-II expression will be increased in the presence of this 
inhibitor, since the transit of LC3-II through the autophagic pathway will be blocked. The 
results showed that, as expected, Baf A1 treatment alone enhanced LC3-II levels in SH-
SY5Y cells (Fig. 3C). More importantly, the levels of LC3-II in cells treated with Baf A1 
and methylone/MDPV together are higher than that treated by Baf A1 alone. This 
suggests that β-KA increases LC3-II levels primarily through the enhancement of 
autophagosomal formation rather than through inhibition of autophagosomal 
degradation. 
 
Figure 3 
 
Further validation of autophagosome formation was assessed by electron 
microscopy analysis. As shown in Fig. 4, non-treated SH-SY5Y cells are characterized 
by regular contours and membrane projections, typical cytoplasmic appearance, and 
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absence of any abnormal feature worthy of consideration (Fig. 4A). In contrast, the 
ultrastructural analysis of cells exposed to methylone and MDPV revealed distinctive 
morphological features of autophagic process. For instance, cells incubated with EC60 
MDPV for 24 h exhibit many vacuoles dispersed throughout the cytoplasm (Fig. 4B, red 
arrowheads), variable in shape and volume. The high-magnification image of a cell 
exposed to EC60 methylone for 6 h (Fig. 4C) shows that these vacuoles present a 
lamellar, vesicular structure surrounded by a double membrane (yellow arrowhead) and 
appear to engulf intracellular contents and whole organelles, including mitochondria 
(blue arrowhead), which are distinguishing morphological features of autophagosomes. 
Of note, in the most prolonged exposure time tested (24 h), methylone- and MDPV-
treated cells also exhibited dark vacuoles with high-density single-membrane structures, 
which are consistent with autolysosome degradation of the enclosed materials. These 
results further support that the autophagic flux is increased in SH-SY5Y cells exposed to 
β-KA. 
 
Figure 4 
 
Autophagy precedes apoptosis and involves oxidative stress 
 
There is a close crosstalk between the autophagic and apoptotic pathways, with 
common signaling factors maintaining a balance that regulates cytoplasmic contents and 
cellular turnover, respectively (Marino et al. 2014). Considering that methylone and 
MDPV trigger apoptosis in SH-SY5Y cells (Valente et al. 2017), we aimed at determining 
which mechanism takes place first. As depicted in Fig. 5, the markers of autophagy 
herein studied, namely LC3-I/LC3-II turnover (Fig. 5A) and formation of AVOs (Fig. 5B), 
are significantly increased at a concentration and time of exposure (EC30, 2 h) at which 
apoptosis and the reduction in cell viability are absent, as suggested by caspase 3 
activity (Fig. 5C) and MTT reduction measurements (Fig. 5D), respectively. This result 
was clearly more evident for methylone, for which the rise in LC3-II/LC3-I ratio and 
percentage of AO+ events are accompanied by a significant increase in ROS and RNS 
production (Fig. 5E), suggesting an involvement of oxidative stress in the activation of 
autophagy. 
 
Figure 5  
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N-acetyl-L-cysteine attenuates β-keto amphetamines-induced neurotoxicity by inhibiting 
autophagy and apoptosis 
 
To assess the contribution of oxidative stress to autophagic activation, we 
evaluated the effects of the antioxidant NAC in the expression of LC3-II, caspase-3 
activation, cell viability and ROS and RNS production in SH-SY5Y cells exposed to 
methylone and MDPV for 24 h. As depicted in Fig. 6, NAC, acting as a ROS scavenger, 
completely reversed the production of reactive species elicited by methylone and MDPV 
to control levels (Fig. 6A), while partially, but significantly, decreasing cell death induced 
by methylone and MDPV from approximately 60% to 47.8 ± 1.5 and 37.8 ± 2.0%, 
respectively (Fig. 6B).  In addition, a visible decrease of LC3-II expression was observed 
in the presence of NAC (p<0.05) (Fig. 6C), indicating a decrease in autophagosome 
formation, and thus an inhibition of β-KA-induced autophagic activity. Furthermore, NAC 
was also able to reduce methylone- and MDPV-induced apoptosis, as confirmed by the 
significant decline in caspase 3 activation of about 68 and 73 %, respectively, in the 
presence of the antioxidant (Fig. 6D). Taken together, these results suggest that NAC 
attenuates β-KA-induced neurotoxicity through the partial blocking of both autophagy 
and apoptosis, with oxidative stress playing a key role in this regulation. 
  
Figure 6 
 
Discussion 
 
Autophagy is a programed and evolutionarily-conserved catabolic process 
through which, at basal levels, cells digest intracellular contents in order to eliminate 
damaged organelles or unfolded proteins and maintain cellular homeostasis (Mizushima 
2007). Autophagy involves the formation of double membrane-bound structures called 
autophagosomes that engulf cytosolic aged proteins and organelles, particularly 
mitochondria. Autophagosomes ultimately fuse with lysosomes to form single membrane 
autolysosomes, within which the cargo is degraded (He and Klionsky 2009). Under 
various cellular and environmental stress conditions, such as nutrient depletion and 
oxidative stress, autophagy can be induced to maintain or promote cell survival or, upon 
extended insult, may be detrimental and act as a mode of cell death, either by cellular 
atrophy and collapse of cellular functions (autophagic or type II cell death), or through 
the activation of apoptotic (or type I cell death) or necrotic (or type III) cell death, 
suggesting that autophagy plays a key role in controlling cell metabolism and fate 
(Galluzzi et al. 2008; He and Klionsky 2009; Jaeger and Wyss-Coray 2009). 
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Here, we provide the first evidence that β-KA are able to induce a robust 
autophagic response in dopaminergic neurons in vitro. Our findings showed that 
methylone and MDPV, two commonly abused β-KA derivatives, elicited morphological 
and biochemical changes consistent with autophagy and neurodegeneration. Both drugs 
prompted the formation of AVOs and increased expression of the autophagy-
associated protein LC3-II in a concentration- and time-dependent manner. In accordance 
with these results, electron microscopy confirmed the increased autophagic flux in 
dopaminergic SH-SY5Y cells after drug exposure, as evidenced by the visualization of 
abundant double-membrane autophagosomes and autolysosomes. Bafilomycin A1 
further demonstrated that LC3 turnover was primarily related to the enhancement of 
autophagosome formation/maturation rather than to the blockade of autophagosomes 
and lysosomes fusion. Additionally, we provide evidence that methylone- and MDPV-
mediated induction of autophagy is an early event following drug exposure. Indeed, the 
autophagy markers (AVOs formation and LC3 turnover) were consistently positive in SH-
SY5Y cells as early as 2 h after drug exposure. More importantly, our results indicate 
that, at this time point, no effects on the apoptotic marker (i.e. caspase-3 activation) or 
cell viability were observed, thereby indicating that autophagy may be an initial process 
that precedes apoptotic cell death. 
Consistent with previous works (den Hollander et al. 2014; Rosas-Hernandez et 
al. 2016a; Valente et al. 2017), the present study showed that ROS are generated during 
neuronal exposure to β-KA, with this effect being more pronounced for methylone and 
already visible after 2 h of exposure. It is known that excessive accumulation of ROS 
may hamper the cellular homeostasis, leading to oxidative stress and mitochondrial 
dysfunction (Chakrabarti et al. 2014), and that basal autophagy enables the physiological 
turnover of damaged organelles, long-lived proteins, and cytoplasmic contents (He and 
Klionsky 2009). Under mild oxidative conditions that surpass the cell defenses, 
autophagy is upregulated as an adaptive stress response, degrading and recycling 
oxidized (damaged) biomolecules, whereas excessive oxidative stress may result in 
autophagic cell death (Navarro-Yepes et al. 2014). Recent studies support the role of 
ROS and RNS as intracellular signal transducers, triggering autophagosome formation 
and autophagic degradation, and thus, by disposing cells of oxidatively damaged 
proteins and organelles, autophagy helps reduce the elicited oxidative stress (Filomeni et 
al. 2015). In line with this, in vitro studies show that the generation of ROS is involved in 
methamphetamine-induced autophagy in neuronal cells (Chandramani Shivalingappa et 
al. 2012; Huang et al. 2017; Li et al. 2012). For instance, Huang et al. (2017) showed 
that 5 mM methamphetamine induces significant ROS generation in neuron-glial cells 
after 1 h of exposure and upregulation of autophagic biomarkers after 3 h, while cell 
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damage, as determined through the LDH leakage assay, was only evident after 6 h of 
treatment. A similar mechanism can be postulated for methylone and MDPV, activating 
autophagy to alleviate oxidative stress and protecting neuronal cells from apoptotic cell 
death. Supporting this hypothesis, we showed that, though methylone increased ROS 
levels 2 h after drug exposure, we were unable to detect any evidence of cell death or 
apoptosis activation, suggesting that ROS production induced by methylone (and to a 
less extent by MDPV) may play a role in cell survival at an initial stage rather than 
instigate a toxic effect. 
The disruption of the intracellular redox status has been extensively implicated in 
the neurotoxicity of amphetamines, and involves several mechanisms including 
increased generation of ROS and RNS, oxidative deamination of released 
catecholamines, mitochondrial dysfunction, metabolism of the methylenedioxy ring, 
excitotoxicity, microglial activation, depletion of antioxidant systems and hyperthermia 
(Carvalho et al. 2012; Halpin et al. 2014). Due to the structural similarities of methylone 
and MDPV to these illicit substances, it may be postulated that synthetic cathinones elicit 
neuronal oxidative stress through mechanisms similar to those of amphetamines. For 
instance, direct oxidation of accumulated DA in the presynaptic cleft and subsequent 
formation of reactive DA quinones appears to contribute to the neuronal production of 
ROS by methamphetamine (LaVoie and Hastings 1999), and it may also be expected 
from synthetic cathinones that have the ability to decrease the reuptake of DA, which is 
the case of the derivatives herein studied. Furthermore, evidence shows that both 
methylone and MDPV undergo O-demethylenation of the methylenedioxy ring, 
analogous to MDMA, with formation of catechols (Pedersen et al. 2013; Strano-Rossi et 
al. 2010), which, for MDMA, are well-known precursors of the highly reactive and ROS 
generating ortho-quinones (Monks et al. 2004). Hyperthermia is another important factor 
contributing for the exacerbation of oxidative damage induced by amphetamines 
(Carvalho et al. 2012), and both methylone and MDPV were reported to elicit the rise in 
body temperature in humans (Barrios et al. 2016; Borek and Holstege 2012) and animal 
models (Anneken et al. 2015; King et al. 2014). Of note, we recently demonstrated the in 
vitro potentiation of MDPV-induced hepatotoxicity by hyperthermia, characterized by the 
increase in both oxidative stress and mitochondrial dysfunction markers (Valente et al. 
2016b). Additionally, mitochondria are also a major source of ROS and recent studies 
support the ability of β-KA, including methylone and MDPV, to impair mitochondrial 
respiratory function in vitro (den Hollander et al. 2014; den Hollander et al. 2015; 
Nakagawa et al. 2009; Valente et al. 2016a; Valente et al. 2016b; Valente et al. 2017), 
which is characterized by marked ATP depletion, increased calcium levels and 
mitochondrial depolarization. 
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Our group has recently demonstrated that oxidative stress is involved in 
methylone- and MDPV-elicited neuronal cell death, eliciting the generation of ROS and 
RNS, decline in the intracellular levels of GSH and increased oxidized glutathione levels 
(Valente et al. 2017). NAC is a thiol-based antioxidant that acts as a ROS scavenger and 
as a precursor for GSH biosynthesis (Firuzi et al. 2011). Based on NAC's beneficial 
effects, we hypothesize that it may elicit a protective effect against β-KA-induced 
neurotoxicity by modulating oxidative damage. Previous studies showed that apoptosis is 
a common mechanism of cell death induced by methylone and MDPV, with evident DNA 
fragmentation, chromatin condensation and formation of pyknotic nuclei, and caspases 
activation (Adam et al. 2014; Rosas-Hernandez et al. 2016a; Valente et al. 2016a; 
Valente et al. 2016b; Valente et al. 2017). Therefore, we also examined the relationship 
between cellular redox status, autophagy, and apoptotic cell death following drug 
exposure. Our results revealed that NAC completely reversed the redox imbalance 
elicited by methylone and MDPV and, most importantly, partially attenuated both 
autophagic and apoptotic activity, as demonstrated respectively by the decrease in LC3 
turnover and caspase-3 activity, which resulted in a significant decrease of cell death. 
ROS-mediated events may not be the sole redox-related event involved in the regulation 
of autophagy. Other factors, such as GSH redox status, have also been shown to 
regulate autophagy (Filomeni et al. 2010). In line with this, Chandramani Shivalingappa 
et al. (2012) showed that the activation of autophagy by methamphetamine in 
dopaminergic neurons was associated with the depletion of GSH, and NAC, acting as 
the precursor for the biosynthesis of GSH, significantly reduced autophagy and 
apoptosis in methamphetamine-treated cells, thereby exhibiting neuroprotective effects. 
Nonetheless, we have recently shown that the decrease in neuronal GSH levels elicited 
by methylone and MDPV in the present in vitro model is a later event, with ROS and 
RNS production taking place before GSH depletion (Valente et al. 2017), leading us to 
consider that NAC protective effects against β-KA neurotoxicity may be primarily related 
to its ROS scavenging properties. Altogether, our study highlights the central role of 
cellular redox status both in the mechanism of neuroprotection and modulation of 
autophagy.  
There are several signaling pathways described in the literature by which ROS 
may regulate autophagy, including the blockade of the inhibitory pathway of the 
mechanistic target of rapamycin (mTOR) (Lee et al. 2012), and upregulation of several 
pro-autophagic genes, such as p53, p62, extracellular regulated kinase (ERK), hypoxia-
inducible factor-1 and adenosine monophosphate-dependent protein kinase (AMPK) (Li 
et al. 2015; Scherz-Shouval and Elazar 2011). For instance, MDMA-induced neuronal 
autophagy appears to involve AMPK signaling, but not the inhibition of the mTOR 
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complex (Li et al. 2016; Li et al. 2014), whereas methamphetamine targets the mTOR 
and the ERK1/2 pathways (Ma et al. 2014). Further studies are underway to ascertain 
which molecular signaling pathways may be involved in autophagy triggered by β-KA 
and in its regulation by oxidative stress. 
The crosstalk between autophagy and apoptosis is complex and decisive to 
cellular fate. Under certain cellular conditions, autophagy can promote cell survival and 
halt apoptosis, while in other circumstances, it may culminate in cell death, either 
independently or in close collaboration with apoptosis (Eisenberg-Lerner et al. 2009). 
The two mechanisms are regulated by common factors and each can regulate and 
modify the activity of one another (Marino et al. 2014). Our finding that NAC, acting as an 
antioxidant, can alleviate methylone- and MDPV-stimulated autophagy while rescuing 
cells from apoptotic cell death, further supports the role of autophagy as a cellular self-
defence response against β-KA-induced oxidative stress and subsequent cell death. 
 
Conclusions 
 
To the best of our knowledge, this is the first report demonstrating that methylone 
and MDPV induce autophagy in human dopaminergic SH-SY5Y cells, thus constituting a 
new insight into the context of β-KA-related neurotoxicity. Our work also demonstrates 
that increased ROS levels is one of the pivotal mechanisms involved in β-KA-induced 
neurotoxicity and autophagy in dopaminergic SH-SY5Y cells. Furthermore, scavenging 
of free radicals such as ROS and RNS, using NAC, partially attenuated β-KA-induced 
upregulation of autophagy and apoptosis, leading to a significant reversion of the 
neuronal cell death elicited by these substances. These findings highlight the importance 
of cell redox status in β-KA-induced dopaminergic cell death and support the use of 
antioxidant agents to ameliorate the neurotoxic effects of these new psychoactive 
substances. Further studies will be necessary to confirm the effectiveness of NAC on the 
prevention of β-KA-induced dopaminergic degeneration in vivo. 
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Figures 
 
Fig. 1 Representative phase contrast images demonstrating morphological changes in dopaminergic SH-
SY5Y cells exposed to a β-KA. Cells treated with EC60 methylone for 2 h (D), 6 h (E) and 24 h (F) exhibit a 
visible time-dependent neurite retraction and intracellular vacuoles increase in number and size (yellow 
arrowheads), when compared to control cells observed at the same time points (A – C) 
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Fig. 2 Representative phase contrast (A and C) and fluorescence (B and D) micrographs of dopaminergic 
SH-SY5Y cells stained with acridine orange (AO) after exposure to a β-KA. Cells treated with EC60 MDPV 
for 6 h (C and D) present acidic vesicular organelles stained in red, appearing in both cell stroma (red arrow) 
and neurites (yellow arrow), which are scarce or absent in control cells (A and B). Quantification of AO+ 
events in dopaminergic SH-SY5Y cells exposed to methylone and MDPV (E and F). Both compounds 
elicited a significant increase of AO+ events in a time- (E; EC30) and concentration-dependent manner (F; 24 
h). ***p<0.001, ****p<0.0001 vs. control. #p<0.05, ##p<0.01, ###p<0.001 
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Fig. 3 Representative blots showing LC3I/LC3II and α-tubulin expression and LC3II/LC3I ratio in cells 
exposed to(A) EC30 methylone or MDPV for 2, 6 and 24 h, (B) EC10, EC30 and EC60 methylone or MDPV for 
24 h, and to (C) 40 nM Baf A1 and/or EC60 methylone or MDPV for 24 h. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs. control 
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Fig. 4 Representative transmission electron micrographs demonstrating increased autophagic vacuoles in 
dopaminergic SH-SY5Y cells exposed to β-KA. Compared to control cells (A; 15 000 x magnification), 
cultures exposed to EC60 MDPV for 24 h (B; 12 000 x magnification) exhibit autophagic vacuoles (red 
arrowheads) scattered throughout the cytoplasm. These vacuoles, already present after 6 h of exposure to 
EC60 methylone (C; 30 000 x magnification), present double membrane (yellow arrowhead), characteristic of 
autophagosomes, which engulf large amounts of cellular content and even whole organelles, such as 
mitochondria (blue arrowhead) 
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Fig. 5 (A) LC3II/LC3I ratio, (B) quantification of AO+ events, (C) caspase 3 activation, (D) MTT reduction and 
(E) ROS and RNS production in cells exposed to EC30 methylone or MDPV for 2 h. *p<0.05, ***p<0.001, 
****p<0.0001 vs. control 
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Fig. 6 Evaluation of (A) ROS and RNS production (B) MTT reduction, (C) LC3I/LC3II turnover (with 
representative blots) and (D) caspase 3 activation, after 24 h of incubation of dopaminergic SH-SY5Y cells 
with 5 mM NAC and/or EC60 methylone or MDPV. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs. control. 
#p<0.05, ####p<0.0001 
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Section IV – Integrated discussion 
 
The current knowledge on the potential harmful effects arising from the abuse of β-
keto amphetamines is very limited, and aside from reported clinical complications and 
pharmacological modes of action, little is known about the mechanisms of cytotoxicity 
involved in the end-organ effects, in particular acute liver failure and CNS damage. 
In the present thesis, we aimed at unveiling the cellular hepato- and neurotoxicity 
mechanisms prompted by β-keto amphetamines. Considering their chemical and 
pharmacological resemblance to non-keto amphetamines, comparative toxicological 
studies were conducted in the presence of MDMA, a widely recognized hepato- and 
neurotoxicant. 
Experimental data incorporated in this thesis covered the assessment of 
mechanisms known to have an important role in the cytotoxicity mediated by classical 
amphetamines, namely oxidative stress, mitochondrial dysfunction, activation of 
programmed cell death pathways and hyperthermia. The obtained results were extensively 
discussed within each chapter from the previous section. In this section, the intent is to 
integrate all data and discuss the factors that may play a major role in the hepatotoxicity 
and neurotoxicity of β-keto amphetamines. 
 
Characterization of the common mechanisms involved in the in vitro toxicity 
triggered by β-keto amphetamines in hepatic and neuronal cell models, and the 
relevance of structural modifications on the observed cytotoxicity 
 
 In the assessment of the hepatotoxic and neurotoxic potential of frequently abused 
cathinones, we found the activation of common mechanisms of oxidative stress, 
mitochondrial dysfunction and programmed cell death. Like MDMA, β-keto amphetamines 
elicited hepatic and neuronal cell death in a concentration-dependent manner, though with 
variable potencies among derivatives (Manuscripts I and III). As aforementioned, the 
lipophilicity of compounds may influence their toxicity by determining their ability to cross 
bilipid layers and reach target cells. In fact, we found a direct correlation between the 
predicted lipophilicity of the tested compounds and their hepatotoxic potential, i.e. the 
compound with lower log P value, methylone, was the least hepatotoxic drug, while MDPV 
and pentedrone, with log P values higher than MDMA, were the strongest hepatotoxicants 
in both in vitro models used, namely primary rat hepatocytes (PRH) and the human 
hepatoma cell line HepaRG (Manuscript I). Accordingly, methylone was also less toxic than 
MDMA and MDPV in neuronal cells (Manuscript III). These results are in line with what is 
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acknowledged from the chemical structure of β-keto amphetamines: 1) the ketone group 
greatly increases the polarity of synthetic cathinones, which decreases their permeability 
and consequently reduces their psychostimulant and toxic potential when comparing to their 
non-keto analogues; 2) the pyrrolidine ring has an opposing effect, conferring greater 
permeability to pyrovalerone derivatives (Valente et al. 2014).  
The studied cathinones triggered hepatic and neuronal oxidative stress through 
mechanisms similar to long-studied amphetamines, namely with increased production of 
ROS and RNS and GSH depletion (Manuscripts I, II and III). Intriguingly, ROS and RNS 
production elicited by each compound diverged from their toxic potential. Therefore, in an 
attempt to explain the differences found among derivatives, we assessed their reducing 
potential and found that methylone, pentedrone and 4-MEC, which elicited significant ROS 
and RNS production in PRH at lower concentrations, were the derivatives with higher redox 
potential, while MDPV, one of the most hepatotoxic derivatives, exhibited lower reducing 
ability (Manuscript I). In dopaminergic SH-SY5Y cells, methylone also elicited more 
generation of ROS and RNS than MDPV (Manuscripts III and IV), while MDMA was unable 
to trigger this mechanism (Manuscript III). In agreement to these results, we showed that 
MDMA, contrarily to cathinones, has virtually no redox potential (Manuscript I), which is also 
in conformity with the work of den Hollander et al. (2014). As weak bases, synthetic 
cathinones exhibit higher electron-donor capacity than MDMA, which combined with their 
ability to undergo keto-enol tautomerization, may validate the elevated redox potential, while 
the molecular stabilization from the pyrrolidine ring might be counteracting this effect 
(Coppola and Mondola 2012b; Leffler et al. 2014).  
Recent in vivo studies showed that 4-MMC induces neuronal lipid peroxidation with 
adaptative regulation of antioxidant enzymes, including catalase, superoxide dismutase, 
glutathione peroxidase and NO synthase (Budzynska et al. 2015; Ciudad-Roberts et al. 
2016; Lopez-Arnau et al. 2015). In our in vitro models, β-keto amphetamines induced GSH 
depletion and consequent GSSG formation (Manuscripts I, II and III). As a major 
endogenous antioxidant barrier, GSH is responsible for, among other protective functions, 
the direct scavenging of reactive species in hepatic and neuronal cells (Bains and Shaw 
1997; Chen et al. 2013). In this process, GSH is oxidized into GSSG, thus explaining the 
results observed in the present thesis (Manuscript I and III). Furthermore, Meyer et al. 
(2014) validated the formation of GSH conjugates with five methylenedioxy cathinones, 
including methylone and MDPV, hypothesizing a conjugation at the aromatic ring, which is 
also conceivable for non-methylenedioxy derivatives, such as pentedrone and 4-MEC. This 
GSH conjugation may aggravate the depletion of GSH without interfering with GSSG levels. 
Our results also suggest a crosstalk between oxidative stress, mitochondrial 
dysfunction and dysregulation of cellular calcium homeostasis, which was supported by the 
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increase in intracellular Ca2+ levels in PRH exposed to MDPV (Manuscript II), depletion of 
ATP (Manuscripts I, II and III), Δψm disruption in dopaminergic cells (Manuscript III), and 
the activation of the mitochondria-dependent apoptotic pathway, substantiated by the 
activation of caspase 9 in both target cells (Manuscripts I, II and III). Accordingly, the work 
of Nakagawa et al. (2009) showed that methylone elicited significant Δψm dissipation in 
isolated rat hepatocytes, accompanied by concentration-dependent ATP depletion, 
membrane blebbing and cell death, while 4-MMC was shown to inhibit the mitochondrial 
respiration in neuronal cells (den Hollander et al. 2014). Mitochondrial impairment might 
also lead to the exacerbation of the oxidative damage through the formation of 
mitochondria-derived ROS (Brookes et al. 2004), but it remains unclear whether 
mitochondrial dysfunction is potentiating the oxidative stress triggered by these substances. 
Nonetheless, the contribution of the oxidative damage to the overall cytotoxicity of β-keto 
amphetamines was confirmed by the protective effects of the antioxidant agents AA 
(Manuscript I) and NAC (Manuscripts I and IV) against induced cell death, which may be 
acting as ROS and RNS scavengers, AA may regenerate other antioxidants, and NAC can 
enact the synthesis of GSH (Firuzi et al. 2011; Maxwell 1995). 
As previously suggested for MDMA (Capela et al. 2013; Dias da Silva et al. 2013), 
β-keto amphetamines also seem to have targeted death receptors in PRH and 
dopaminergic neurons, leading to the activation of mitochondria-independent apoptosis, as 
ascertained by the activation of caspase 8 attained with all derivatives in both in vitro models 
(Manuscripts I, II and III). Regardless of the upstream pathway of programmed cell death 
being triggered, the signaling cascades of such pathways ultimately converge to activate 
common downstream mechanisms, specifically the effector caspase 3 or 7 (McIlwain et al. 
2013). Accordingly, we found that β-keto amphetamines triggered the activation of caspase 
3 in PRH and dopaminergic SH-SY5Y cells (Manuscripts I, II and III). In both models, we 
also observed cellular morphological changes consistent with apoptotic cell death, namely 
cell shrinkage, chromatin condensation and formation of pyknotic nuclei, with an apparent 
increase in apoptotic events and a progression from an early to a late stage apoptosis in a 
concentration-dependent manner (Manuscripts I, II and III). In PRH, it was also possible to 
observe the existence of necrotic events at higher concentrations of β-keto amphetamines 
(Manuscripts I and II), while in neuronal cells, they were infrequent (Manuscript III). These 
data suggest that necrosis may be a more preeminent mechanism of cell death in the liver. 
 
Relevance of metabolic activation in β-keto amphetamines-induced hepatotoxicity 
 
In our study on β-keto amphetamine-induced hepatotoxicity (Manuscript I), 
methylone, MDPV, pentedrone and 4-MEC were 3.2- to 5.2-fold less potent in the human 
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HepaRG cell line than in PRH, which may be related to the level of metabolic enzyme 
expression in each model. In fact, HepaRG is a hepatoma-derived cell line obtained from a 
poor cytochrome P450 (CYP) 2D6 metabolizer individual (Guillouzo et al. 2007). 
Importantly, CYP2D6 is the main phase I metabolizing enzyme of synthetic cathinones 
(Negreira et al. 2015; Pedersen et al. 2013), which explains the higher susceptibility of PRH 
to cell death induced by these substances. The co-incubation with the selective CYP2D6 
inhibitor, quinidine, partially prevented the β-keto amphetamines-elicited cell death, which 
supports the hypothesis of CYP2D6-mediated bioactivation of synthetic cathinones, a 
mechanism fully accepted for amphetamine derivatives (Carmo et al. 2007; Carmo et al. 
2006).  
As previously mentioned, the metabolic bioactivation plays an important role in the 
expression of MDMA-induced hepatotoxicity (Carvalho et al. 2004b). In this process, the 
methylenedioxy ring is opened, resulting in the formation of catechol metabolites, which are 
further oxidized into highly reactive ortho-quinones and semiquinones, that may enter redox 
cycling with formation of ROS and RNS, thus contributing to the elicited oxidative damage 
(Carvalho et al. 2012). Although the formation of ortho-quinones has not been reported to 
date for β-keto amphetamines, the demethylenation process and formation of catechol 
metabolites was shown to occur both in vitro and in vivo (Kamata et al. 2006; Meyer et al. 
2010a; Pedersen et al. 2013; Strano-Rossi et al. 2010), and recent evidence suggest that 
these metabolites exhibit higher cytotoxicity than their parent compounds (Wojcieszak et al. 
2016). Taken together, these data support the in vitro hepatic bioactivation of synthetic 
cathinones and its potentiating effect towards cell death. 
 
Role of hyperthermia on β-keto amphetamines-induced hepatotoxicity 
 
A prominent acute toxic effect of β-keto amphetamines is hyperthermia (Barrios et 
al. 2016; Beck et al. 2015; Zona et al. 2016), and the rise in temperature has been shown 
to potentiate the toxicity induced by MDMA in liver (Carvalho et al. 2001b; Pontes et al. 
2008c) and neuronal in vitro models (Capela et al. 2006).  
For the evaluation of the role of hyperthermia in β-keto amphetamines-induced 
hepatotoxicity (Manuscript II), we chose MDPV, one of the most prevalent derivatives and 
known to induce robust increases in human body temperature up to 41.7 oC (Borek and 
Holstege 2012; Frohlich et al. 2011; Kesha et al. 2013; Mugele et al. 2012; Murray et al. 
2012). We found that the increase in incubation temperature from 37 to 40.5 ºC significantly 
aggravated the hepatotoxic potential of MDPV in PRH, and potentiated all oxidative stress 
and mitochondrial dysfunction markers herein studied. This included a significant 
enhancement of ROS and RNS generation, and GSH and ATP depletion, a substantial, 
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though not significant, increase in Ca2+ intracellular levels, and a precipitation of both 
intrinsic and extrinsic apoptotic cell death pathways, as ascertained by the activation of 
caspase 8 and 9, as well as caspase 3, at lower concentrations. In agreement with previous 
works (Santos-Marques et al. 2006; Skibba et al. 1989), we showed that hyperthermia per 
se, elicited a significant decrease in GSH levels in non-treated PRH. We also observed 
morphological changes in control cells under hyperthermic conditions, namely the presence 
of pyknotic nuclei and fragmented chromatin, consistent with early apoptotic cell death. Of 
note, activation of caspases induced by MDPV reached a peak at the second highest 
concentration tested (0.8 mM), suffering a decrease at the highest one (1.6 mM). 
Microscopical analysis with fluorescent nuclei dyes (Hoechst 33342 and propidium iodide) 
evidenced the increased prevalence of necrotic events under hyperthermia. These results 
suggest that the increase in temperature rendered cells more vulnerable to necrosis, which 
was also described in PRH and HepG2 cells exposed to MDMA (Dias da Silva et al. 2013; 
Pontes et al. 2008c). Taken together, our data suggest that the thermoregulation 
impairment elicited by synthetic cathinones most certainly contributes to increased liver 
damage, and it may also potentiate neurodegeneration. 
There is a great number of mechanisms by which amphetamines may induce 
hyperthermia (Carvalho et al. 2012). However, apart from the inhibitory effects on α-
adrenoceptors (Simmler et al. 2013a; Simmler et al. 2014), there is still a lack of 
experimental data on the pro-hyperthermic mechanisms activated by β-keto amphetamines. 
 
Role of autophagy on β-keto amphetamines-induced neurotoxicity 
 
Autophagy is a programmed catabolic process through which, at basal levels, cells 
digest intracellular contents to eliminate damaged organelles or proteins, and maintain 
cellular homeostasis (Mizushima 2007). In this process, the damaged cytoplasmic content 
is engulfed by doubled-membrane vacuoles, called autophagosomes, and redirected to 
lysosomes for degradation and recycling (He and Klionsky 2009).  
In the last experimental work, we presented the first evidence that β-keto 
amphetamines are able to induce neuronal autophagy (Manuscript IV). Our data showed 
that methylone and MDPV trigger the formation of AVOs in dopaminergic SH-SY5Y cells, 
and induce neurite retraction, two hallmark mechanisms of autophagy-related 
neurodegeneration (Chu et al. 2009; Paglin et al. 2001). Cells exposed to these two β-keto 
amphetamines also exhibited morphological and biochemical changes consistent with 
autophagic activation, which includes the instigation of autophagosome formation, with 
evident progression to autolysosomes, and increased expression of the autophagy-related 
protein LC3-II in a concentration- and time-dependent manner. 
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 Under stress conditions, autophagy is known to be upregulated as an adaptive 
mechanism to promote cell survival. At extreme circumstances, it may be detrimental, acting 
as a programmed cell death pathway (autophagic cell death), or by enacting cell death by 
apoptosis or necrosis (Galluzzi et al. 2008). A growing number of in vitro studies support 
the ability of MDMA and METH to trigger autophagy in neuronal cells (Chandramani 
Shivalingappa et al. 2012; Kanthasamy et al. 2006; Larsen et al. 2002; Li et al. 2016; Li et 
al. 2014; Li et al. 2012; Mercer et al. 2017), however, the influence of autophagic activation 
on amphetamines-induced neurotoxicity remains a debatable matter, with evidence 
supporting either a neuroprotective role for autophagy (Mercer et al. 2017), or a mechanism 
of cell death potentiation (Li et al. 2016). Our data suggest that β-keto amphetamines-
induced autophagic activation is an early neuronal event, with substantial upregulation of 
the autophagy markers (LC3 turnover and AVOs formation) already after 2 h of exposure. 
These effects also preceded the induction of cell death and caspase 3 activation, supporting 
the activation of autophagy prior to apoptosis, which is in line with other in vitro studies 
regarding METH-induced neurodegeneration (Huang et al. 2017; Kanthasamy et al. 2006; 
Ma et al. 2014). Interestingly, experimental evidence supports a complex interplay between 
the two programmed cell death pathways (Boya et al. 2005; Eisenberg-Lerner et al. 2009; 
Gonzalez-Polo et al. 2005; Yu et al. 2004), but further studies are required to ascertain the 
role of β-keto amphetamines-induced autophagy on neuronal apoptotic cell death. 
Finally, considering the demonstrated potential of β-keto amphetamines to disrupt 
the neuronal redox balance and the key role of ROS on the regulation of autophagic activity 
(Li et al. 2015), we assessed the effects of NAC in the neurotoxicity elicited by methylone 
and MDPV, and particularly in the modulation of oxidative stress, autophagy and apoptosis. 
Our results support a neuroprotective role for this thiol-based antioxidant agent, eliciting a 
significant reversion of drug-induced cell death and complete inhibition of ROS and RNS 
production. Importantly, NAC partially inhibited methylone- and MDPV-elicited autophagy 
while reducing cell death by apoptosis, which highlights the central role of cellular redox 
status in the modulation of autophagy and neuroprotection.  
A general overview of the putative mechanistic pathways triggered by β-keto 
amphetamines in hepatic and neuronal cells is presented in figure 4. 
Notwithstanding the usefulness of in vitro data for the comprehension of toxicity 
mechanisms at the cellular, biochemical, and molecular levels, in vitro models have several 
limitations, including the absence of biokinetics or interaction with other systems and 
organs, making it difficult to mimic in vivo exposure. This may lead to the misinterpretation 
of acquired data and an erroneous extrapolation of the effects to the human. Therefore, the 
requirement of in vivo studies should never be underestimated. 
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Section V – Final conclusions and perspectives for future 
work 
 
The experimental work conducted under the scope of this thesis has unveiled pivotal 
mechanisms underlying the hepatotoxicity and neurotoxicity of β-keto amphetamines. 
Overall, data presented herein allowed us to conclude the following: 
 
• β-keto amphetamines trigger in vitro hepatotoxicity and neurotoxicity with a potency 
comparable to the classical amphetamine derivative MDMA 
• The common mechanisms of cytotoxicity in hepatic and neuronal cells include the 
imbalance of the cellular redox status and consequent oxidative damage, and the 
impairment of mitochondrial functions 
• The potential of each β-keto amphetamine derivative to induce oxidative stress and 
cell death appears to be correlated with their chemical properties, namely their 
lipophilicity/permeability and electron-donor capacity 
• β-keto amphetamines activate both mitochondria-dependent (intrinsic) and 
mitochondria-independent (extrinsic) pathways of apoptotic cell death, in both 
hepatic and neuronal cells 
• Hepatic metabolic bioactivation of β-keto amphetamines may be involved in the 
hepatotoxicity of these substances 
• Hyperthermia exacerbates the hepatotoxic effects of the derivative MDPV 
• β-keto amphetamine-induced toxicity in neuronal cells involves the activation of 
autophagy 
• The modulation of oxidative stress by means of an antioxidant agent, such as NAC, 
may be beneficial in the treatment of β-keto amphetamine-related intoxications due 
to its ability to regulate both programmed cell death pathways, apoptosis and 
autophagy 
 
Nonetheless, future work is required to attain full understanding of the mechanism 
of action of these drugs, to ascertain the relevance of the present in vitro findings to the 
overall adverse effects following β-keto amphetamine abuse, and to aid in the development 
of a comprehensive treatment approach of β-keto amphetamine-related intoxications. 
Future perspectives may potentially involve the following work: 
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• To clarify the relevance of metabolic bioactivation in β-keto amphetamines-induced 
cytotoxicity through the assessment of the cellular toxic potential of endogenously 
generated metabolites 
• To elucidate the mechanisms involved in the altered thermoregulation reported for 
β-keto amphetamines 
• To evaluate the toxic effects of β-keto amphetamines and respective metabolites in 
other target organs, such as the heart and kidneys, as well as the potential for 
eliciting BBB dysfunction 
• To explore the role of autophagy in β-keto amphetamine-elicited toxicity, identifying 
the signaling pathways involved in autophagic activation, and finally to clarify the 
crosstalk between oxidative stress, autophagy and apoptosis elicited by these 
substances  
• To validate the significance of in vitro data presented in this thesis through in vivo 
studies 
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